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Abstract 
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive and ultimately lethal disease of 
the lung characterised by excessive synthesis and deposition of extracellular matrix (ECM). 
The 5-year survival rate for IPF is lower than that of breast, prostate and skin cancer, with 
the average mortality rate currently standing at 3 years post diagnosis. Incidence and 
mortality appear to be on the rise, and prevalence is expected to increase in an aging 
population. Recently several new drugs have been approved (Pirfenidone, Nintedanib and 
Pamrevlumab). However, the pathobiology of IPF still remains elusive and there is an ever 
more pressing need to elucidate the molecular processes behind this disease to identify 
potential therapeutic targets. 
It is widely believed that at the cellular level, the key mediators of fibrosis are the fibroblast 
cell and their profibrotic phenotype, the myofibroblast. In normal homeostasis the 
myofibroblast is activated to synthesise new ECM during wound healing. In IPF there is 
believed to be a dysregulation in this process leading to persistent activation of 
myofibroblasts after the healing response is complete. Transforming growth factor – β (TGF-
β) is known to be one of the master regulators of wound healing has been shown to be 
capable of activating myofibroblasts. However, research has looked downstream in the 
TGF – β signalling pathway to another protein - connective tissue growth factor (CCN2). 
CCN2 is considered a key downstream mediator of the profibrotic effects of TGF- β and has 
been shown to induce a fibrotic response independently of TGF-β both in vitro and in animal 
models of IPF. A clinical trial of a monoclonal antibody to CCN2 (Pamrevlumab) has 
demonstrated the ability to reverse the fibrosis in various murine models of fibrosis and is 
showing promising efficacy in human trials. The mechanism of action of CCN2 in fibrosis is 
still yet to be fully understood. The aim of this thesis was to utilise the murine bleomycin 
model of IPF to further investigate the role of CCN2 in fibrosis.  
Two new double transgenic mouse lines were generated, containing a CCN2 floxed transcript 
and a tamoxifen-inducible cre recombinase (CreERT2). Two different CreERT2 were used to 
facilitate loss of function of CCN2 in fibroblast cells specifically (Col1α2-CreERT2), or in all cells 
(ROSA-CreERT2). A dosing regimen for initiating recombination in vivo was established, and 
the phenotype in the lungs characterised for both new mouse lines. A third double transgenic 
mouse line was generated to examine the expression pattern of the Col1α2-CreERT2 during 
adulthood and embryonic development using a dual fluorescent reporter construct 
(mT/mG).  A protocol was established for the induction of fibrosis in these mice using 
bleomycin, and a novel imaging protocol using an ex vivo µCT scanner was developed to 
enable full imaging of unfixed lungs prior to genetic and histological analysis. 
In summary, the studies reported in this thesis presented novel findings on the role of CCN2 
in the pathogenesis of fibrosis. Two novel transgenic mouse lines were established for the 
genetic manipulation of CCN2 in vivo. These were used in conjunction with the bleomycin 
model, which was established for the first time at the University of Liverpool. The results 
from these experiments unveiled unexpected results and raised further questions as to the 
role CCN2 plays in homeostatic regulation of ECM production by demonstrating a potent anti-
fibrotic effect of CCN2. A third transgenic mouse line was used to characterise the expression 
profile of a fibroblast specific CreERT2 developed by the Bou-Gharios lab group and found that 
the fibroblast specificity was prevalent in a wider population of fibroblasts than described 
previously. 
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1.1 The Respiratory System 
 
The human respiratory system is a highly complex organ that primarily functions to facilitate 
respiration via ventilation and gas exchange whilst providing a level of protection against 
environmental pathogen exposure (Leeman, Fillmore, & Kim, 2014). Ventilation is the 
physical process of drawing in and exhaling air from the lungs. Gas exchange is the 
biochemical process whereby oxygen (O2) diffuses out of the air, into the blood, and is 
subsequently used for metabolic cell respiration in the production of energy. Waste gases 
such as carbon dioxide (CO2) are removed from the body and diffuse from the blood back 
into the air to be exhaled. Gas exchange occurs exclusively in the lungs, whereas the entire 
respiratory system is involved in breathing. This process must remain efficient to prevent 
build-up of toxic waste gases, maintain stable pH levels and provide sufficient energy to 
sustain life. 
The organs and tissues that comprise the respiratory system are identified in Figure 1.1. 
Airflow is continuous from the nose and mouth to the alveoli, this is known as the respiratory 
tract. The respiratory tract can be divided into two sub categories; the upper respiratory tract 
and the lower respiratory tract. The upper respiratory tract is comprised of the nose, pharynx 
and larynx and is responsible for the conduction of air. This region of the respiratory system 
cleans, warms and humidifies the inhaled air. The lower respiratory tract comprises of the 
trachea, bronchi, bronchioles and alveoli, broadly described as ‘the lungs’. Gas exchange 
occurs exclusively in the lower respiratory tract. This introduction will focus on the structure 
and function of the lungs. For detailed anatomy on the other tissues and organs in the 
respiratory system see Albert, Spiro, & Jett, 2008 and Levitzky, (2007). 
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Figure 1.1. The respiratory system consists of the airways, the lungs, and the respiratory muscles that mediate the 
movement of air into and out of the body. Contributed by Wikimedia Commons, LadyofHats (Public Domain). 
 
1.2 The Lungs 
 
Three main components make up the entirety of the lung – air blood and tissue. The human 
lung is divided into three lobes on the right and two lobes on the left. The two primary 
functions of the lung are maintaining the gas exchange balance of O2 entering the body and 
CO2 leaving, and host defence against the particles and pathogens that are introduced to the 
body via respiration (Nomellini and Chen, 2012). The gross structure of the lung reflects this 
critical role of the lungs in homeostasis with blood contributing up to 50 % of the overall 
weight of an adult lung (Armstrong et al., 1982) and a gas volume ranging from 2.5 L – 6 L at 
maximum expiration and inspiration respectively (Effros, 2006; Nomellini & Chen, 2012). The 
secondary functions of the lung lend to a much more diverse range of roles which is reflected 
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at the micro scale with Marciniak & Lomas, (2012) reporting over 40 different cell types 
present in the lung. Both these macro and micro structures are essential for understanding 
the homeostatic regulation of the lungs and the areas where dysregulation can occur, 
resulting in respiratory disease.  
The major function of the lung is to facilitate gas exchange between the air and blood 
compartments, which takes place in the alveolar region. In the adult lung, the alveolar-
capillary barrier that permits efficient gas exchange is formed by thin cytoplasmic extensions 
of alveolar type I (AETI) cells and capillary endothelial cells, separated by a common fused 
basement membrane. 
1.2.1 Development 
 
Human lungs first begin to develop during embryogenesis at around 7 weeks, with epithelial 
differentiation occurring between 16-26 weeks. Final remodelling and maturation of the 
lungs occurs postnatally, with new alveoli forming up to 8 years of age (Albert, Spiro and Jett, 
2008). They then mature into a highly branched, specialised structure to maximise the 
exposure of the cardiovascular system to oxygen (Morrisey and Hogan, 2010).  
1.2.2 Airways 
 
The largest structural component of the airways is the trachea, this branches at the carina 
into the right and left mainstream bronchi, which subsequently divide into the lobar bronchi. 
This branching is asymmetric with 3 lobar bronchi forming on the right hand side of the lungs 
and 2 forming on the left (Weinberger, Cockrill and Mandel, 2014). The conducting airways 
subdivide and branch a further 15 - 20 times to form the respiratory bronchioles in the 
conducting section of the airway. The conducting airways transport gas and protect the rest 
of the lung from inhaled pathogens and particles.  
Several layers of tissue contribute to the structure of the airways, each serving a specialised 
purpose. The intraparenchymal bronchioles are surrounded with smooth muscle, consisting 
of up to 20 % total tissue thickness. The elastic fibres present enable the stretch for 
inspiration and subsequent recoil for expiration. These elastic fibres are a required at all 
levels of the respiratory system and are essential components of the connective tissue in the 
lung, although smooth muscle is no longer present at the respiratory zone itself (Culver, 
2012). The Mucosal layer consists primarily of pseudostratified columnar epithelial cells (PCE 
cells). Particles are trapped in the tracheobronchial secretions and migrated to the pharynx 
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by the ciliated epithelial cells. (Weinberger, Cockrill and Mandel, 2014). PCE cells are 
interspersed with goblet cells that secrete mucins into the airway lumen. Basal cells comprise 
of the local “stem cell” population and are capable of differentiating into the superficial 
mucosa cell populations (ciliated cells and secretory goblet cells) (Weinberger, Cockrill and 
Mandel, 2014). A secondary source of progenitor cells is the club cell (previously known as 
Clara cells). These are a prominent cell type in the terminal airway and have numerous 
functions in the lung. The first is their progenitor cell capabilities. Club cells are able to 
differentiate into the ciliated cells (Plopper & Hyde, 1992), secrete mucous, immune 
molecules and metabolise some inhaled chemicals (Peão et al., 1993; Levitzky, 2007a). The 
final cell of note in the airways is the mast cell. These cells contain secretory granules 
consisting of a number of inflammatory mediators, capable of inducing bronchoconstriction, 
mucus production and increased permeability of the lungs (Levitzky, 2007b). These cell types 
are of significant importance, not only due to their homeostatic roles, but their responses to 
irritants and the role this plays in respiratory disease pathogenesis (Weinberger, Cockrill and 
Mandel, 2014). 
1.2.3 Lung Parenchyma 
 
The lung parenchyma is the location of gas exchange and consists of the alveoli, capillaries, 
and other interstitial tissues. There are two sequential connective tissue compartments in 
the lung, described by Hayek (1960). The alveolar wall (parenchymal interstitium), and the 
extra-alveolar connective tissue. The connective tissue, consisting of collagen, elastin and 
reticulin, protects the alveoli during inspiration and expiration by modulating the expansion 
and recoil tensions experienced by the tissues (Young, Moore & Hutchins, 1980).  
1.2.4 Alveoli 
 
Alveoli first begin to appear surrounding respiratory bronchioles, roughly 17 branching 
generations into the lung. The frequency of alveoli increases and following the 20th 
generation of bronchioles the entire airway wall is comprised of alveoli, or alveolar ducts. 
Eventually these progress into alveolar sacs (Effros, 2006). The 300 million alveoli are around 
250 μm in diameter and provide an approximate surface area of 90 m2 for gas exchange. This 
number is an estimate and depends largely on the overall size of the lung. The alveolar 
surface area accounts for up to 99.5 % of the internal surface area of the lungs (Ochs et al., 
2004). Alveoli are mainly composed of a thin layer of squamous epithelial cells , and are 
almost completely surrounded by capillaries, up to 1,000 per alveolus (Levitzky, 2007b).  
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1.2.5 Type I & Type II Alveolar Epithelial cells 
 
On the internal (air) side of the lung the alveolus is lined by two morphologically distinct types 
of alveolar epithelial cells: Type I (AETI) and Type II (AETII). The presence and function of 
these cells is highly conserved within mammalian species (Stone et al., 1992). AETI cells 
constitute the squamous epithelium that forms the blood-air barrier (Ward and Nicholas, 
1984) this network forms the gas exchange surface of the alveolus. AETII cells produce and 
secrete pulmonary surfactants which act to protect the lung against toxins and infectious 
particles that are inhaled during respiration (Mondrinos et al., 2013). AETII cells also act as 
progenitor cells for repair for both AETI & AETII cells following injury to the alveolar 
epithelium (Fehrenbach, 2001), and  express receptors for several growth factors, enzymes 
and matrix proteins (Allen et al., 2001; Bejvl et al., 2013).  
Recently AETI cells have also been shown to have potential immunomodulatory functions 
(Wong, Chapin and Johnson, 2012; Yamamoto et al., 2012). The previous consensus from 
studies in animal models of lung injury, hypothesised that damage to the alveolar epithelium 
is repaired by proliferation and transdifferentiation of AETII cells to AETI cells. AETI cells were 
considered to be terminally differentiated cells with no proliferative capabilities (Rock et al., 
2011; Barkauskas et al., 2013). However, recent in vitro studies have demonstrated that 
cultured AETI cells have a high proliferative potential (Gonzalez, Allen and Dobbs, 2009; 
Wang and Hubmayr, 2011). This potential proliferative capacity and phenotypic plasticity of 
the TI cell in vitro indicate the potential for AETI cells participation in lung repair after injury 
in vivo.  
AETII cells are also important in the initial innate immune response to pathogens. They 
secrete a variety of cytokines to activate macrophages, recruit monocytes, and trigger the 
adaptive immune system (J. Wang et al., 2011). AETII cells are considered important in 
various lung diseases (Kasper & Haroske, 1996) as they can repair the alveolar epithelium. 
Although during severe and chronic injury it is probable that the repair process is not solely 
carried out by these cells (Bhattacharya & Matthay, 2013). In interstitial lung disease, TII cell 
hyperplasia is a common pathologic feature. 
1.2.6 Macrophages 
 
Macrophages, first identified in the 19th century by Russian bacteriologist, Elie Metchnikoff 
(Gordon, 2008), are present in almost all tissues of the body, and are amongst the most 
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abundant immune cell in the respiratory tract. They are the cellular effectors of the innate 
immune system and play crucial roles in the development, metabolism, and maintenance of 
homeostasis. Macrophages are essential for maintaining a local tolerance to the pathogens 
and antigens inhaled during respiration (Kopf, Schneider and Nobs, 2014; Ballinger and 
Christman, 2016; Byrne, Maher and Lloyd, 2016). As well as removing pathogens via 
phagocytosis, macrophages are responsible for the production of a number of cellular 
mediators which act to initiate or suppress immune responses (Levitzky, 2007b). The tissue 
localisation of the macrophage largely determines its phenotype and mechanism of action 
(Minutti et al., 2017). 
Several populations of pulmonary macrophages have been identified of which interstitial and 
alveolar macrophage populations are the most prominent, located in the lung interstitium 
and alveoli respectively (Guilliams et al., 2013). Other subpopulations of macrophages have 
been identified in lung pleural spaces, in the vasculature, and in the airways. These 
subpopulations are poorly characterised due to difficulties in their isolation (Laskin, Malaviya 
and Laskin, 2015).  
Two major subpopulations of macrophages are described, proinflammatory (M1) 
macrophages and anti-inflammatory / wound repair (M2) macrophages (Martinez et al., 
2008; Laskin et al., 2011). M1 macrophages release proinflammatory cytokines to initiate the 
Th1 immune response and are microbicidal in nature (Laskin et al., 2011; Murray and Wynn, 
2011; Wynn, Chawla and Pollard, 2013). M2 macrophages are primarily involved in wound 
repair and downregulating inflammation through the release of anti-inflammatory cytokines, 
and by phagocytizing apoptotic neutrophils. M2 macrophages also synthesize mediators such 
as TGF-β, VEGF and EGF that act on wound repair and tissue remodelling (Wynn, Chawla and 
Pollard, 2013; Laskin, Malaviya and Laskin, 2015). Macrophage activation is a dynamic 
process and the microenvironment in the lung is subject to constant changes. Macrophages 
have been shown not to  be terminally differentiated into the M1/2 phenotype and have 
been shown to be capable of participating in both the pro- and anti-inflammatory response 
(Levitzky, 2007b; Mosser & Edwards, 2008) in order to respond effectively to these changes.  
Alveolar macrophages first populate the lung during embryogenesis and are maintained for 
many months. The turnover rate is approximately 40 % per year, with minimal replenishment 
from hematopoietic precursors (Maus et al., 2006; Yona et al., 2013). Resident and monocyte 
derived alveolar macrophages have been shown to persist for up to a year following acute 
lung injury and act to resolve inflammation by clearing cellular debris, recruiting M2 
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macrophages, and aiding in remodelling of the lung parenchyma (Janssen et al., 2011; 
Misharin et al., 2017).   
1.3 Pulmonary interstitium  
 
1.3.1 Macrophages continued 
 
The pulmonary interstitium includes the alveolar epithelium, basement membrane, 
perivascular and perilymphatic tissues and the pulmonary capillary endothelium. It is divided 
into the axial, parenchymal and peripheral zones, surrounding the bronchioles, parenchyma 
and pleura respectively (Society, 2010). 
Interstitial macrophages are located within the parenchymal zone of the interstitium (Crapo 
et al., 1983) where they account for approximately 40 % of pulmonary macrophages and 2 % 
total cell population of the lung (Lehnert, Valdez and Holland, 1985; Crowell et al., 1992; 
Sebring and Lehnert, 1992). Though difficult to isolate and generally overlooked, current 
research into IM’s suggest a more prominent role in regulating the negative feedback of 
inﬂammatory responses (Liegeois et al., 2018). The response to bacterial products such as 
lipopolysaccharide (LPS) and CpG-DNA, by producing IL-10 (Harlotte et al., 2002; Roy et al., 
2003) has been linked to the hygiene hypothesis (Strachan, 1989; von Mutius, 2007) and the 
increase in prevalence of respiratory diseases in society today. 
First proposed in humans by Strachan, (1989) the "Hygiene Hypothesis" is a theory that 
suggests that if a juvenile immune system is not challenged sufficiently during development 
it fails to mature correctly and may not react appropriately when encountering pathogens or 
environmental triggers, (such as viruses, bacteria, pollen and animal dander) later in life. An 
increase in instance of immune-related health problems such as asthma atopic dermatitis, 
and hay fever have been reported in recent years, correlating with a declining incidence of 
most infectious diseases (Wills-karp, Santeliz and Karp, 2001; Bach, 2017). Although the 
phenomenon gained interest in humans in the late 1980's, the origin of this hypothesis can 
be traced to earlier experiments with animals, predominantly rodents maintained in SPF 
facilities (Abrams, Bauer and Sprinz, 1963; Wostmann et al., 1970; Clarke et al., 2013; 
Luczynski et al., 2016). Exposure of low doses of an infectious agent lead to rapid rates of 
infection and increased death rates in SPF adolescent and young adult animals when 
compared to normally raised counterparts. A slow or attenuated immune response was 
identified in these animals.  
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1.3.2 Fibroblasts and Myofibroblasts 
 
Fibroblasts are found in every tissue of the body, are of mesenchymal origin and, depending 
on their location, display multiple morphologies (Baum and Duffy, 2011). Fibroblasts are 
typically spindle-shaped cells found in the interstitial spaces of organs.  During development 
of the lung, fibroblasts coordinate organogenesis and budding of the lung from the foregut. 
Fibroblasts are metabolically active cells, capable of synthesizing, secreting, and degrading 
extracellular matrix (ECM) components (Murray et al., 2009). In adulthood they are the 
primary source of ECM proteins and are key cells in homeostasis and maintenance of the 
ECM (Effros, 2006). 
The myofibroblast is a differentiated form of the fibroblast characterised by the presence of 
microfilament bundles (stress fibres) and expression of α – smooth muscle actin (α – SMA). 
They are the predominant cell type in the tissue surrounding contractive wounds and are 
responsible for wound closure (Tomasek et al., 2002). Mechanical stress and  TGF – β1 are 
both key regulators  of myofibroblast differentiation, whereby TGF-β can stimulate 
differentiation by both the SMAD activation pathway (Van De Water, Varney and Tomasek, 
2013) and via non-canonical pathways (Tomasek et al., 2005).  
Dysregulation of myofibroblast activation leads to excessive synthesis and deposition of the 
collagen I and collagen III - rich matrix seen in fibrotic pathology such as idiopathic pulmonary 
fibrosis (IPF) (Leask, Denton and Abraham, 2004). Myofibroblasts are mechanically 
responsive cells and excess deposition of ECM alters the forces experienced in the 
surrounding tissue leading to persistence of myofibroblasts characteristic of fibrotic diseases 
such as fibrosis (Van De Water, Varney and Tomasek, 2013).  
 
1.4 Comparative Anatomy of Human and Mouse Lungs 
 
Mice are the most commonly used vertebrate animal in research with approximately 80% 
of human disease studies involving mice (Bryda, 2013). Rodents are ideal candidates for 
research models as they are small, inexpensive and easy to handle. The ability to map 
genomes led to the discovery that 99% of human genes have an equivalent in mice, which 
has resulted in mice being the preferred model for genetic manipulation studies to 
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determine the roles genes play in homeostasis and disease (The Jackson Laboratory, 2018; 
MRC, 2001).  
Although there is genetic similarity between species, there are considerabe differences in 
structure from the human lung, outlined in Figure 1.2 and Table 1.1. The total lung capacity 
of the mouse is about 1 mL compared to 6,000 ml of a human (Irvin and Bates, 2003). 
Similar to human anatomy, the mouse lung consists of 5 lobes, arranged in a different 
distribution (Figure 1.2). The lung parenchyma of the mouse occupies a smaller proportion 
of the total lung than humans (mouse: 18%, human: 12% lung volume) (Irvin and Bates, 
2003). The blood-gas barrier and structural components of the parenchyma are 
considerably smaller than that of the human (Table 1.1), which might have important 
implications for both gas exchange and parenchymal lung mechanics and must be 
considered when modelling human disease. To date, mice have been extensively used for 
modelling human respiratory disease. The availability of immunological reagents and the 
convenience of genetic manipulation (transgenic and gene knockout mice) makes the 
mouse model the most commonly employed (Han et al., 2018). This will be discussed 
further in Chapter 3.
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Figure 1.2. Regional anatomy of mouse and human lungs. A) Mouse lungs, B) Human lungs taken from (Suarez, Dintzis and Frevert, 2012).
A) B)
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Table 1.1. Comparative anatomy of mouse and human lungs. Adapted from Fox et al., 2006; Suarez, Dintzis and 
Frevert, 2012 
 
1.5 Pulmonary Fibrosis 
 
Pulmonary fibrosis (PF) is a severe, chronic and progressive disease state that is the final 
common pathway for many parenchymal diseases of the lung. It is characterised by chronic 
and excessive ECM deposition leading to distortion of the normal lung architecture, 
ultimately leading to respiratory failure.  
PF is an umbrella term for a group of over 200 rare interstitial lung diseases (ILDs) sharing 
similar pathology and clinical symptoms.  These diseases are characterised by damage to the 
lung parenchyma as a result of fibrosis and inflammation (Raghu, Nicholson and Lynch, 2008). 
Although sharing common characteristics, each disease presents with variable prognosis, 
treatment and outcome. Some ILDs have known aetiologies such as systemic disorders of the 
ECM (rheumatoid arthritis, systemic sclerosis), domestic and occupational exposures to 
asbestos, dust and other inhaled irritants, genetic inheritance (neurofibromatosis) or can 
occur as a result of drug treatments (bleomycin in chemotherapy) (Society, 2002). The 
remaining pathologies of unknown aetiology are classified under the umbrella term 
idiopathic interstitial pneumonias (IIPs).  
Identifying and classifying these diseases has proven problematic. Since 1969 various 
classification systems have been proposed to distinguish the ILD’s into distinct categories. In 
Feature Mouse Human
Gross Lung lobes 4 right, 1 left 3 right, 2 left
Airway Generations 13 - 17 17 - 21
Airway branching pattern Monopodial Dichotomous
Diameter of main bronchus (mm) 1 Oct-15
Respiratory rate (breaths per minute) 80 - 230 12 - 16
Tidal volume (mL) 1 6,000
Tissue Diameter of terminal bronchiole (mm) 0.01 0.6
Alveoli ( µm) 39 - 80 200 - 400
Blood-gas barrier thickness (µm) 0.32 0.62
Airway cellular composition Lung Parenchyma
Epithelial thickness (µm) 8 - 17 40 - 50
Ciliated cells (%) 28 - 36 37
Clara cells (%) 59 - 61
Mucous goblet cells (%) <1 10
Serous cells (%) <1 3
Basal cells (%) <1 32
Other (%) 2 - 14 18
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2002 a new classification system was agreed upon by consensus of the European Respiratory 
Society and the American Thoracic Society (Society, 2002), this was revised further in 2013 
(Travis et al., 2013) resulting in the current classification guidelines currently in use in clinic 
today (Figure 1.2). Following this classification, it is now possible to identify these diseases in 
the clinic based on their symptomatic presentation, histological biopsy characteristics and 
radiological patterning. Statistical evaluation on the prevalence and mortality associated with 
ILD has subsequently been possible and used to understand the burden and cost associated 
with ILD both in the UK and across Europe. Recent initiatives and publications in the UK such 
as the National Institute for Health and Care Excellence (NICE) care guidelines (NICE, 2013) 
have since aimed to implement a standard of care across the UK which was further supported 
by efforts to standardise patient identification (Thickett et al., 2014) in order to address the 
increasing incidence of lung disease. 
 
Figure 1.3. Current classification guidelines for diagnosis of IPF adapted from (Society, 2002). 
 
1.5.1 Idiopathic Pulmonary Fibrosis 
 
IPF is a chronic, progressive and ultimately lethal disease of the lung with no known cause 
(Raghu et al., 2011).  Following the consensus in ILD classification, IPF has been identified as 
the most commonly occurring IIP, accounting for up to 64 % of cases (Kim, 2006). Subsequent 
analysis of incidence and survival of IPF patients by Strongman, Kausar, & Maher (2018) 
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describes a trend of increasing incidence in IPF cases in the UK, whilst prognosis remains 
incredibly poor with an average life expectancy of 3 - 4 years following diagnosis. This is in 
line with previous analyses on the prevalence of IPF, (Coultas et al., 1994; Gribbin et al., 2006; 
Navaratnam et al., 2011) and the subsequent mortality (Johnston et al., 1990; Hubbard et al., 
1996). Based on recent projections Navarro and Driscoll, (2017) describe that an average of 
5,000  deaths per year are seen in patients with IPF.  
IPF is rare in people below the age of 45, with the average age of onset being around 70. 
There has been no observed pattern in the geographical distribution of cases, and no racial 
or ethnic predisposition has been reported (Coultas et al., 1994). The clinical course of IPF is 
highly variable with some patients remaining stable for longer periods of time, whilst others 
experience acute exacerbations leading to rapid progressive respiratory failure and eventual 
death (Herzog et al., 2014). Traditional anti-inflammatory therapies, which are the main line 
of therapy used in the treatment of all IIDs show no effect in IPF (Society, 2002) and until 
recently the only treatment options for IPF patients were to target the symptoms. However, 
2013 saw the approval of new antifibrotic therapies Pirfenidone (NICE, 2013; King et al., 
2014), followed by Nintedanib in 2015 (Richeldi et al., 2014). Current trials are also underway 
for a targeted monoclonal antibody therapy, FG-3019 / Pamrevlumab (Raghu et al., 2012, 
2016; Lipson et al., 2017). Current reports indicate that these drugs have shown an ability to 
slow disease progression in some patients. However, there is still no curative treatment 
option for IPF and the pathophysiology of this disease remains poorly understood (Hui Hoo 
and B Whyte, 2012). 
1.5.2 Pathogenesis of IPF  
 
As suggested by its name, the aetiology of IPF is unknown. However studies using tissues 
from patients  and from animal models have revealed some insight into some of the factors 
contributing to the development of this disease (Moore and Hogaboam, 2008; Lindahl et al., 
2013; Williamson, Sadofsky and Hart, 2015). A recurring finding and current hypothesis is 
that fibrosis arises as a result of dysregulation in wound healing. This is suspected to be a 
response to repetitive alveolar injury in genetically susceptible individuals (Liu, Nepali and 
Liou, 2017). In 5 % of cases of pulmonary fibrosis, individuals have one or more affected first-
degree relatives (Garcia-Sancho et al., 2011).  Genetic factors (Zhou and Wang, 2016) and 
exposure to drugs such as bleomycin (Reinert et al., 2013), amiodarone (Wolkove and 
Baltzan, 2009), and methotrexate (Jakubovic et al., 2013) have all been shown to cause IPF, 
although the typical progression of IPF resulting from these is slower than that of IPF in 
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general. One of the more recent hypotheses on the pathogenesis of IPF is that AETII cell 
dysfunction causes the fibrotic response as a result of protein misfolding and ER stress, which 
ultimately leads to secretion of TGF-β and other profibrogenic factors (Haschek & Witschi, 
1979; Selman, King, & Pardo, 2001). Epithelial mesenchymal transition (EMT) has previously 
been considered to be an important part of the fibrotic response, however recent lineage 
tracing studies indicate this is unlikely to be the case (Rock et al., 2011). Mutations of 
surfactant proteins A and C (SP-A and SP-C) are thought to cause some types of familial 
pulmonary fibrosis, and this is thought to be due to protein misfolding and ER stress (Korfei 
et al., 2008; Lawson et al., 2011; Maitra, Wang, Gerard, Mendelson, & Garcia, 2010; Tanjore, 
Blackwell, & Lawson, 2012; Zhong et al., 2011). 
A number of reviews have discussed the current theories on the initiation and progression of 
IPF in greater detail (Selman, King and Pardo, 2001; Wolters, Collard and Jones, 2014; 
Berngard and Afshar, 2016; Richeldi, Collard and Jones, 2017; Wolters et al., 2018). However, 
none of these has been widely accepted and further research into IPF is desperately required. 
 
1.6 Extracellular matrix and the Fibrotic lung 
 
1.6.1 Collagen 
 
The collagen superfamily in vertebrates comprises of over 50 collagens and collagen-like 
proteins (Hulmes, 2008). In mammals, collagens are the most abundant protein, accounting 
for up to 30 % total protein mass. 28 collagen proteins have been identified in humans, and 
classified into smaller subfamilies (Kadler et al., 2007; Ricard-Blum, 2011). These are listed in 
Table 1.1.  
Collagens are trimeric ECM molecules, consisting of three polypeptide chains ranging 
between 662 – 3152 amino acids in length (Gordon and Hahn, 2010). These α - chains are 
composed of a characteristic repeating peptide triplet sequence of  Gly-X-Y, where X is 
commonly proline and Y is hydroxyproline (Miller, 1985). The presence of glycine causes 
these chains to form the triple helical domains commonly referred to as collagenous domains 
or triple helix motif (Gordon and Hahn, 2010). These α - chains can combine into 
homotrimers such as collagen III or heterotrimers containing up to three different α - chains 
e.g. collagen I consisting of two α1 chains and one α2 chain. Kirk et. al. (1984) determined 
that the predominant collagens of the lung are types I and III, accounting for a total of 90 % 
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of total lung collagen, therefore for the purposes of this thesis these two collagen types will 
be discussed further. 
Table 1.2. Collagen sub-families (Hulmes, 2008). 
Sub - Family Members 
Fibrillar Collagens Types I, II, III, V, XI, XXIV and XXVII 
Fibril associated and related collagens 
Types IX, XII, XIV, XVI, XIX, XX,XXI and 
XXII 
Beaded filament forming collagens Type VI 
Basement membrane and associated collagens Type IV, VII, XV and XVIII 
Short chain collagens and related proteins 
Types VIII and X; C1q; hibernation-
related proteins HP-20, HP-25 and HP-
27; emilins 1 and 2; adiponectin; CTRPs 
1-7: inner ear 
(saccular) collagen 
Transmembrane collagens and collagen-like 
proteins 
Types XIII, XVII, XXIII and XXV/CLAC-P; 
ectodysplasins; macrophage scavenger 
receptors I-III; MARCO; SRCL; 
gliomedin; 
CL-P1 
Collectins and ficolins 
Mannan binding protein; surfactant 
proteins A and D; conglutinin; CL-43; 
CL-46; CL-L1; CL-P1; L-, M- and H-
ficolins  
Other collagens and collagen-like proteins 
Emu1; collagen XXVI/Emu2; collagen 
XXVIII; acetylcholinesterase tail subunit 
 
1.6.2 Fibrillar Collagen 
 
Fibrillar collagens have been described in almost all animals and are the components of 
striated fibrils (Exposito et al., 2010). Collagens I and III are both classified as fibril-forming 
interstitial collagens. Both are predominantly found in tissues with elastic properties such as 
skin, lung and vasculature (Hulmes, 2008). Fibrillar collagen provides tensile strength which 
is of particular importance in organs such as the lungs, which experience constant 
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stretch/relax stress. Collagens I and III are distributed throughout the pulmonary interstitium 
to provide the structural support required by the alveolar-capillary network (Seyer, Kang and 
Rodnan, 1981). Although epithelial cells, endothelial cells, and smooth muscles are capable 
of producing these collagens, fibroblasts (previously discussed) are thought to be the main 
source of Collagen I and III in the lung. 
1.5.3 Collagen Synthesis 
 
Collagen biosynthesis is a complex, multi-step process that requires both intracellular and 
extracellular processing to form a ‘mature’ collagen protein. This process is outlined in Figure 
1.3. The collagen genes are transcribed to mRNA which is ribosome-bound. This is translated 
into procollagen α - chains in the rough endoplasmic reticulum (rER). Of the subsequent 
posttranslational modifications, hydroxylation of proline and lysine residues is of notable 
importance. The formation of 4-hydroxyproline and hydroxy-lysine is essential for ensuring 
the triple helices remain stable through the formation of intramolecular hydrogen bonds 
(Gelse, Poschl and Aigner, 2003). 
Further post-translational modifications are required before the procollagen molecules can 
be transported to the Golgi complex and secreted into the extracellular space. These include 
trimerization, chain folding, and formation of disulphide bonds. The final stage in processing 
of the procollagen molecules requires the cleavage of the C- and N-propeptide groups and 
formation of covalent cross-links. A number of enzymes and proteases control these 
processes including the ADAMTs and the lyase oxidase (LOX) family and are essential for the 
formation of collagens I and III (Herchenhan et al., 2015). LOX enzymes act to convert the 
lysine or hydroxy-lysine residues in the C- and N- terminal regions of the procollagen chains 
to peptidyl aldehydes. These residues are then able to react with several other molecules to 
form the covalent cross-links that are required for stable collagen fibril formation (Hulmes, 
2008). 
A fibrillar procollagen α - chain contains one of the aforementioned collagenous domains 
made of approximately 338 Gly-X-Y triplets (Ramshaw, Shah and Brodsky, 1998). This triple 
helical region is flanked by the N- and the C-pro-peptides. Figure  shows the processing of a 
procollagen molecule to a mature collagen protein. The glycine and peptide bonds are 
frequently contained within or alongside the helical structure, rendering collagen highly 
resistant to proteolysis.
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Figure 1.4. Mechanism of collagen I synthesis. Adapted from (https://step1.medbullets.com/biochemistry/102078/collagen). A) In the fibroblast nucleus; ribosomes translate pre-pro-
collagen α – chain sequence. B) Hydroxylation of Proline and Lysine residues. C) Pro-collagen, translocation from the nucleus to the cytoplasm occurs, ER sugars are added (hexagons). D) 
Formation of triple helix and folding of globular domains, secretion from cell. E) In extracellular space; Removal of N and C terminal domains. F) Deamination of lysine residues, formation 
of crosslinks to form Collagen fibres.
A
B
C
D
E
F
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1.6.4 Collagen deposition in a normal and fibrotic lung  
 
Contradictory to the original hypothesis that collagen was inert, it has since been conclusively 
proven that a dynamic state of synthesis and degradation of collagen exists within the lung. 
Up to 10 % of the total collagen in an adult mammal lung is synthesised and degraded over a 
single 24-hour period (McAnulty and Laurent, 1987), with in vivo and in vitro studies finding 
that up to 30 % of this degradation occurs intracellularly within minutes of synthesis 
(Bienkowski, Baum and Crystal, 1978; McAnulty and Laurent, 1987). These studies were the 
first indicator that the fibroblast cell may not be a quiescent cell population, only active 
during a disease state, but rather constitutively active, producing and degrading collagen 
both intra- and extracellularly.  
In a disease state this synthesis/degradation equilibrium is disturbed, resulting in excessive 
synthesis and disorganised deposition of collagen. Phenotypically, this results in an abnormal 
and progressive thickening of the alveolar interstitium, which ultimately destroys the 
architecture and functionality of the alveoli for gas exchange (Martin-Mosquero et al., 2006). 
As previously mentioned, the two most abundant collagens in the lungs are collagens I and 
III in a ratio of approximately 2:1 (Seyer, Kang and Rodnan, 1981). Several studies 
investigating fibrosis found different ratios of both collagens, yet failed to conclusively 
determine whether an altered ratio of collagen I to III was sufficient to cause the disease 
state, or a product of the processing and sample type examined i.e. post mortem vs. biopsy 
(Bateman et al., 1983; Kirk et al., 1984). The current consensus is that excessive production 
of collagen is the important physiological change that leads to the establishment and 
progression of fibrosis rather than the change in ratios. 
Animal models of pulmonary fibrosis, such as the bleomycin model have demonstrated 
increases in pro-fibrotic markers such as TGF-β1 and fibronectin, as well as the procollagen 
genes Col1α1, Col1α2 and Col3α1 (Amtje Moeller et al., 2008), which are comparable to 
biomarkers found in human studies (Giménez et al., 2017.; Guiot, Moermans, Henket, 
Corhay, & Louis, 2017; Zhang, Kaminski, & Simmons, 2012). These correlate with the increase 
in collagen production. Conversely, alternative studies have identified a decrease in the 
degradation of collagen by examining the expression of matrix metalloproteinases (MMPs) 
and tissue inhibitors of metalloproteinases (TIMPs) in patients presenting with IPF (Selman 
et al., 1986; Dancer, Wood and Thickett, 2011; Leeming et al., 2012). Increases in TIMPs that 
are greater than the associated MMPs lead to a state of persistent matrix deposition. 
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Therefore, current literature is inconclusive as to whether a state of increased synthesis, 
decreased degradation or a combination effect leads to the development of fibrosis in IPF. 
Excess collagen is deposited in fibrotic foci, these are used as one of the key diagnostic 
elements when examining histological samples from lung biopsy. The presence and 
prevalence of these foci are linked to disease progression, with an increase in incidence 
indicating a decreased likelihood of survival (King et al., 2001). The rate of collagen deposition 
by fibroblasts is therefore one of the primary predictors of disease progression. The 
mechanisms regulating this deposition are therefore attractive therapeutic targets. 
1.7 TGF - β function and signalling  
 
For evolution of complex, multicellular organisms to continue, a tightly regulated system for 
the communication and control of individual cells is required. Basic physiological processes 
such as cell proliferation, differentiation, metabolism and apoptosis are regulated by an 
intricate signalling system comprised of cytokines, growth factors and polypeptide hormones 
(Biernacka, Dobaczewski and Frangogiannis, 2011). Of these factors TGF – β is particularly 
important.   
TGF - β isoforms form a superfamily of growth factors together with bone morphogenetic 
proteins (BMPs) and growth differentiation factors (GDFs) (Györfi, Matei and Distler, 2018). 
TGF - β proteins are multi-functional growth factors that are secreted and stored in the ECM 
as a latent complex. This enables spatial and temporal regulation during homeostasis 
(Massagué, 2012). TGF - β is considered a master regulator of tissue regeneration and repair, 
as such dysregulation of TGF – β leads to pathologies such as fibrosis (Denton and Abraham, 
2001; Ihn, 2002; Leask, 2004).  
The pro-fibrotic effects of TGF - β have been shown to be mediated through the downstream 
effector; CCN2. Upregulation of CCN2 is mediated by the canonical SMAD signalling pathway 
(Figure 1.5). TGF - β induces the expression of CCN2 via a functional Smad3 binding site in 
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the CCN2 promoter, which in turn stimulates myofibroblast differentiation and collagen 
synthesis (Duncan et al., 1999). 
 
Figure 1.5. Schematic model of CTGF promoter activation through TGFβ/Smad signalling. Upon TGFβ stimulation, 
Smad2/3 and Smad4 associate, move to the nucleus, make a complex with YAP/TEAD, and recruit p300 to the 
promoter to activate CTGF expression (Nakanishi et al., 2012). 
 
1.8 CCN Family  
 
The CCN gene family, whose name is derived from the early nomenclature of the first three 
proteins to be identified (Cyr61, CTGF and NOV) consists of six members. Previous 
nomenclature and original literature citing their discovery each of these family members can 
be found in Table  (Malik, Liszewska and Jaworski, 2015). In 2003 Brigstock et al. proposed a 
unification of the CCN protein nomenclature in order to reduce confusion and challenges in 
tracking research involving this protein family. 
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Table 1.3. CCN family proteins and their previous nomenclature. 
CCN Family 
Name 
Previous Nomenclature 
CCN1 
CYR61, CTGF-2, IGFB10, IGFB-rP4 (Lau and Nathans, 
1987) 
CCN2 
CTGF, IGFBP8, IGFBP-rP2, HBGF-0.8, ecogenin, FISP12 
(Bradham et al., 1991) 
CCN3 NOV, NOVH, IGFBP9, IGFBP-rP3 (Joliot et al., 1992) 
CCN4 WISP-1, Elm-1 (Hashimoto et al., 1998) 
CCN5 WISP-2, CTGF-L, CTGF-3, HICP, Cop-1 (Zhang et al., 1998) 
CCN6 WISP-3 (Pennica et al., 1998) 
 
The CCN family are cysteine-rich matricellular proteins that are relatively small; 
approximately 35 – 40 kDa. The members of this protein family share similar mechanisms of 
action due to their shared primary structure. This comprises of 38 cysteine residues 
conserved throughout the peptide which form four distinct, multifunctional binding domains 
preceded by a secretory amino peptide. The exception being CCN5, which lacks the fourth 
structural domain and contains only 28 conserved cysteine residues, shown in Figure 1.6 
(Brigstock, 1999; Jun and Lau, 2011). CCN proteins share a common intron/exon pattern. 
Each containing five exons, where the first exon corresponds to the signal sequence, and the 
remaining four corresponding to one of the protein domains (Holbourn, Acharya and Perbal, 
2008a). 
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Figure 1.6. Domain structures and binding ligands of the CCN family of proteins. 
 
The first domain shares 32 % homology to insulin-like growth factor binding proteins (IGFBPs) 
and is therefore termed the IGFBP-binding domain. The second domain encodes a von 
Willebrand type C (VWC) repeat, mediating interactions with integrins and growth factors 
such as BMPs and TGF - β. The third domain is a type-1 thrombospondin (TSP) repeat, known 
to mediate the ability of TSP to bind to ECM proteins, MMPs, and integrins. The final C-
terminal (CT) motif contains a cysteine knot (Leu, Lam and Lau, 2002; Gao and Brigstock, 
2004; Hall-Glenn and Lyons, 2011).  
CCN proteins have been found to share similarities in their molecular mechanisms of action 
and the cellular processes that they regulate. These include but are not limited to cell 
adhesion, migration, proliferation, survival, and differentiation. Current research suggests 
that these activities are tissue and cell dependent with the same CCN family member 
displaying antagonistic effects depending on their location. There are many reviews available 
which explore this family of proteins and their  actions in greater depth (Holbourn, Acharya, 
& Perbal, 2008; Jun & Lau, 2011; Leask & Abraham, 2006; Malik et al., 2015; Perbal & 
Takigawa, 2005; Perbal, 2013; Wu et al., 2016; Yeger & Perbal, 2007). 
Our research has investigated the actions of the second member of this family – CCN2, 
previously known as CTGF. We will examine the physiological roles this protein plays in 
further detail. 
IGF 
Binding 
Protein 
Domain
Von 
Willebrand 
Factor-
Type C 
Repeat
Thrombospondin 
Type-1 Repeat
CCN 1 - 4, 6
CCN 5
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1.8.1 CCN2 
 
CCN2 is the second member of the CCN protein family. Early analysis of CCN2 function in vivo 
focused primarily on its role as a mediator of ECM synthesis in multiple fibrotic diseases. 
However, CCN2 and the remaining CCN family members have also been found to play key 
roles during development, as well as modulating cell adhesion, proliferation, survival, 
migration, and ECM production across a diverse range of cell types during adulthood.  
During embryogenesis, CCN2 is highly expressed in mesenchymal cells and acts to mediate 
renal, cardiovascular and skeletal development (Liu et al., 2011; Ramazani et al., 2018).  
Expression of CCN2 was found to be critical for development when a global knockout model 
of CCN2 noted premature mortality of pups, caused by respiratory failure owing to rib 
malformation (Ivkovic et al., 2003). Expression of CCN2 is limited during adulthood unless a 
disease state is present (Liu et al., 2011). 
Regulation of CCN2 occurs both at the transcriptional and post -translational level and is 
controlled by a variety of factors (Ramazani et al., 2018). At the transcriptional level, CCN2 
expression is induced by stimuli such as growth factors, cytokines, hormones, mechanical 
stress, outlined in Figure 1.7 (Kubota and Takigawa, 2015). These stimuli can act directly, or 
by recruiting transcription factors (Jun and Lau, 2011). TGF - β was one of the first cell-
signalling molecules to be implicated as a regulator of CCN2 and many of the TGF - β 
responses involve CCN2 to varying degrees (Leask and Abraham, 2006; Shi-wen et al., 2006; 
Arnott et al., 2007; Ponticos et al., 2009; Holmes et al., 2001; Leask et al., 2003; Geisinger et 
al., 2012).  
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Figure 1.7. Transcriptional and post-transcriptional regulation of the CCN2 gene. The structures of the CCN2 gene 
and its mRNA are illustrated at the centre. Transcription factors and post-transcriptional regulatory molecules that 
are known to directly regulate CCN2 expression are summarized. 
 
Aberrant expression of CCN2 has been associated with several fibrotic diseases such as 
systemic sclerosis, and lung, kidney and liver fibrosis; reviewed by (Ramazani et al., 2018), in 
addition to being associated with osteoarthritis and cancer (Planque and Perbal, 2003; 
Omoto et al., 2004; Leask, 2009). In animal models of IPF CCN2 has been shown to be 
increased in fibroblasts (Lasky et al., 1998; Liu et al., 2011; Yang et al., 2014; Ashley et al., 
2017). CCN2- deficient animals have fewer myofibroblasts and decreased ECM disposition, 
indicating that CCN2 is necessary for induction of fibrosis in these animals (Liu et al 2011). 
Based on this evidence CCN2 is likely a good and viable target for pharmaceutical 
intervention in IPF further research in vivo is required to elucidate the specific role CCN2 
plays in the pathogenesis of this disease.  
 
  
1.9 Hypothesis Statement 
 
I hypothesise that the loss of function of CCN2 prior to induction of bleomycin will provide a 
beneficial effect and will impair the cells ability to produce extracellular matrix. I 
hypothesise that this effect will be more profound when CCN2 functionality is removed in a 
ubiquitous manner, compared to a fibroblast specific loss of function.      
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1.10 Aims 
1.1 Generation of Transgenic animals 
Four single transgenic mouse colonies will be established at the University of 
Liverpool, each containing one of the following: a CCN2 floxed gene, a dual 
fluorescent reporter construct, a fibroblast specific tamoxifen inducible Cre 
recombinase or a ubiquitously expressing tamoxifen inducible Cre recombinase. 
These animals will be bred to generate novel double transgenic mouse lines to 
examine the effects of CCN2 loss of function in a bleomycin model of IPF.  
1.2 Generation of double transgenic animals  
Two double transgenic mouse lines will be established for the inducible loss of 
function of CCN2. Mice homozygous for the CCN2 floxed gene will be bred with 
mice containing either the fibroblast specific tamoxifen inducible Cre recombinase 
or the ubiquitously expressing tamoxifen inducible Cre recombinase.  Offspring 
from these breeding pairs will be interbred to generate colonies homozygous for 
the CCN2 floxed gene and positive for one of the Cre recombinase genes.  
1.3 Characterisation of expression of fibroblast specific Cre in double transgenic 
animals 
A dual fluorescent reporter mouse line will be bred with the fibroblast specific 
tamoxifen inducible Cre recombinase line to generate a double transgenic colony 
homozygous for the reporter construct and positive for the fibroblast specific Cre 
recombinase. Tamoxifen will be administered at different stages of development 
and adulthood to investigate the localisation pattern of activity of the fibroblast 
specific Cre recombinase. 
2. Testing the Bleomycin model of Fibrosis  
3. Testing the loss of function CCN2 models  
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2. Materials and Methods  
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2.1 Declaration of Ethics 
 
All procedures performed during this research project were carried out in accordance with 
the UK Home Office guidelines and regulations under the Animals (Scientific Procedures) Act 
1986 (ASPA). This work was carried out under the project licences granted to Professor 
George Bou-Gharios PPL70/9060, and a personal licence (PIL. I0BCA5D31) granted to Amy 
Horwell for the completion of experiments, Schedule 1 (Sch1) humane killing of mice and the 
collection and use of the resultant tissue for analysis.  
2.2 Mouse Husbandry 
 
All mice were housed and maintained within the University of Liverpool’s Biomedical 
services unit (BSU) in accordance with Home Office UK guidelines. Mice were maintained 
in a specific pathogen free (SPF) environment, under a 12-hour light/dark cycle, and 
granted access to food and drinking water ad libitum.  
2.3 Mouse Colony establishment and maintenance 
 
2.3.1 Inducible fluorescent reporter line (Col1α2-R26TmG) 
 
Founder breeding pairs were established by breeding female mice containing the reporter 
construct B6CB; 129-(Cg)-Gt (ROSA) 26Sortm4 (ACTB-tdTomato,-EGFP) Luo/Liv (Muzumdar 
et al., 2007), purchased from Jackson Laboratories, 007676, with male mice containing the 
Col1α2 driven CreERT2 B6CB-Tg (Col1a2-17=1.5kbenh-350mp-CreErt2)3.18/Liv, generated by 
the Bou-Gharios lab (Bou-Gharios et al., 1996; De Val et al., 2002; Li et al., 2017). The resulting 
offspring were genotyped for both mTmG and Cre transgenes as heterozygous, double 
transgenic (mTmG +/-, Cre +/-). 
Further crossing of littermate male and female mice was used to establish and maintain a 
colony of double transgenic mice (mTmG +/+, Cre +/-) on a mixed background; B6CB;129-
Tg(Col1a2-17=1.5kbenh-350mp-CreErt2)3.18-(Cg)-Gt(ROSA)26Sortm4(ACTB-tdTomato,-
EGFP)Luo/Liv (strain identifier – Col1α2-mTmG) at the University of Liverpool, UK. 
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2.3.2 Inducible knock out of CCN2 in Fibroblasts (Col1α2-CCN2fl) 
 
Founder breeding pairs were established from transgenic mice containing the CCN2 floxed 
transgene B6; 129S-CTGFtm1.Alea, (provided by Dr Andrew leask, (Ponticos et al., 2009; Liu 
et al., 2011)) bred with mice carrying the transgene for a Col1α2 driven CreERT2 B6CB-Tg 
(Col1a2-17=1.5kbenh-350mp-CreErt2) 3.18/Liv, generated by the Bou-Gharios Lab (Bou-
Gharios et al., 1996; De Val et al., 2002; Li et al., 2017). The resulting offspring were 
genotyped and heterozygote CCN2 floxed +/-, Cre +/- animals were interbred to yield and 
maintain a colony of double transgenic mice (CCN2 floxed +/+, Cre +/-) on a B6CBA 
background; B6CB; 129S-Tg (Col1a2-17=1.5kbenh-350mp-CreErt2)3.18-CTGFtm1.Alea/Liv 
(strain identifier – Col1α2-CCN2fl) at the University of Liverpool, UK.  
2.3.3 Inducible Ubiquitous knockout of CCN2 (ROSA-CCN2fl) 
 
A founder breeding pair was generated by breeding a male mouse containing the CCN2 floxed 
transgene B6;129S-CTGFtm1.Alea (Ponticos et al., 2009; Liu et al., 2011), with a female 
mouse containing a ubiquitously expressed ROSA26CreERT2 B6CB;129-
Gt(ROSA)26Sortm1(cre/ERT)Nat/Liv bought from the Jaxson lab, Stock No: 008463 (B6.129-
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J), (Badea, Wang and Nathans, 2003)s. The resulting offspring 
were genotyped and heterozygous, double transgenic (CCN2 floxed +/-, Cre +/-) animals were 
interbred to yield and maintain a colony of double transgenic mice (CCN2 floxed +/+, Cre +/) 
on a mixed background; B6CB; 129S-CTGFtm1.LeaskGt (ROSA) 26Sortm1 (Cre/ERT) Nat/Liv 
(strain identifier – ROSA-CCN2fl) at the University of Liverpool, UK. 
2.4 Mouse Colony Genotyping 
 
2.4.1 Proteinase K based DNA Extraction 
 
Genomic DNA extracted from ear punch biopsies was used to identify each animal. Notches 
were obtained from all experimental animals. DNA from all strains was extracted using the 
following protocol. 
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Proteinase K from Tritirachium album (Sigma Aldrich) was prepared to a final concentration 
of 10 mg/mL in 50 % glycerol. 10 µL proteinase K was added to 100 µL lysis buffer and 
incubated at 55 °C overnight in a water bath.  
Samples were then vortexed and the tissue dissolved. If tissue remained solid / failed to 
dissolve a further 10 µL proteinase K was added and the sample incubated further (up to 
1 hour) at 55 °C. Samples were then centrifuged at 14,000 xg for 7 minutes. The supernatant 
was transferred to a clean, labelled 1.5 mL eppendorf and the remaining tissue was 
discarded. An equal volume of isopropanol (Sigma Aldrich) was added to the supernatant and 
the tube inverted several times. Samples were centrifuged at 14,000 xg for 3 minutes and 
the supernatant removed. A clear pellet of DNA remained in the bottom of the eppendorf. A 
final 30 s centrifugation step was carried out at 14,000 xg and any remaining supernatant 
was pipetted off. The DNA was then left to air dry at room temperature for a maximum of 
10 minutes. DNA was reconstituted in 50 µL ddH2O for one hour at room temperature, or at 
4 °C overnight. DNA concentration was then determined using a NanoDrop 200 prior to PCR 
analysis. A 260/230 value ≥ 0.6 was acceptable for genotyping PCR.   
2.4.2 Solutions 
 
2.4.2.1 Lysis Buffer 
 
2.4.2.2 Proteinase K stock 
10 mg/mL in 50 % Glycerol stored at -20 °C 
Reagent Volume
50mM Tris-HCL 
(pH8)
4.5 mL of 2 M stock 
solution
0.1M NaCl
7 mL of 3 M stock 
solution
1% SDS
8 mL of 10 % stock 
solution
20mM EDTA
7.2 mL of 500 mM 
stock solution
ddH2O 144.3 mL
Autoclave solution and store at room 
temperature
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2.4.3 Polymerase Chain Reaction (PCR) 
 
For a single gene PCR reaction (CCN2 Floxed, mTmG), 100 ng DNA was added to a 25 µL PCR 
reaction mix containing 0.2 µL GoTaq® G2 Flexi DNA Polymerase, 5 µL 5X Green GoTaq® Flexi 
Buffer, 2 µL 25 mM MgCl2 (all reagents supplied with GoTaq® G2 Flexi DNA Polymerase, 
Promega) with the addition of 0.5 µL 10 mM dNTPs (Bioline) and 0.5 µL 10 pM specific 
primers (Table 2.1., Eurofins Genomics). ddH2O was added to make a final reaction volume 
of 25 µL.  
For a duplex PCR reaction (Cre / LacZ plus Internal), 100 ng DNA was added to a 25 µL PCR 
reaction mix containing 0.2 µL GoTaq® G2 Flexi DNA Polymerase, 5 µL 5X Green GoTaq® Flexi 
Buffer, 3 µL 25 mM MgCl2 (all reagents supplied with GoTaq® G2 Flexi DNA Polymerase, 
Promega) with the addition of 1 µL 10 mM dNTPs (Bioline) and 0.5 µL 10 pM specific primers 
(Table 2.1., Eurofins Genomics). ddH2O was added to make a final reaction volume of 25 µL. 
PCR conditions for all reactions were: initial denaturation for 5 minutes at 94 °C, followed by 
35 cycles of denaturation at 94 °C for 30 seconds, annealing at primer specific temperatures 
(Table 2.1., for primer specific annealing temperatures) for 45 seconds, elongation at 72 °C 
for 1 minute, then a final elongation at 72 °C for 5 minutes. Once finished the reaction was 
maintained at 4 °C until electrophoresis. 
2.4.4 Agarose Gel Electrophoresis 
 
Agarose gels of 1-2 % were prepared by melting agarose (Sigma Aldrich) in 1 % TAE in a 
microwave, 4 µL of SYBRSafe (Invitrogen) was added to 200 µL gel. Gels of 1 % were used for 
DNA fragments below 500 bp, 2 % was used for fragments larger than 500 bp. In order to 
estimate DNA fragment size, one well was loaded with 5 µL of 2-Log DNA Ladder (NEB). 15 µL 
of PCR reaction mix was added to each well. Samples were electrophoresed for ≥ 50 minutes 
at 120 V on a 2 % agarose gel. Expected band sizes for each gene are described in Table 2.1. 
Resultant gels were visualised using a Biorad transluminator and ImageLab software.  
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Table 2.1. Primer sequences used for genotyping of transgenic animals 
 
  
Gene Primer I.D. . Primer Sequence (5' -> 3')
Annealing 
Temperature 
(°C)
Amplicon Size
Cre Cre010 (HELpr010) FOR GCATTACCGGTCGATGCAACGAGTGATGAG 68 389 bp
Cre011 (HELpr011) REV GAGTGAACGAACCTGGTCGAAATCAGTGCG
Col1α2 enhancer + Cre Col1α2 enh Fw FOR AGAGTTCTGCCCACTCCCTT 60 479 bp
Col1α2 enh Rv REV GCCTCCAAAAACGTCTCCAC
Internal Internal012 (HELpR012) FOR TGGACAGGACTGGACCTCTGCTTTCCTAGA 68 194 bp
Internal013 (HELpR013) REV TAGAGCTTTGCCACATCACAGGTCATTCAG
LacZ LacZ008 (HELpR008) FOR GTTGCAGTGCACGGCAGATACACTTGCTGA 68 389 bp
LacZ009 (HELpr009) REV GCCACTGGTGTGGGCCATAATTCAATTCGC
CTGF CTGF Flx FOR AATACCAATGCACTTGCCTGGATGG 65
Floxed = 1003 bp 
Wild Type = 878 bp 
CTGF Flx REV GAAACAGCAATTACTACAACGGGAGTGG
(recombined             
587 bp)
mTmG oIMR7318 FOR CTC TGC TGC CTC CTG GCT TCT 61
mTmG = 128 bp 
Wild type = 212 bp
oIMR7319 REV CGA GGC GGA TCA CAA GCA ATA
oIMR7320 REV TCA ATG GGC GGG GGT CGT T
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2.5 Mouse Treatments 
 
All animals used in gain and loss of function experimental cohorts were ≥ 6 weeks of age 
before any treatments were administered. For lineage tracing experiments, tamoxifen 
treatments were administered at different stages during embryonic development and 
postnatally. Where the same animal was administered multiple treatments; i.e. tamoxifen 
followed by bleomycin injury, one-week recovery was given after completion of the first 
treatment before administering the second. 
2.5.1 Tamoxifen 
 
For a final concentration of 10 mg/mL, 50 mg Tamoxifen (Sigma Aldrich), was added to 4.5 mL 
corn oil (Sigma Aldrich) and 500 µL 100 % Molecular grade Ethanol (Sigma Aldrich). This was 
sonicated for a total of 5 minutes until tamoxifen crystals dissolved.  
2.5.1.1 Tamoxifen – Col1α2-CCN2fl 
A dose of 0.025 mg/g was administered intraperitoneally (I.P.) to each animal on 
experimental days 1, 3, and 5. All animals were weighed prior to dosing and the volume 
adjusted accordingly based on whole grams of weight.  For example, following this protocol 
a 20g mouse would receive an I.P. dose of 200 µL containing 2 mg of tamoxifen. 
2.5.1.2 Tamoxifen – ROSA-CCN2fl 
A dose of 0.0125 mg/g was administered via I.P. injection to each animal on experimental 
days 1, 3, and 5. All animals were weighed prior to dosing and the volume adjusted 
accordingly based on whole grams of weight. For example, following this protocol a 20g 
mouse would receive an I.P. dose of 200 µL containing 1 mg of tamoxifen.  A reduced dose 
of tamoxifen was required for transgenic animals inducing the ubiquitous CCN2 loss of 
function. Poor recovery and early termination of animals was required when 0.025mg/g was 
dosed during preliminary studies. We postulate that this is a result of the role of CCN2 in the 
repair pathway although this was not investigated as part of this PhD.   
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2.5.1.3 Tamoxifen – Col1α2-R26TmG 
Embryonic Development - A single I.P. dose of 3 mg tamoxifen (300 µL tamoxifen at 10 
mg/mL concentration) was administered intraperitoneally in a total volume of 300 µL 
alongside a 3 mg dose of Progesterone (Sigma Aldrich) to the pregnant female at Embryonic 
Days 13.5 and 15.5. 
Adulthood - Mice of 6-7 weeks of age were administered an I.P. dose of 0.0125 mg/g on 
experimental days 1, 3, and 5. They were then allowed to recover and maintained as 
previously described for 7 days, 14 days and 3 months. For example, following this protocol 
a 20g mouse would receive an I.P. dose of 200 µL containing 2 mg of tamoxifen. A further 
group were administered bleomycin (described in 2.5.2) and left for 14 Days prior to tissue 
collection. 
2.5.2 Bleomycin 
 
A stock solution of bleomycin at 0.15 mg/mL was prepared in sterile PBS. A single dose of 
0.375 ng/g was delivered via oropharyngeal aspiration (OA) e.g. a 20g mouse was 
administered a volume of 50 µL for a total dose of 0.0075 mg bleomycin. Animals were 
anaesthetised using isoflurane. An elastic band wrapped around an icebox was used as a 
suspension system to open the airways and expose the back of the throat. Animals were 
suspended via their incisors and forceps used to hold the tongue outside the mouth during 
administration as previously described by (Lakatos et al., 2006). Animals were weighed daily 
in the 3 days immediately following bleomycin administration, and bi-weekly for the duration 
of the experimental time frame.  
2.6 Micro-computed tomography (µCT) Analysis 
 
2.6.1 Unfixed scans 
 
Animals were Sch1 using an overdose of Pentoject (pentobarbital). Lungs and trachea were 
exposed and a monoject #202 blunt 20-gauge x 1.5” blunt needle was inserted into the 
trachea. Cotton thread was used to seal the airway around the needle and lungs were 
manually inflated prior to removal from the ribcage. Isolated lungs were suspended in 3 % 
potassium Iodide (KI) and stabilised between two Styrofoam guides. A Bruker Skyscan 1272 
ex-vivo µCT system was used to scan lungs at a resolution of 20 µm, using a 0.25 mm 
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aluminium filter and 0.3 ° rotation step. Images were reconstructed using Skyscan NRecon 
software using the following settings:  
Table 2.2 Reconstruction settings for µCT scan analysis. 
 
An average X-Ray attenuation value for each scan was determined using a macro developed 
by Professor Rob Van ‘T Hof, using CtAN software (see Appendix). 
 
2.6.2 Fixed and dehydrated scans 
 
Lungs were isolated as described in section 2.6.1, and fixed in 10 % neutral buffered formalin 
(NBF) overnight at 4 °C. They were then dehydrated through the following series of ethanol 
concentrations: 70 %, 80 %, 90 %, 100 %, 100 %. Lungs were suspended in 6x the total tissue 
volume of each solution for 1.5 hours. They were then suspended in hexamethyldisilazane 
(HMDS) (Sigma Aldrich, 440191) for 1.5 hours, before drying in a fume hood for 2 hours. 
Lungs were then scanned using the Bruker Skyscan 1272 ex-vivo µCT system, at a resolution 
of 13 µm, using a 0.25 mm aluminium filter and 0.3 ° rotation step. 
2.7 RNA Analysis 
 
2.7.1 Tissue homogenisation 
 
Tissues were snap frozen in liquid nitrogen (LN2) and stored at -80 °C until RNA extraction 
was carried out. 70 % Ethanol (EtOH) and RNase Zap (Invitrogen™ AM9780) were used to 
clean the working area and mortar and pestle which were subsequently cooled using LN2. 
The tissue samples were added to the mortar and manually homogenised into a powder. The 
powder was collected into a clean, labelled, DNase and RNase free tube. 1 mL TRIzol® 
(Invitrogen™, 15596026) was added and the sample shaken vigorously. Samples were 
incubated at room temperature for 5 minutes then centrifuged for 3 minutes at 8,000 xg at 
Smoothing 2
Misalignment 
Compensation
-2
Ring artifacts reduction 12
Beam Hardening correction 38%
Log values 0.0   -   0.03
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4 °C. The supernatant was transferred to a second clean, DNase and RNase free tube and 
200 µL chloroform was added. The tube was sealed tightly and vigorously shaken, then 
incubated at room temperature for 5 minutes. The sample was then centrifuged at 16,000 xg 
for 15 minutes at 4 °C. The clear aqueous phase was pipetted off and split between two fresh 
RNase and DNase free 1.5 mL centrifuge tubes. 
2.7.2 RNA Extraction using Qiagen RNeasy mini kit 
 
A 1:1 ratio of 70 % EtOH was added to the sample and pipetted to mix before being 
transferred to a Qiagen RNeasy mini kit spin column inside a 2 mL collection tube. RNA 
isolation was carried out according to the following Qiagen RNeasy kit instructions. Samples 
were centrifuged at room temperature, at 8,000 xg for 15 seconds. The run-through in the 
collection tube was discarded and this step repeated if sample volume exceeded 700 µL until 
the total volume was run through the column. 700 µL of RW1 buffer was added to the column 
and the sample was centrifuged at 8,000 xg for 15 seconds at room temperature, flow 
through was discarded. 500 µL Buffer RPE was added to the column and the sample was 
centrifuged at 8,000 xg for 15 seconds at room temperature, flow through was discarded. A 
second volume of 500 µL was added to the column and the sample was centrifuged at 
8,000 xg for 2 minutes at room temperature. The spin column was then placed into a new 
2 mL collection tube and the old collection tube and flow-through was discarded. The 
samples were then centrifuged for 1 minute at full speed (16,000 xg) and the spin column 
transferred to a new 1.5 mL collection tube. RNA was eluted in a total volume of 50 µL RNase 
free water. An initial volume of 30 µL RNase free water was added directly to the spin column 
membrane and left to incubate for 3 minutes before centrifuging at 16,000 xg for 3 minutes. 
A second volume of 20 µL RNase free water was added directly to the membrane and left to 
incubate for 2 minutes. Samples were then centrifuged for 2 minutes at 16,000 xg. RNA 
concentration and purity was determined using a NanoDrop 200. Samples were immediately 
used for cDNA synthesis or stored at -80 °C.    
2.7.3 RNA Extraction using Isopropanol 
 
A single volume of 500 µL isopropanol was added per 1 mL TRIzol® used for initial tissue 
disruption. The sample was mixed vigorously and incubated at room temperature for 15 
minutes then subsequently centrifuged for 10 minutes at 12,000 xg at 4°C. The supernatant 
was removed and discarded to leave a clear pellet of RNA. 1 mL of 70 % EtOH was added to 
the pellet and centrifuged for 1 minute at 12,000 xg. The EtOH was removed and the pellet 
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air dried for no longer than 10 minutes. 50 µL of RNase free water was added to the pellet 
and gently pipetted to re-suspend the RNA. RNA concentration and purity was determined 
using a NanoDrop 200. A minimum 260/230 ratio of 1.90 and 260/230 ratio of 2.0 was 
required for RNA samples to be used for transcript analysis. Samples were immediately used 
for cDNA synthesis or stored at -80°C.    
2.7.4 cDNA Synthesis 
 
The High-Capacity cDNA reverse transcription kit (Applied Biosystems) was used for cDNA 
synthesis. A total concentration of 2 µg RNA was added to a 20 µL reaction consisting of 2 µL 
10x RT Buffer, 2 µL 10x RT Random Primers, 0.8 µL 25x dNTP mix (100 mM) and 1 µL 
MultiScribe® Reverse Transcriptase (50 U/µL). RNase free water was added to a final volume 
of 20 µL.   
 
2.7.5 Real Time PCR 
 
Quantitative PCR (qPCR) was carried out using the SensiMIX™ SYBR® Hi-ROX kit (Bioline) for 
genes listed in Table 2.3. A reaction volume of 20 µL consisting of 0.01 µg cDNA (2 µL cDNA 
stock diluted 1:20), 10 µL SYBR Green, 0.6 µL forward and reverse primer and 6.8 µL ddH2O 
was used and plated in triplicate. Samples were analysed using a Corbett Rotor Gene RG-
6000 using cycling parameters:  Initial hold for 10 minutes at 95 °C followed by 40 cycles of 
95 °C for 10s, 60 °C for 15s, 72 °C for 20s and acquire on the green channel. A melt curve was 
generated at the end of every run to confirm a single amplification product was present. 
Rotor-Gene 6000 series software version 1.7 was used to analyse the results. The 
housekeeping gene 18s was used for all experiments and ΔΔCt values were calculated and 
normalised to this gene. 
2.7.6 Primer Validation 
 
Prior to use for qPCR, calibration curves for all primers were generated and compared to 18s. 
Melt curve analysis and end stage PCR was also performed to ensure that single products 
were obtained at the expected product size. See appendix for details.  
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Table 2.3. Primers and sequences used for RT-qPCR analysis. 
Gene Primer I.D. . Primer Sequence (5' -> 3')
Temperature 
(°C)
Amplicon 
Size
18s 18s Tas FOR GGAAAGCAGACATCGACCTCA 60 130bp
18s Tas REV AGTTCTCCAGCCCTCTTGGT
CCN2 CCN2 FOR CACAGAGTGGAGCGCCTGTTC 60 165bp
CCN2 REV GATGCACTTTTTGCCCTTCTTAATG
Collagen I Col1α2 FOR GCAACAGTCGCTTCACCTACA 60 138bp
Col1α2 REV CAATGTCCAAGGGAGCCACAT
Fibronectin Fibronectin ED-A FOR GATGATATGGAGAGCCAGCCC 60 101bp
Fibronectin ED-A REV GCAGTAAAGCTGGTGGGTGT
Collagen III COL3a1 FOR CTGTAACATGGAAACTGGGGAAA 60 144 bp
COL3a1 REV CCATAGCTGAACTGAAAACCACC
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2.8 Histological Analysis 
 
2.8.1 Cryogenic histology 
 
The following protocol was adapted from (Ono et al., 2014). The tissues of interest, such as 
embryos of different developmental stages, lung and other internal organs were dissected 
and fixed overnight in 4 % paraformaldehyde at 4 °C. Samples were then washed twice in PBS 
and transferred to 30 % Sucrose/PBS and incubated overnight at 4 °C. Finally samples were 
transferred to 30 % sucrose / PBS:OCT (1:1) and incubated overnight at 4 °C. Tissues were 
then embedded in OCT embedding media (TissueTek, Sakura) using cork discs and moulds 
(Electron Microscopy Solutions). The samples were left to solidify on a sheet of dry ice and 
immediately transferred to storage at -80 °C until required. A Leica CM1850 cryostat was 
used to section the tissues at 5 – 7 µm. Sections were collected on Superfrost™ Plus 
microscope slides (ThermoScientific) and imaged using a Zeiss Axio Observer apotome 
microscope and Axio Cam MR R3 camera. When not in use slides were stored at -80 °C and 
protected from light exposure to reduce colour bleaching. For fluorescent imaging a 
wavelength of 610 nm was used to image the tdTomato and 519 nm for EGFP. Images were 
viewed using ZEN Blue microscopy software. 
2.8.2 Paraffin Wax histology 
 
2.8.2.1 Tissue Processing  
Adult soft tissues were isolated from animals Sch1 by overdose of anaesthetic 
(pentobarbital), and immediately suspended in 6x total tissue volume of 10 % NBF. Tissues 
were fixed overnight at 4 °C in 6x total tissue volume of NBF prior to processing and 
embedding in paraffin wax blocks as per the following protocol: 
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Table 2.4. Processing protocol using a Leica EM TP6 tissue processor for paraffin wax embedding of adult mouse 
soft tissue. 
 
2.8.2.2 Tissue Sectioning 
5 μm sections were cut using the Micron HM355S microtome with cool-cut and tissue 
transfer system (Thermo Scientific) and collected on Superfrost™ Plus microscope slides 
(ThermoScientific). Slides were stored at room temperature prior to use for staining and 
analysis. 
2.8.2.3 Sample Staining 
Slides were de-waxed using the following protocol (Table 2.5). Once dewaxed, slides were 
stored in water until staining. 
 
Table 2.5. Parameters for dewaxing of paraffin embedded sections. 
 
  
Reagent
Immersion Time 
under vacuum 
(Minutes)
Temperature
Drain time 
(seconds)
70 % Ethanol 30 Ambient 80
90 % Ethanol 30 Ambient 80
100 % Ethanol 10 Ambient 80
100 % Ethanol 10 Ambient 80
100 % Ethanol 10 Ambient 80
100 % Ethanol 15 Ambient 80
Xylene 10 Ambient 120
Xylene 20 Ambient 120
Xylene 30 40 °C 120
Wax 240 60 °C 140
Reagent
Immersion Time 
(Minutes)
Xylene 2
Xylene 2
100 % Ethanol 2
100 % Ethanol 2
H2O Until Use
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2.8.2.4 Haematoxylin Eosin Stain (H&E stain) 
The following staining protocol was used for Haematoxylin and Eosin staining of paraffin 
embedded sections.  
 
Table 2.6. Staining schedule for Haematoxylin and Eosin staining of 5µm sections of paraffin embedded mouse 
lung. 
 
 
Stained slides were imaged using a Zeiss LSM 800 confocal microscope. 
 
2.8.2.5 Goldners Trichrome Stain 
All stains and reagents were prepared freshly prior to use and the following staining schedule 
used. 
 
2.8.2.5.1 Solutions 
 
2.8.2.5.1.1 Weigarts Haematoxylin 
 
A working solution of Weigarts Haematoxylin was made by mixing equal parts of solution A 
with solution B. 
 
 
 
Reagent
Immersion Time 
(Minutes)
Haematoxylin 5
H2O 1
Acid Alcohol 0.25
H2O 5
Eosin 3
H2O 0.25
70% Ethanol 0.5
90% Ethanol 0.5
100% Ethanol 0.5
Xylene 2
Xylene 2
CV1 - Coverslip Auto
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2.8.2.5.2 Solution A 
10 g Hematoxylin crist. C.I.75290 was added to 1 L 95 % EtOH.  
 
2.8.2.5.3 Solution B 
12 g Ferric Chloride was added to 40 mL water and 10 mL Hydrochloric Acid. ddH2O was 
added to make a total volume of 1 L. 
 
2.8.2.5.4 Acid Fuchsin- Ponceau 
A working solution of acid fuchsin was made by adding 6 mL solution A and 2 mL solution B 
to 9 mL 2 % Acetic acid and 73 mL ddH2O.  
 
2.8.2.5.5 Solution A 
1 g Ponceau 2R was added to 100 mL ddH2O. 
 
2.8.2.5.6 Solution B 
1g Acid Fuchsin was added to 100 mL ddH2O. 
 
2.8.2.5.7 Phosphhotungstic-acid- Orange G 
3 g phosphotungstic acid and 2 g Orange G was added to 100 mL distilled water. 
 
2.8.2.5.8 Light Green 
1 g Light green was added to 1 mL Acetic acid and 500 mL ddH2O. 
 
32 
 
Table 2.7. Staining schedule for Goldner's Trichrome staining of 5 µm sections of paraffin embedded mouse lung. 
 
Stained slides were imaged using a Zeiss LSM 800 confocal microscope. 
Reagent
Immersion Time 
(Minutes)
Weigert's Haematoxylin 10
H2O 10
Acid Fuschin 15
1% Acetic Acid 2
PTA Orange 5
1% Acetic Acid 0.5
Fast Green 10
1% Acetic Acid 3
70% Ethanol 2
90% Ethanol 2
100% Ethanol 3
Xylene 5
Xylene 5
CV1 - Coverslip Auto
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2.9 Immunohistochemistry 
 
This protocol and stained slides were provided by Mr. Lorenzo Ramos-Mucci at the University 
of Liverpool. Paraffin embedded lungs were sectioned, and the slides provided to Mr. Ramos-
Mucci who carried out the antibody staining procedure detailed below. Stained slides were 
then imaged using a Zeiss LSM 800 confocal microscope. This protocol was adapted from DAB 
(Vector Labs, SK-4100), Avidin/Biotin blocking kit (Vector Labs, SP-2001), and Vectastain 
(Vector Labs, PK-6100). 
Slides were dewaxed following the protocol described in Table 2.5. A ring was drawn around 
each lung section using a Pap pen. For this staining protocol no antigen retrieval was 
required. Slides were washed twice at 5 min intervals in PBS-T prior to incubation in 3 % H2O2 
for 15 min at 37 °C. A second series of washes in PBS-T at 5 min intervals was followed by an 
Avidin/Biotin blocking kit: Avidin 15 min, Biotin 15 min. Blocking steps were carried out at 
room temperature. Slides were then washed for 5 minutes in PBS and blocked with -10 % 
goat serum in PBS - BSA (0.1% BSA) for 1 hour at room temperature. Following two further 
5-minute wash steps in PBS, primary antibody (Anti-CTGF Antibody (Abcam, ab6992)), PC, 
Rabbit) was added at 1/1000 dilution in PBS and incubated overnight at 4 °C. The following 
day slides were washed in PBS 3 times for 10 minutes before adding the secondary antibody 
(anti-rabbit diluted 1/200 in PBS) for 1 hour and incubating at room temperature. While 
slides were washed in PBS at 3 10-minute intervals, the Vectastain (1 mL PBS, 10 µL A, 10 µL 
B), was combined and stored in dark for 30 min prior to use. Slides were incubated in 
Vectastain for 30 minutes at room temperature. After two 5-minute washes with PBS, DAB 
(2.5 mL H2O, 1 drop buffer, 2 drops DAB, 1 drop H2O2) was added and slides were left for 
1 minute until colour developed. Slides were then washed with ddH2O, dehydrated using the 
ethanol concentration’s and timings outlined in Table 2.6.  
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2.10 Cell Culture  
 
The following protocol for the isolation of lung fibroblasts was developed by Mr. Michele 
Scotto di Masse at the University of Liverpool.  
 
A 1x solution of Hanks’ Balanced Salt Solution (HBSS) was prepared using the following 
reagents: 
 
 
A working solution of 1 mg/mL collagenase/HBSS solution was made by diluting 1 mL of 
100 mg solution of Collagenase Hystolyticum (Sigma Aldrich, C26474) in 9 mL HBSS. Mice 
were Sch1 by cervical dislocation and the lungs immediately isolated and suspended in ice 
cold PBS for transfer to a tissue culture hood. Using a sterile scalpel blade, lungs were 
transferred to a sterile petri dish and chopped until the tissue resembled a pulp. Chopped 
tissue was transferred to a sterile T25 flask. The petri dish was rinsed with the 
collagenase/HBSS solution and added to the lung pulp in the T25 flask. Tissue was incubated 
in a shaking water bath at 37 °C for 60 minutes, or until the tissue started forming sticky 
fibres. To break up clumps, the homogenate was pipetted against the inside of the flask using 
a 10 mL stripette, the homogenate was then filtered into a sterile 50 mL falcon tube using a 
0.44 µm filter. The sample was then centrifuged at 330 xg for 5 minutes. The supernatant 
was discarded, and the tissue pellet washed with 20 mL 1x HBSS. HBSS was removed from 
the pellet and discarded. The remaining tissue sample was centrifuged at 330 xg for 
5 minutes. Any residual supernatant was discarded. The tissue pellet was resuspended in 
5 mL warm DMEM, high glucose (supplemented with 10 % FBS, 5 mL L-Glutamine (200 mM) 
and 100 I.U/ penicillin and 100μg/mL streptomycin (Thermofisher, 10500064, 25030081, 
15140-122)). Cells were incubated in a tissue culture incubator for 4-5 days at 37 °C, 5 % CO2. 
Cultures were maintained in fully supplemented DMEM. 
Reagent
Volume required for 
1x HBSS solution 
(mL)
Hanks’ Balanced Salt Solution 10x (Sigma 
Aldrich, H1641) 100
Sodium bicarbonate solution (7.5%), sterile-
filtered, NaHCO3 (Sigma Aldrich, S8761)
4.7
Hepes Buffer (Sigma Aldrich, H0887) 10
Penicillin-Streptomycin (10,000 U/mL), 
(ThermoFisher Scientific, 15140122) 10
ddH2O 875.3
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2.10.1 4-Hydroxytamoxifen (4-OHT) treatment of cells 
 
To make a 10 mM stock of (Z)-4-Hydroxytamoxifen (4-OHT) (Sigma Aldrich, H7904-5MG), 
1.25 mL of 100% ethanol (Sigma Aldrich, 51976) was added to the 5 mg vial of 4-OHT. The 
stock solution was pipetted into 12 µL aliquots and stored at -20 °C until use. The 10 nM stock 
solution was serially diluted as follows to produce a 100 nM working solution for 4-OHT 
treatment of cells. 5 µL of stock solution was added to 495 µL of DMEM, high glucose 
(Thermofisher scientific, 11965092) to make a 100 µM solution. 20 µL of the 100 µM solution 
was added to 1980 µL DMEM, high glucose to make a 1 µM solution. 200 µL of the solution 
was added to 1800 µL DMEM, high glucose (supplemented with 10 % FBS and 100 I.U/ 
penicillin and 100μg/mL streptomycin) to make a 100 nM working solution. 2 mL of 100 nM 
solution were added to 6-well plates. Cells were incubated for 12 hr in 5 % CO2 at 37 °C. 
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3. Establishing the Bleomycin Model of Idiopathic 
Pulmonary Fibrosis 
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3.1 Animal models of disease 
 
Animal models are an essential tool for investigating the pathology and mechanisms of 
human disease. Although limited by their inability to encapsulate the full range of features 
present in human disease, they remain a useful means for examining key physiological traits 
and as a screening platform for candidate pharmaceutical molecules. The pathogenesis of 
IPF still remains controversial and elusive, with attempts to understand the scientific basis of 
the disease and identification of novel therapeutic targets relying predominantly on animal 
models.  
3.1.1 Animal models of IPF 
 
Spontaneous development of fibrosis has been observed in species such as cats, dogs and 
horses (Webb and Armstrong, 2002; Cohn et al., 2004; Williams et al., 2007). These cases are 
informative for comparative medicine however they are impractical for laboratory 
investigation. Therefore, research over the last few decades has predominantly focussed on 
development of murine models of IPF. Most frequently used are: radiation damage (Paun et 
al., 2010; Haston, 2012) and instillation  of a variety of molecules to the lung, including: silica 
(Barbarin et al., 2005; Lakatos et al., 2006; Roggli et al., 2010), Fluorescein isothiocyanate 
(FITC) (Roberts et al., 1995; Davis, Leslie and Hemenway, 1998; Moore et al., 2005), asbestos 
(Padilla-Carlin et al., 2011; Cyphert et al., 2012; Rasmussen and Pfau, 2012) and bleomycin 
(Ponticos et al., 2009; Egger et al., 2013; Scotton et al., 2013; Gilhodes et al., 2017). Of these 
models, bleomycin is perhaps the most widely used, and was the animal model employed to 
characterise the drugs currently available for treatment of IPF; Nintedanib and Pirfenidone 
(Schaefer et al., 2011; Wollin et al., 2014). 
3.1.2 Bleomycin model of IPF 
 
Bleomycin is a chemotherapeutic antibiotic isolated from the bacterium Streptomyces 
verticillus (Umezawa et al., 1967; Adamson, 1976). Fibrosis was noted as a major adverse 
effect when bleomycin was used for the treatment of human cancer. Subsequent animal 
trials characterised its ability to induce fibrosis in a number of species such as dogs 
(Fleischman et al., 1971), mice (Adamson and Bowden, 1974) and rats (Thrall et al., 1979). 
Different susceptibilities to bleomycin have been observed in the murine models, with CBA 
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and C57Bl/6 being the preferred strains of choice (Schrier, Kunkel and Phan, 1983; Phan and 
Kunkel, 1992).  
The therapeutic potency of bleomycin is attributed to its ability to induce single and double-
strand DNA breaks, which interrupts the progression of the cell cycle (Williamson, Sadofsky 
and Hart, 2015). This process has been described in detail in a number of publications (Lopez-
Larraza, De Luca and Bianchi, 1990; Sidik and Smerdon2, 1990; Smith, Bauer and Povirk, 1994; 
Chen et al., 2008) however the reason fibrosis occurs as a result of this process is still 
undetermined. It is hypothesised that an overproduction of reactive oxygen species (ROS) 
instigates an inflammatory response causing pulmonary toxicity, activation of fibroblasts and 
subsequent fibrosis due to a lack of the enzyme bleomycin hydrolase (Chaudhary, Schnapp 
and Park, 2006).  
Over recent decades several methods of instillation of bleomycin to the lungs have been 
trialled and the resulting fibrotic pathologies compared. These include subcutaneous (SC), 
intravenous (IV), intranasal (IN), intratracheal (IT) and oropharyngeal aspiration (OA) routes 
of administration (Lindenschmidt et al., 1986; Braun et al., 1996; Egger et al., 2013; 
Williamson, Sadofsky and Hart, 2015).    
For this research project, the OA method of administration was used as described by (Lakatos 
et al., 2006). Animals were anaesthetised using isoflurane, suspended by their incisors and 
forceps used to hold the tongue outside the mouth during administration. This process is 
shown in Figure 3. and described in more detail in methods section 2.2.2. As the animal 
regains consciousness from anaesthesia, a reflex inhalation occurs because of the restriction 
of the nose by the forceps, resulting in delivery of the bleomycin suspension to the lungs. 
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Figure 3.1. Method of oropharyngeal aspiration of bleomycin in mice. Image taken from (Lakatos et al., 2006). A, 
Anesthetized mouse is suspended by the cranial incisors on a thin rubber band. B, The tongue of the animal is held 
outside the mouth using forceps. C, The nose is pinched shut using forceps. The bleomycin suspension is pipetted 
into the back of the throat. A reflex inhalation occurs as the animal regains consciousness, delivering the bleomycin 
to the lungs. 
 
A B C
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3.2 Chapter Aims 
 
The aims of this chapter were as follows: 
1) Establish and characterise a model for bleomycin-induced IPF. 
The first objective was to reproduce the results previously described for the induction of a 
bleomycin induced fibrosis by the Bou-Gharios lab group. The second objective addressed 
the characterisation of this model. Lung tissue from this experiment was assessed using qPCR 
and histology to confirm the induction of fibrosis. 
2) Develop a dosing regimen for the administration of bleomycin. 
To address future requirements of inducible transgene activation using tamoxifen, a 
combined dosing regimen of tamoxifen followed by bleomycin was assessed for tolerance 
and adverse effects in the animals. Alternative doses of bleomycin were assessed for their 
ability to induce fibrosis up to 28 days following administration.  
3) Develop a method for the assessment of fibrosis in lung following administration of 
bleomycin. 
Bleomycin is known to induce variable responses between subjects. Therefore, there was a 
requirement for a method of analysis to be developed that enabled visualisation of the whole 
lung whereby samples of lung tissue could be subsequently used for histological and qPCR 
analysis. A second requirement for a quantitative assessment to be made from these whole 
analyses led to the development of an automated macro to assess the total x-ray attenuation 
value of the lungs.  
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3.3 Establishing the baseline response to bleomycin administration 
 
In order to establish the baseline response to bleomycin treatment in non-transgenic / wild 
type (WT) animals, an initial experiment was performed testing the bleomycin model of IPF 
using mixed background (B6CBA F1) male mice. Three combined treatment groups were 
examined:  
1) Oil then bleomycin, (O/B) 
2) Tamoxifen then PBS, (T/B) 
3) Tamoxifen then bleomycin, (T/B) 
Treatments were administered to animals as described in methods section 2.5.1.  
The transgenic animal models utilise a tamoxifen dependent CreERT2, therefore tamoxifen 
treatment was combined with bleomycin to account for any adverse effects that the 
combined therapy might induce. Oil was used as a vehicle for the tamoxifen and PBS as a 
vehicle for the bleomycin. Previous research by the Bou-Gharios lab group had established 
in-house protocols using a concentration of 0.025 mg bleomycin, with individual animals 
receiving a 50 µL dose in saline (Ponticos et al., 2009) and the same protocol was used in this 
experiment.  
Thirty-six mice were assigned to one of three treatment groups (4 animals per treatment, 3 
treatments) and timepoints (3 timepoints). Lungs were collected at days 7, 14 and 28 post 
bleomycin administration Tamoxifen / oil was administered following the dosing schedule 
outlined in the methods section 2.5.1. Bleomycin was subsequently administered using the 
oropharyngeal aspiration method outlined in Figure 3.1.   
Animals were treated as described in methods sections 2.5.1.1 and 2.5.2.As timepoints of 7, 
14 and 21 days post bleomycin were reported by Ponticos et al., (2009), and survival up to 
84 days has previously been reported for this model (Scotton et al., 2013), adverse effects 
were not anticipated.  
One animal was culled due to ill health following I.P. injection of oil (treatment group 7 days 
O/B). This was considered unrelated to the treatment as all remaining animals receiving oil 
or tamoxifen displayed no adverse response. Adverse events occurred around day 10 with 
one animal being found dead in cage (D.I.C) and two more animals appeared moribund, with 
piloerection and hunching and were therefore culled. Assessment of the mice during the 
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24 hr period prior had not raised any concerns over ill health. All three animals belonged to 
the O/B treatment group. Three of the four remaining animals receiving the same treatment 
(O/B) survived to the final timepoint of 28 days. Around day 16 four more animals exhibited 
signs of ill health and were culled. Two were treated with T/P and two with T/B. As with the 
previously culled animals, no signs of ill health were noted in the 24-hr period prior to culling. 
During the study an overall mortality rate of 25 % was observed with 15% attributed to the 
O/B treatment group and 5% from both the T/P and T/B treatment groups. Animals that 
experienced weight loss exceeding 20 % of their start weight and/or exhibited signs of illness 
(hunching, piloerection), and were culled via cervical dislocation at earlier time points to 
negate a breach of Home Office licence conditions. Lungs were collected from the culled 
animals and the left lobe isolated for histological analysis. The remaining lobes were snap 
frozen and analysed by qPCR for the expression of collagen I, using the COL11α2 gene as a 
readout.  
The sections taken for histology enabled visualisation of the extent of fibrosis that had 
formed at each time point (Figure 3.2, (A – I)). At 7 days the O/B treatment group showed 
early fibrotic foci formation particularly surrounding the blood vessels and bronchioles (A, 
black arrows). The tamoxifen and PBS treatment exhibited a more widespread thickening of 
the epithelial lining of the alveoli (Figure 3.2 B, black arrows) predominantly in the area 
immediately surrounding the bronchioles. The tamoxifen and bleomycin treatment showed 
widespread and established tissue deposits throughout the section (Figure 3.2 C, black 
arrows). The lungs collected from O/T and T/P treated mice (Figure 3.2, A - B) still retained 
some regions of normal lung morphology, for example the individual alveoli could still be 
identified, and blood vessels were easily distinguishable from the surrounding tissue. In T/B 
treated mice the main anatomical feature that could be identified was the bronchioles. Most 
of the structural integrity of the alveoli in these animals was lost or unrecognisable. By 14 
days all animals displayed increased levels of immune infiltrates, as was apparent by the 
increase in haematoxylin stained nuclei (Figure 3.2, D – I), however this staining was present 
in all sections and was particularly obvious in tissue surrounding the airways.  O/B treated 
animals (Figure 3.2, D) demonstrated thickening of the alveolar epithelium which was 
comparable to that seen in T/P treated lungs at 7 Days (Figure 3.2, B), whereas T/P (Figure 
3.2, E) and T/B (Figure 3.2, F) treated lungs showed increased similarity in morphology to T/B 
at 7 Days (Figure 3.2, C). The tissue deposition was more widespread, and the alveoli were 
more difficult to identify. At 28 days, all groups showed a decrease in fibrosis, with a 
reduction in infiltrate presence when compared to the same treatment at 14 days. O/B 
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treated lungs demonstrated comparable levels of fibrosis to the same treatment at 7 days 
(Figure 3.2, A & G).  
In lung sections from both T/P and T/B groups, there was an increased instance of alveoli that 
retained somewhat normal morphology when compared to the 14-day treatment 
counterparts. 
The qPCR analysis on the remaining lobes of the lungs examined the levels of COL1α2 gene 
as a readout of collagen I synthesis. Sample cycle threshold (Ct) values were normalised to 
untreated animals of the same background and are expressed as a fold change using the ∆∆Ct 
method. Significance was determined using a one-way ANOVA, and Tukey’s post hoc test. At 
7 days the T/P treatment was the only group to show a significant increase in COL1α2 
transcript (Figure 3.2, J) with a mean ∆∆Ct of 3.46 (s.e.=0.9). The mean ∆∆Ct values for O/B 
and T/B treated lungs was 0.98 (s.e.=0.24) and 1.03 (s.e.=0.17) respectively.  At 14 days the 
O/B and T/P ∆∆Ct values weren’t significantly different for the O/B and T/P groups, mean 
1.21 (s.e.=0), 1.06 (s.e.=0.07) respectively (Figure 3.2, K). Whereas the T/B treatment 
averaged a ∆∆Ct of 2.41 (s.e.=1.03). Finally, at 28 days the T/P group failed to reach 
significance; 1.39 (s.e.=0.61) whereas both the O/B and T/B groups showed increased 
transcription of the COL1α2 gene with mean ∆∆Ct values of 2.11 (s.e.=0.42) and 1.75 
(s.e.=0.14) (Figure 3.2, L). At each time point. a different treatment group displayed the 
largest increase in expression fold change; 7 days was the T/P group, followed by T/B at 14 
days and O/B at 28 days.  
The variation in these results highlighted the importance of assessing the extent of fibrosis 
in the entire lung. For this experiment, individual lobes were only able to be analysed for 
either histology or qPCR. It was not possible to confirm whether the histological data was 
representative of the entire lung and by extension it cannot be determined whether the qPCR 
results were accurate for the remaining lobes. Oropharyngeal aspiration of bleomycin is a 
notoriously variable model, with the potential to see a different effect on each lobe within 
the lung. It was therefore decided to adopt a method that would enable the assessment of 
the extent of fibrosis in the whole lung, prior to further analysis.  
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Figure 3.2. Histological evaluation and qPCR analysis of lung samples taken from B6CBA WT mice. Lungs were collected at 7 (J), 14 (K) and 28 (L) Days following treatment with 
tamoxifen and bleomycin or vehicle treatment. Images A – I are representative histology sections collected at designated time points from each treatment group. Lung lobes were 
processed for wax histology and stained with H&E. Anatomical features are identified as follows: a- alveoli, br-bronchioles, v-blood vessels. Black arrows indicate regions of fibrosis. 
Scale bars represent 200 µm. Graphs J – L represent qPCR analysis for the Col1α2 gene. ∆∆Ct fold change results are plotted, significance was determined using a one-way ANOVA, 
and Tukey’s post hoc test.
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3.4 Micro computed tomography (µCt) analysis of the lungs 
 
3.4.1 Chemical dehydration and scanning of the lung 
 
Following a discussion with Professor Rob Van ‘T Hof at the University of Liverpool, it was 
decided to utilise the Bruker Skyscan 1272 ex-vivo µCT scanner and a protocol developed at 
Edinburgh University to examine the lungs of the mice. Whole lungs were isolated from 
healthy adult mice, dehydrated and scanned at 13 µm resolution, following the protocol 
outlined in methods section 2.6.2. Example images from the resulting scans are shown in 
Figure 3.3.  
The first whole lung scan was performed using a healthy control animal to ensure that 
anatomical features would be identifiable in a lung with no morphological defects. Individual 
2D images from the same region in the 3D reconstruction can be seen from the X, Y and Z 
planes (red, green and blue boxes respectively; Figure 3.3, A). Tissue is identified by 
differential shades of grey, depending on its x-ray attenuation capabilities, i.e. denser tissue 
is represented in a darker shade of grey.  The coloured lines indicate the location of the 2D 
scan images in relation to their position in the 3D reconstruction. Images in DataViewer 
software are displayed as shown in Figure 3.3, A & C. A more detailed image can be viewed 
at full resolution by looking at individual planes as shown in Figure 3.3, B & D. All scans can 
be viewed as part of the 3D reconstruction as in Figure 3.3 or can be accessed individually.  
Using the 3-plane view of the control scan we were able to identify key anatomical features 
of the lung including the trachea, bronchioles, and heart (Figure 3.3, A). At a higher resolution 
(Figure 3.3, B) we were then able to identify smaller features such as the blood vessels and 
the alveoli, where the grey outlines within the gross structure of the lung is staining of the 
epithelial lining of the alveoli by hexamethyldisilazane (HMDS).  
The next step was to determine if regions of fibrosis could be identified using the same 
protocol. A single dose of bleomycin was administered to a WT (B6CBA F1) mouse, as per the 
previous protocol and the lungs collected 14 days later for processing and scanning. As with 
the control lung, it was possible to identify the same key anatomical features of the lung 
using the 3-plane view (Figure 3.3, C). Dense regions were also identified which we 
hypothesised to be fibrotic scar tissue deposits (indicated by the black arrows). At a higher 
resolution (Figure 3.3, D) the structure of the alveoli could be identified in regions of normal 
tissue morphology but not in fibrotic regions.    
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The limitation of the scanning protocol was that RNA was unable to be extracted from the 
samples after the processing and scanning was complete. The aims of the project were to 
examine the effects of CCN2 removal on the bleomycin model of IPF both at the phenotypic 
and genetic level. Therefore, a method of scanning the lungs was required that resulted in a 
comparable level of morphological detail achieved by these scans, without the requirement 
for chemical dehydration. 
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Figure 3.3. µCT scans of chemically dehydrated mouse lungs. Representative X, Y and Z plane images (red box, green box and blue box respectively) from a control mouse (A & B) and 
from a bleomycin treated mouse collected at 14 days following a single 0.025 mg dose in 50 µL PBS (C & D). Coloured lines indicate the location of the 2D scan images in relation to 
their position in the 3D reconstruction. Lungs were scanned using a SkyScan 1272 µCT system at a resolution of 13 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Images were 
reconstructed using Skyscan Nrecon software and visualised using DataViewer. Images shown are single representative sections from individual mice. A & C show the example view 
when analysing the scans in DataViewer software. B & D represent full size resulution of each scan image. Anatomical features are identified by the following: tr- trachea, br- 
bronchioles, He- heart, v- blood vessels, a- alveoli and black arrows indicate fibrotic regions.
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3.4.2 Inflated and suspended scanning of unfixed lungs 
 
A protocol was developed, which utilised the contrast in x-ray attenuation capabilities of a 
liquid compared with air. Lungs were manually inflated, isolated and suspended in PBS for 
the duration of the µCT scan. A lower resolution of 20 µm was used to reduce the total time 
required for the scan to approximately 13 minutes, and this allowed for isolation of a lobe 
for histology and snap freezing of the remaining lung tissue in liquid nitrogen for RNA 
isolation and gene expression analysis. 
Representative 2D images from a single scan performed using a healthy control mouse are 
shown in Figure 3.4. The same images, Figure 3.4, A – C, in the X, Y and Z planes (red, green 
and blue boxes respectively) are repeated in D – F with an added outline to clarify the location 
of the lung in the PBS. The coloured lines indicate the location of the 2D scan images in 
relation to their position in the 3D reconstruction.  Performing this experiment highlighted 
several issues. The first was the lungs floated to the top of the bijou. The depth of the scanner 
is limited, making it difficult to capture the whole lung inside the field of view for analysis. It 
also meant that the bijou needed to be completely filled to maintain an equal contrast field 
surrounding the lung. Thirdly the x-ray attenuation capability of the tissue was not 
substantially different to the PBS. A relatively obvious difference in the greyscale value of the 
air compared to the other constituents (light grey/white regions) is seen in Figure 3.4 
However, the tissue and PBS resulted in very similar greyscale values, which would be difficult 
to distinguish between in future analysis of the scans when assessing the extent of tissue 
fibrosis (Figure 3.4, A – C).   
From these scans only the gross structures of the trachea, bronchioles and heart were able 
to be identified. Finer details such as the alveoli and blood vessels seen in Figure 3.2, were 
unable to be identified.  This may in part be due to the level of inflation in the lung, a better 
inflation would have increased the contrast between the air, tissue and surrounding PBS. 
However, it was concluded that the density of the PBS did not produce sufficient contrast to 
the tissue and alternative solutions in which to suspend the lungs were sought. It was also 
decided to explore alternative methods of suspending and immobilising the lungs at the 
centre of the tube to prevent them floating to the top of the bijou, as well as reducing 
movement artefacts and subsequent loss of detail during the scans.   
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Figure 3.4. µCT scan images of unfixed, inflated mouse lungs suspended in PBS. Representative X, Y and Z plane images (red box, green box and blue box respectively) are shown. 
Lungs were isolated from a healthy adult control animal immediately after Sch1 by anaesthetic overdose and manually inflated prior to extraction. Isolated lungs were then suspended 
in PBS for µCT scanning. Lungs were scanned using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Images were reconstructed 
using Skyscan Nrecon software and visualised using DataViewer. Images shown are single representative sections from a single mouse. Anatomical features are identified by the 
following: tr- trachea, br- bronchioles, He- heart. A – C are the images as seen, D – F emphasise the outline of the lung and heart, identified by the dotted line. 
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3.4.3 Investigating the effects of adding different concentrations of KI to the PBS 
suspension for µCT scanning of unfixed lungs 
 
To increase the x-ray attenuation capability and subsequently increase the greyscale value of 
the suspension agent, candidate molecules to add to the PBS that would have a minimal 
effect on the lung tissue were investigated. The first candidate molecule was potassium 
iodide (KI). KI has been used in medicine and as a dietary supplement since the 1820’s and 
has been identified by the WHO as one of the safest medicines available (Oriel, 1994; WHO, 
2015). It is highly soluble in water, which suited the purpose of the experiment as a contrast 
agent. The effect of adding different concentrations of KI to PBS was investigated. We tested 
concentrations of 1, 3, 5, 7 and 10 % (wt / vol) (0.06 M, 0.18 M, 0.30 M, 0.42 M and 0.60 M 
respectively) KI and suspended the lungs between Styrofoam cubes to immobilise them to 
the centre of the bijou.  
Adding 1 % (wt / vol) KI, failed to demonstrate any significant difference in greyscale value 
(Figure 3.5, A), when compared to the scans in PBS (Figure 3.4). However, the improvement 
in inflation and immobilisation of the lungs did show a marked improvement in the quality of 
the scan.  At 3 %, even with the decrease in inflation of the lung, there was a clearer 
distinction in the contrast between the lung tissue and the contrast agent, particularly with 
identification of the heart (He, Figure 3.5, B). This was also seen in the 5 % (wt / vol) KI scan 
(Figure 3.5, C) as the outline of the lung was still clearly visible, even with the movement 
distortion of the image. There was no further change in greyscale value when the 
concentration of KI was increased to 7 and 10 % (wt /vol) KI (Figure 3.5, D & E). When 
compared to the results using 5 % (wt /vol) KI (Figure 3.5, C) there was no further 
improvement in contrast when increased concentrations of KI were used.  
Based on these results we decided that future scans of unfixed lungs would use a 
concentration of 3 – 5 % (wt /vol) KI suspended in PBS and suspended between Styrofoam 
blocks. 
3.4.4 Scanning of inflated, unfixed lungs using 3 – 5 % KI contrast agent 
 
Using these parameters, the lungs of two healthy adult mice were scanned; one male and 
one female, with a view to adopting this method of scanning for future experiments using 
the transgenic animal strains.  Representative images in the X and Y viewing planes from 
lungs isolated from a female (Figure 3.6, A – H) and a male (Figure 3.6, I – P) healthy, 
54 
 
untreated adult mouse are shown in Figure 3.6. Images were collated from different regions 
of the 3D scan and anatomical features are identified using the previously described notation.  
In these scans, the lung could easily be identified within the contrast agent (light 
grey / white), and there was a distinct difference in the greyscale value of the tissue within 
the lung when compared to the surrounding KI. The inflation of the lung and resolution of 
the scan was sufficient to enable us to identify normal alveolar structure from these scans to 
a level of detail comparable to Figure 3.2.  
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Figure 3.5. µCT scans of unfixed, inflated mouse lungs suspended in different concentrations of KI contrast agent. Single images are shown for 1, 3, 5, 7 and 10 % (wt / vol) KI contrast 
agent (A – E respectively). Lungs were isolated from a healthy adult control animal immediately after Sch1 by anaesthetic overdose and manually inflated prior to extraction. Isolated 
lungs were then suspended between pieces of Styrofoam (sf) for µCT scanning. Lungs were scanned using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium 
filter, 0.3 ° rotation step). Images were reconstructed using Skyscan Nrecon software and visualised using DataViewer. Anatomical features are identified by the following: tr- trachea, 
br- bronchioles, He- heart.  
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Figure 3.6. µCT scans of unfixed, inflated mouse lungs isolated from healthy control animals and suspended in 3 – 5 % (wt / vol) KI contrast agent. A series of images from a single 
scan are shown in the X (E - H, M - P) and Y (A - D, I - L) plane of view using DataViewer software. Lungs were isolated from a healthy adult control Female (A - H) and Male (I - P) 
mouse immediately after Sch1 by anaesthetic overdose and manually inflated prior to extraction. Isolated lungs were then suspended between pieces of Styrofoam (sf) for µCT 
scanning. Lungs were scanned using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Images were reconstructed using Skyscan 
Nrecon software and visualised using DataViewer. Anatomical features are identified by the following: tr- trachea, br- bronchioles, He- heart. 
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3.5 Establishing a reproducible model of fibrosis 
 
Following the mortality rate and instance of adverse events during the WT study, the 
treatment schedules described for bleomycin models of IPF in recent literature were 
reassessed. The aim was to identify a bleomycin dose, which would result in sufficient fibrosis 
to be visualised using the µCT scanning technique but induce a less severe response in the 
animals. The results of this literature search are presented in Table 3.1.  
When comparing the dose of 0.25 mg per mouse used in the initial experiment (section 2.5.2) 
with the published literature it was confirmed that a concentration comparable to other 
research groups had been used. However, it was decided to undertake a dose response 
experiment using lower concentrations of bleomycin. The following concentrations of 
bleomycin in PBS were prepared: 0.025 mg/mL, 0.5 mg/mL, 0.1 mg/mL and 0.2 mg/mL 
trialled and delivered at a volume of 2.5 µL per whole gram of weight. The resulting doses of 
bleomycin received by each group were: 0.0625 ng/g, 0.125 ng/g, 0.25 ng/g and 0.5 ng/g. 
Lungs were examined for signs of fibrosis at 28 days post bleomycin administration using the 
µCT scanning protocol established and described in section 2.6. Three WT mice were assigned 
to each concentration of bleomycin, representative scans of each group are shown in Figure 
3.7. At 28 days mice treated with 0.0625 ng/g and 0.125 ng/g showed no signs of fibrosis 
(Figure 3.7, A & E, B & F). Animals dosed with 0.25 ng/g showed some signs of fibrosis with a 
thickened alveolar lining indicated by red arrows (Figure 3.7, C & G), whereas animals 
receiving 0.5 mg/g showed extensive fibrosis throughout the lung (red arrows, Figure 3.7, 
D & H). All animals survived for the duration of the experiment and no adverse reactions 
were observed.  
For the experiments researching the fibrotic effects in transgenic animals, investigation of 
three timepoints; 7, 14 and 28 days were planned. Therefore, based on these dose-response 
results it was decided to trial a dose of 0.375 ng/g of bleomycin. It was hypothesised that a 
slightly higher concentration than 0.25 ng/g would result in a fibrotic phenotype more 
extensive than that seen in Figure 3., C & G, but less than 0.5 ng/g (Figure 3.7, D & H) without 
the severe response in the animals and risk losing the later timepoints due to illness. Three 
mice were treated as previously described in methods section 2.5.2, with a single dose of 
0.375 ng/g bleomycin in PBS and the lungs were collected for analysis at 14 days. 
The µCT scans exhibited a good extent of fibrosis present in the lung by 14 days in each of 
the subject animals (Figure 3.8, red arrows). A good distribution of the fibrosis throughout 
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the lung was able to be identified. The pairs of scan images in Figure 3.8, (A - C) represent 
individual animals, with each scan representing a different depth of the lung. All pairs of 
images show regions of fibrosis (red arrows), indicating that the fibrosis had extended 
throughout the lung and not just remained in the superficial regions surrounding the main 
airways. As with the scans in the previous dose-response experiment, we were able to 
distinguish not only the lung from the KI contrast agent, but the key anatomical features of 
the lungs including the trachea, heart and bronchioles.  
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Table 3.1. Literature search results for bleomycin treatment of mice and associated parameters for consideration during treatment. 
Animal Age Sec Bleomycin Dose 
Volume Administered 
& vehicle 
Number of 
Administrations 
Sample time 
points 
Reported Mortality Reference 
7 - 9 weeks Male 
0.1 - 0.25 - 0.5 
mg/kg 
40 µl saline 6 x once daily 7, 14, 21, 28 
40 % at 0.5 mg/kg – 
20 % weight loss (Egger et al., 2013) 
8 - 10 weeks Male 
0.05 mg/mouse (50 
IU / mouse) 
50 µl saline 1 
3, 7, 10, 14, 21, 
28, 84, 168 
- (Scotton et al., 2013) 
8 - 10 weeks Male 1 - 2 mg/kg 50 µl saline 1 7, 10, 14 
50 % saline, 33.3 % 
bleomycin 
(Scotton et al., 2009) 
 Male 1.25-2.5 mg/kg 50 µl saline 1 7, 14, 21 - (Tsukui et al., 2013) 
6 - 7 weeks Male 0.055 mg 50 µl saline 1 3, 7, 14 - (Moshai et al., 2014) 
6 - 7 weeks Male 0.055 mg 50 µl saline 1 3, 7, 14 - 
(Bantsimba-
Malanda et al., 
2010) 
- - 
0.08 mg (0.08 
units) 
intratracheal injection 1  - (Tanjore et al., 2009) 
- - 
0.04, 0.06, 0.08 
units 
intratracheal injection 1 7, 14, 21, 28 - (Lawson et al., 2005) 
6 - 7 weeks Male 5 & 10 mg/kg 
50 µl saline 
intratracheal injection 
1 21 
at 10 mg/kg 20 % 
mice survived to day 
17 
(Y. Wang et al., 
2015) 
7 - 8 weeks Male 5 mg/kg PBS 1 3, 7, 14, 28 - (Dong et al., 2015) 
10 weeks Male 
3 mg/kg (3 
units/kg) 
50 µl saline 1 3, 8, 15, 21 - (Guo et al., 2015) 
8 weeks Male 1.5 mg/kg 50 µl saline 1 7,21 days - (Lan et al., 2015) 
20 weeks Male 80 mg/kg 200 µl saline tail vein 1 14, 21, 28 days - (Ni et al., 2015) 
20 - 22 g - 2 mg/kg - 1 28 days 65 % dead by 28 days 
(X. Wang et al., 
2015) 
8 - 10 weeks Female 
2.5 mg / body 
weight 
saline continuously via 
pump 
7 days continuously 7, 14, 28 days - (Yatomi et al., 2015) 
5-9 weeks Female 0.12 units 50 µl saline 1 7, 14, 21 days - 
(Ponticos et al., 
2009) 
8 weeks Female 
1.25 mg/kg (1.25 
units/kg) 
- 1 21 days - 
(Kurundkar et al., 
2016) 
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Figure 3.7. X and Y plane views of µCT scans of inflated mouse lungs treated with different concentrations of bleomycin and collected 28 days post administration. Lungs were isolated 
immediately after Sch1 by anaesthetic overdose and manually inflated prior to extraction. Isolated lungs were then suspended in 5 % KI, between pieces of Styrofoam (sf) for µCT 
scanning. Lungs were scanned using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Images were reconstructed using Skyscan 
Nrecon software and visualised using DataViewer. Anatomical features are identified by the following: br- bronchioles, He- heart. Air bubbles in the scan are denoted by ab. Red 
arrows indicate fibrotic regions within the lungs. Pairs of images were taken from animals treated with the associated concentration of bleomycin: A & E: 0.0625 ng/g, B&F: 0.125 ng/g, 
C & G: 0.25 ng/g, D & H: 0.5 ng/g. Images A - D are taken in the Y-field of view, E - H are taken in the X-field of view. 
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Figure 3.8. µCT scans of unfixed, inflated mouse lungs isolated at 14 days from mice treated with 0.375 ng/g bleomycin in PBS. Lungs were isolated immediately after Sch1 by 
anaesthetic overdose and manually inflated prior to extraction and suspension in 5 % KI. Lungs were scanned using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm 
aluminium filter, 0.3 ° rotation step). Images were reconstructed using Skyscan Nrecon software and visualised using DataViewer. Anatomical features are identified by the following: 
tr- trachea, br- bronchioles, He- heart. Air bubbles in the scan are denoted by ab. Red arrows indicate fibrotic regions within the lungs. Pairs of images were taken from the same 
animal. A - C each represent a different mouse. 
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3.6 Macro analysis of the µCT scan 
 
Whilst the µCT images provided qualitative data into the extent of fibrosis in the lungs, the 
interpretation of the extent of fibrosis in one lung compared to another was dependent on 
the researcher examining the scans. There was a need to assign an independent, quantitative 
value to the scanned lungs to increase the reliability in the data when interpreting the effects 
of CCN2 removal in the transgenic animals. Professor Van ‘T Hof developed a macro using 
the CtAN software that was able to analyse the greyscale (x-ray attenuation) values of each 
pixel within the designated region of the scan and assign an overall average greyscale value 
to the dataset (see appendices).    
The macro was designed to assign a greyscale value between 0 – 255 to every pixel, where 
air is white or 0 and black is 255. The frequency of each of these values was then totalled to 
give an overall average x-ray attenuation (greyscale) value. Numbers of pixels assigned each 
grey value were presented as histograms (Figure 3.9), where the percentage frequency of 
each greyscale value is plotted against the assigned grey value. In control lungs (Figure 3.9, 
A & B) the average grey value assigned to female and male lungs was 64.6 and 65.6 
respectively. The distribution is skewed to the left with an initial peak readout at 0, and a 
second around 60 - 70. In bleomycin treated lungs a shift to the right in both female and male 
animals (Figure 3.9, C & D) was seen, indicating an increase in pixels with a greater x-ray 
attenuation value, with mean average grey values of 120 and 83 (Figure 3.9, C & D 
respectively). The peak readout at 0 remained present in both bleomycin treated lungs, 
however the grey values in bleomycin treated lungs were more evenly distributed across the 
higher grey values (Figure 3.9, C & D) when compared to the bell curve pattern seen with a 
clear peak in the control lungs (Figure 3.9, A & B).   
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Figure 3.9. Percentage frequency histograms of pixel density calculated using an x-ray attenuation value macro in CtAN software. Histograms were generated using the readouts from 
female (A & C) and male (B & D) lungs isolated from untreated animals (A & B) and lungs isolated at 14 days from animals treated with 0.375 ng/g bleomycin (C & D). Lungs were 
scanned using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Images were reconstructed using Skyscan Nrecon software and 
analysed using CtAN software.   
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3.7 Histological analysis of lungs 
 
To confirm the dense regions in the lung identified in the µCT scans were in fact fibrosis a 
lobe from experimental lungs was isolated and processed for histology following the protocol 
described in methods section 2.8. Sections of 5 µm were stained with H & E, or Goldner’s 
trichrome stains. Protocols can be found in methods section 2.8. 
H & E stain was used to identify anatomical features of the lung including the bronchioles, 
alveoli and blood vessels as well as fibrotic regions of tissue (black arrows). A stitched image 
taken at 10 x magnification was used to visually assess the level of fibrosis present in the 
whole lung section (Figure 3.10, A & B), where scale bars represent 1 mm. For closer analysis 
of the morphology of the lung, individual images were taken at 10x magnification 
(Figure 3.10, C - F), scale bars represent 500 µm.  
In untreated control lungs the single cell epithelial lining of the alveoli can be seen clearly at 
10x magnification (Figure 3.10, C & D).  Blood vessels can be seen associated with the 
bronchioles, as well as being dispersed throughout the alveoli (Figure 3.10, C & D). The 
morphology demonstrated in Figure 3.10 is consistent with the reported literature for 
healthy murine lungs. In lungs treated with bleomycin (Figure 3.10; B, E & F) dense regions 
of tissue fibrosis are indicated by black arrows. Examination of the whole stitch image 
(Figure 3.10 B) showed these fibrotic regions to be generally localised to the immediate area 
surrounding the bronchioles. Closer examination of individual sections (Figure 3.10, E & F) 
showed increased nuclear staining of the immune infiltrates that are characteristic of the 
bleomycin model of fibrosis. In regions of fibrosis fewer alveoli are visible with a marked 
thickening of the epithelial lining. Blood vessels remain dispersed in a comparable fashion to 
control lungs and are present within regions of fibrosis and associated with bronchioles 
(Figure 3.10, E).  
Goldner’s trichrome stain was used to identify collagen deposits from muscular tissues. Cell 
nuclei appear black, cytoplasm - red and collagen - green. A stitched image taken at 10 x 
magnification was used to visually assess the presence of collagen across in the whole lung 
section (Figure 3.11, A & B), where scale bars represent 1 mm. For closer analysis of the 
morphology of the lung, individual images were taken at 10x magnification (Figure 3.11, 
C - F), scale bars represent 500 µm. Anatomical features of the lung are identified in the figure 
as: bronchioles, alveoli and blood vessels, fibrotic regions of tissue are indicated by black 
arrows.  
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Collagen is a major constituent of the pulmonary interstitium and major structures including 
the bronchioles, blood vessels alveoli and bronchioles. Therefore, green staining of these 
structures was anticipated and seen in both control and bleomycin treated lungs (Figure 3.11, 
A - F). Red staining inside bronchioles demonstrates the presence of the epithelial cells lining 
these structures. A reduction of this staining was seen in the bronchioles of bleomycin 
treated animals when examined at a higher magnification (Figure 3.11, E & F) when 
compared to images taken at the same magnification from healthy control animals (Figure 
3.11, C & D). An increase in nuclear staining was seen in the fibrotic region of bleomycin 
treated lungs (Figure 3.11, E). This is characteristic of the immune infiltrates identified in the 
bleomycin model of fibrosis, which are not present in the lungs of control animals (Figure 
3.11, C & D), or in regions where fibrosis is not present in bleomycin treated lungs (Figure 
3.11, F). The structure of the alveoli is not identifiable in (Figure 3.11, E) the comprehensive 
green staining of the tissue indicates widespread deposits of collagen, with the only 
determinable features being bronchioles and blood vessels. 
Assessment of µCT scans with these subsequent histological analyses confirmed that dense 
regions apparent on µCT scans (Figure 3.8) were synonymous with tissue deposits when 
stained with H & E (Figure 3.10) and that these deposits consisted of collagen (Figure 3.11). 
Histological analysis allowed for analysis of the structural changes occurring at the alveolar 
level, which was not possible to ascertain when analysing the µCT scan. Larger structures 
such as bronchioles could be identified by both analyses and therefore be used to identify 
the same region from a µCT scan on a slide.
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Figure 3.10. Histological evaluation of lung samples after µCT scan using H & E stain. Lungs were isolated immediately after Sch1 by anaesthetic overdose and manually inflated for 
scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Lungs were processed for wax histology and stained with H & E. 
Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels. Black arrows indicate regions of fibrosis. A, Whole lung stitch of control lungs taken at 10x 
magnification. B, Whole lung stitch of bleomycin treated lungs taken at 10x magnification. Scale bars represent 1 mm. C & D, Single images at 10x magnification of control lungs. 
E & F, Single images at 10x magnification images of bleomycin treated lungs. Scale bars represent 500 µm. 
70 
 
71 
 
72 
 
 
Figure 3.11. Histological evaluation of lung samples after µCT scan using Goldner’s trichrome. Lungs were isolated immediately after Sch1 by anaesthetic overdose and manually 
inflated for scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Lungs were processed for wax histology and stained 
with Goldner’s trichrome. Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels. Black arrows indicate regions of fibrosis. A, Whole lung stitch of 
control lungs taken at 10x magnification. B, Whole lung stitch of bleomycin treated lungs taken at 10x magnification. Scale bars represent 1 mm. C & D, Single images at 10x 
magnification of control lungs. E & F, Single images at 10x magnification images of bleomycin treated lungs. Scale bars represent 500 µm. 
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3.8 Discussion 
 
This chapter presents the first original data on the establishment of a murine model of IPF at 
the University of Liverpool, using oropharyngeal aspiration of bleomycin. A novel protocol 
for ex-vivo µCT scanning and method of analysis is described for unfixed whole mouse lungs. 
The bleomycin model is widely described in literature and lab groups globally report in-house 
protocols for establishing a reproducible fibrosis with which to test candidate molecules or 
interventions in the wider context of pulmonary fibrosis (Ponticos et al., 2009; Egger et al., 
2013; Scotton et al., 2013; Gilhodes et al., 2017). This research was unsuccessful in an 
attempt to reproduce a previously established protocol (Ponticos et al., 2009). An 
unanticipated severity of responses meant animals were culled prior to reaching designated 
experimental timepoints and the overall mortality rate of the study was not acceptable under 
local severity limits and Home Office licence conditions. An alternative protocol was 
developed using a lower dose of bleomycin. This was well tolerated by the mice and the data 
in this chapter confirms that this dosing regime was reproducible and produced an 
established fibrosis.  
3.8.1 Establishing a baseline response to bleomycin 
 
The first study in this chapter used thirty-six mixed background (B6CBA F1) male mice aged 
7 weeks to establish the baseline response to bleomycin when administered via OA 7 days 
after a series of I.P. injections of tamoxifen. Research described in chapters 4 and 5 of this 
thesis utilised a tamoxifen dependent CreERT2, therefore it was necessary to determine the 
response to the combined therapy to account for potential adverse effects that might arise 
and would otherwise be masked if bleomycin was administered as a single treatment.  
As timepoints of 7, 14 and 21 days post bleomycin were reported by Ponticos et al., (2009), 
and survival up to 84 days has previously been reported for this model (Scotton et al., 2013), 
adverse effects were not anticipated.  
One animal was culled due to ill health following I.P. injection of oil (treatment group 7 days 
O/B). This was considered unrelated to the treatment as all remaining animals receiving oil 
or tamoxifen displayed no adverse response. Adverse events occurred around day 10 with 
one animal being found dead in cage (D.I.C) and two more animals appeared moribund, with 
piloerection and hunching and were therefore culled. This was surprising as assessment of 
the mice during the 24-hr period prior had not raised any concerns over ill health. All three 
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animals belonged to the O/B treatment group. Three of the four remaining animals receiving 
the same treatment (O/B) survived to the final timepoint of 28 days. Around day 16 four 
more animals exhibited signs of ill health and were culled. Two were treated with T/P and 
two with T/B. As with the previously culled animals, no signs of ill health were noted in the 
24-hr period prior to culling. An increased mortality at earlier time points was associated with 
the oil vehicle treatment. Although there was no obvious explanation as to why, when 
animals receiving tamoxifen suspended in the same vehicle did not demonstrate comparable 
mortality. Recent research into the effects of corn oil and sustained tamoxifen treatment for 
inducible transgenic models have reported conflicting evidence into the adverse effects seen. 
Liu et al., (2018) report effects on fat and glucose metabolism, where animals display fat 
associated weight loss that is independent of activity and food intake, starting at 5 days 
following the initial administration of corn oil and persisting for up to 12 weeks. Whereas 
Hubbard, Chen, & Boyd, (2017) observed no effect on body weight when comparing 
pharmaceutical-grade corn oil with non-pharmaceutical grade corn oil and PBS. This 
experiment used a tamoxifen concentration half that described by Liu et al., (2018), and 
administered 40 % less volume. Furthermore, the onset of weight loss appeared in a far 
shorter time frame and to a much greater degree than reported therefore it is to unlikely 
that the adverse effects seen in this study are unlikely to result from alterations to 
metabolism.  
Interestingly, the extent of fibrosis in the O/B treatment is the most morphologically similar 
to the progression described in the literature (Izbicki et al., 2002) when based on the 
histological pathology. Typical development of fibrosis shows activation of the immune 
system around day 3 following bleomycin instillation, followed by formation of early fibrotic 
foci around day 7, and established regions of fibrosis by day 14. Resolution of this fibrosis 
usually begins around day 21 and by day 28 a marked reduction in fibrosis can be seen when 
compared to 14 days. The histology results for corresponding timepoints for O/B treatment 
correlates to these predictions. For T/P treated lungs it was not expected that any fibrosis 
would develop as PBS is typically administered as a vehicle for bleomycin and tamoxifen 
administration alone should not induce a fibrosis. However fibrotic foci could be clearly seen 
in the lungs of these mice at 14 and 28 days. The pathology seen in these sections also 
correlates closely to that described by  Izbicki et al., (2002). Lungs isolated from T/B treated 
animals displayed an unusually high extent of fibrosis, present as early as 7 days and no 
obvious signs of resolution by day 28. These findings were considered the most concerning 
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(and interesting) as they displayed a grossly exacerbated response to the combined 
treatment, with fibrosis developing at a decidedly accelerated rate.  
Expression patterns of transcription of the COL1α2 gene were expected to correlate with the 
appearance of fibrosis on the histology sections, with peak increases in expression 
anticipated at 14 days. However, none of the analyses carried out on the samples taken 
corresponded to this. Transcript abundance of COL1α2 appeared relatively unaffected by the 
combined treatments with the exception of 28 days, where O/B and T/B treatments showed 
a significant increase in mRNA levels. At 14 days T/B treatment showed significant increase 
in mRNA levels, however closer examination of the data identified a single animal with a 5.5-
fold increase in transcription which increased the mean fold change disproportionately to 
achieve a significant result. The significant increase in T/P treatment is unusual on two 
accounts, the first being that PBS is a vehicle and should not induce a fibrotic response. 
Secondly, as previously mentioned, peak transcription is usually seen at 14 days, whereas for 
these results a mean fold change of 3 is greater than that seen across the entire study.   
Initial considerations were that housing of animals in an SPF unit may have had an 
unanticipated effect on the immune system. As the initial inflammation response to 
bleomycin is believed to be the catalyst for the formation of fibrosis in this model, it would 
follow that animals with juvenile immune systems may exhibit a disproportionate immune 
response to DNA damage by bleomycin. Recent literature supports this idea, with a number 
of recent publications exploring the concept that SPF housing conditions result in a reduction 
of immune cell population numbers and diversity, as well as decreased diversity in the 
genetic profile of these cells (Masopust, Sivula and Jameson, 2017). Beura et al., (2016) 
report that the immune systems of SPF mice compared to that of their wild type counterparts 
is analogous to comparing the immune system of a human neonate to that of an adult. 
Consequently, Stelekati & Wherry, (2012) describe the same phenomenon in humans that 
lack exposure to pathogens also lack diversity in their immune cell populations. They 
speculate as to the effects this has on the recognition of pathogens, innate immune 
responses, priming and differentiation of adaptive effector responses, as well generation and 
maintenance of immunological memory.  
Based on this evidence it was considered highly likely that the exacerbated response was, in 
part, due to an over-stimulation of a juvenile immune system and it is likely that this is the 
reason a fibrotic response to PBS administration was observed. Retrospective consideration 
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into this study led to the conclusion that analyses of immune markers would have provided 
a valuable insight as to whether this was in fact the case. 
The conclusions provided by this study were limited by the requirement to isolate individual 
lobes from the lung for analysis by either histology or qPCR, essentially at random. It was not 
possible to confirm whether either the histological data or qPCR was representative of the 
entire lung when analysed separately. Oropharyngeal aspiration of bleomycin is a notoriously 
variable model, with the potential to see a differential effect on each lobe within the lung 
(Antje Moeller et al., 2008; Scotton and Chambers, 2010; Robbe et al., 2015). This study 
therefore highlighted the requirement to adopt a method that would enable the assessment 
of the extent of fibrosis in the whole lung, prior to further analysis. As well as indicating that 
the dosing regimen with concern to bleomycin treatment would need to be reinvestigated 
to ensure reproducibility of the response and survival of the animals. 
3.8.2 Imaging the whole lung 
 
To address the third aim, to develop a method for the assessment of fibrosis in lung following 
administration of bleomycin, a solution to the aforementioned issue of examining the whole 
lung needed to be identified. Following a discussion with Professor Rob Van ‘T Hof at the 
University of Liverpool regarding this limitation, it was decided that the Bruker Skyscan 1272 
ex-vivo µCT scanner located at the University of Liverpool would be a suitable option for 
assessing the extent and localisation of fibrosis across the lungs.  
Micro-computed tomography (µCT) imaging has seen an exponential rise in popularity over 
recent decades, in line with improvements in the resolution of images obtained and the 
diversity of samples that can be evaluated (Schambach et al., 2010). Although more 
commonly used for imaging of bones (Muller et al., 1998; Bauer and Link, 2009), more recent 
literature describes the use of ex-vivo µCT for finer anatomical components such as blood 
vessels (Downey et al., 2012). Utilisation of this process achieved the aim of visualising the 
fibrotic extent of the whole lung, however the limitation of processing for µCT scanning was 
the inclusion of a chemical fixation step with 10 % NBF. The detrimental effects of fixation on 
DNA and RNA have been described on numerous occasions, with the consensus that it is not 
possible to recover reliable samples of RNA from tissues that have undergone fixation (Finke 
et al., 1993; Tyrrell, Elias and Longley, 1995; Masuda et al., 1999; Srinivasan, Sedmak and 
Jewell, 2002). As the intention of this research was to examine the genetic profile of 
transgenic animals, this posed a major limitation in the study design and protocol. Scotton et 
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al., (2013) approached a similar issue by using an experimental design where sample groups 
were split with 50 % animals’ lungs subjected to µCT imaging and the remaining 50 % were 
snap frozen for qPCR analysis. This approach was considered; however, this would have 
doubled the number of animals required for each study group as a minimum, and still fail to 
account for the intra-animal variability of bleomycin administration. Therefore, attention was 
focussed on modifying the current method of µCT scans to remove the requirement for 
fixation and dehydration.  
A protocol was developed, which utilised the contrast in x-ray attenuation capabilities of a 
liquid compared with air. Different levels of x-ray attenuation (ability to block x-ray waves) 
present as differential shades of grey where dense tissue appears black and air appears white 
on resultant scan images. Scanning of bones includes a liquid phase surrounding the tissue 
to prevent drying, such as PBS (Sharir, Ramniceanu and Brumfeld, 2011). It was decided that 
PBS would be a suitable medium with which to suspend unfixed lungs. X-ray attenuation of 
the liquid phase compared to the gaseous phase was postulated to be provide sufficient 
contrast. However it was evident from the scans that although the contrast between air and 
PBS was sufficient, the difference in x-ray attenuation of the lung tissue compared to that of 
PBS was negligible. Movement artefacts also reduced the quality of the scans as lungs were 
not compact within the bijou. Analysis of these scans identified only the gross structures of 
the trachea, bronchioles and heart. This was in part accounted for by the inept manner of 
lung inflation and compounded by a lack of immobilisation of the lung. The larger issue 
remained of achieving sufficient contrast between the suspension agent and the lung sample.  
To address this issue KI was added to the PBS. The efficacy and safety profile of this molecule 
(Oriel, 1994; WHO, 2015) led to the assumption that its presence would not affect the 
physiology of the lung whilst its solubility did not significantly alter the preparation time for 
scanning. Of the concentrations tested, 3 – 5 % (wt / vol) KI suspension provided sufficient 
contrast to distinguish tissue. Addition of Styrofoam cubes above and below the lung was 
sufficient to immobilise it and reduce movement artefacts to a degree where scan resolution 
was comparable to fixed tissue. As such the aim of developing a protocol for the visualisation 
of lungs was met and the issue of establishing a reproducible model of fibrosis was re-
addressed. 
A literature search and re-examination of the bleomycin specification sheet revealed that the 
international units (IU) of our dosage (0.25 mg/mouse) was 2.23 IU, compared with 0.12 IU 
described by Ponticos et al., (2009). This is an oversight in the reporting of bleomycin 
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treatment doses, as units of activity (IU) are batch dependent, and therefore difficult to 
determine from reported dosing concentrations in ‘mg/kg’. A dose / response experiment 
identified that a single OA administered dose of 0.375 ng/g bleomycin (0.035 IU) was 
sufficient to produce fibrosis that was reproducible, and identifiable using the protocol 
established for µCT scanning.  
Whilst the µCT images provided a qualitative means of assessment of the lungs, the 
interpretation of the extent of fibrosis in one lung compared to another was dependent on 
the researcher examining the scans. The requirement remained to assign an independent 
quantitative value to the scanned lungs, to increase the reliability in our data when 
interpreting the effects of CCN2 removal in our transgenic animals (data presented in chapter 
4). Professor Van ‘T Hof has previously developed software for similar requirements in 
assessing bone morphology (Van ’T Hof et al., 2017), therefore assistance was sought to 
develop a macro capable of analysing the tissue content present in the lung scans. Specifics 
of this process are highlighted in the appendices. In short; a greyscale value between 0 – 255 
was assigned to every pixel, where air is white or 0 and black is 255. The frequency of each 
of these values was then totalled to give an overall average x-ray attenuation value. Numbers 
of pixels assigned each grey value were presented as histograms. The x-ray attenuation 
profile was not affected by gender, with mean x-ray attenuation values of 64.5 and 65.6 
attributed to females and males respectively. Both the distribution of values and mean 
attenuation value was notably different in animals treated with bleomycin. Therefore, it was 
concluded that analysis of scans using this macro was a sufficient quantitative measure of 
fibrosis.  
Further analysis of lungs using this method determined that the scan quality significantly 
impacted the resultant greyscale value determined using this macro. Analysis of scans 
obtained from transgenic and bleomycin treated lungs found that a poor-quality scan of a 
control lung would read-out with a similar distribution and mean to a fibrotic lung. Therefore, 
the decision was made to exclude the macro analysis from the subsequent data chapters of 
this thesis.  
The outstanding requirement for this protocol was to conclusively determine that the dense 
regions postulated to be fibrosis in the µCT scans was in fact a tissue deposit and not a scan 
artefact. This was straightforward to explore by histological examination of the lungs. We 
assessed the lungs using a general H & E tissue stain, and a trichrome stain (Goldner’s 
trichrome). Firstly H & E staining confirmed that the dense area corresponded to the 
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presence of tissue with clear cytoplasmic staining seen across. Trichrome staining further 
confirmed that this tissue was predominantly composed of collagen which was expected for 
the bleomycin model of IPF.  
3.8.3 Summary 
 
The overall aim of this research was to investigate the role of CCN2 in a murine model of IPF. 
Here we described the process for establishing the bleomycin model of IPF at the University 
of Liverpool. The results discussed describe the challenges faced when attempting to develop 
an animal model of disease that is inherently variable by its mechanism of action, and the 
solutions that were adopted to overcome them. The primary outcome was the development 
of a protocol that produced a consistent and established fibrosis in mixed background mice 
(B6CBA F1). This was confirmed with histological analysis by staining with both a general 
tissue stain (H & E) and a collagen specific stain (Goldner's trichrome). The secondary 
outcome of these experiments was the development of a novel method of scanning lungs 
using a Bruker SkyScan 1272 ex-vivo µCT scanner. This method was optimised for unfixed, 
manually inflated lungs, whereby samples could be subsequently analysed for both qPCR and 
histology from the same animal. The third and outcome was the development of a 
quantitative method of assessment of fibrosis utilising the data acquired from the µCT scans. 
This was an important addition to improve the reliability of the data when interpreting the 
effects of CCN2 removal in our transgenic animals.     
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4. Generating the Double Transgenic Animals for Loss of 
Function of CCN2 in a Fibroblast-Specific and Ubiquitous 
Manner 
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4.1 Genetically modified animals as models for disease 
 
The laboratory mouse is an ideal model organism for studying the pathobiology of human 
disease, owing to their physiological similarity to humans, the ease of genetic manipulation 
and their accelerated gestation and life span compared to humans (Gierut, Jacks and Haigis, 
2014). These traits enable the study of disease across their entire life span (approximately 2 
years), a feat impossible in studies of chronic human disease. Genetic manipulation has 
enabled researchers to generate specific loss of function mutations in genes, and subsequent 
study of the resultant phenotypes in vivo from as early as 1989 (Capecchi, 1989). Discovery 
of site-specific recombinase systems that could be controlled in a spatio-temporal manner in 
1994 (Gierut et al., 2014; Nagy, 2000; Nagy, Mar, & Watts, 2009) enabled the study of gene 
functions in a tissue specific manner, and evaluation of the phenotypes arising from genes 
who’s systemic inactivation causes embryonic lethality or profound developmental defects, 
such as the protein of interest in this research; CCN2 (Lambi et al., 2012).   
4.1.1 Cre / Lox recombinase system 
 
Of the site-specific recombinase systems, the most commonly used in current research is the 
Cre / Lox system. Cre (cyclization recombination) is a 38-kDa, site-specific DNA tyrosine 
recombinase derived from P1 bacteriophage. Cre catalyses DNA recombination between two 
loxP sites (locus of crossing over {X} of P1) which are 34-bp palindromic recognition 
sequences (Buchholz et al., 1996). The utilisation of this system requires the insertion of the 
loxP sites at the chromosomal location of interest (subsequently described as a ‘floxed’ gene), 
and expression of the Cre gene by the mouse (Babinet, 2000). CreERT2 is a modified, 
tamoxifen-inducible Cre and is currently one of the most successful used in inducible genetic 
systems (Metzger et al., 1995; Schwenk et al., 1998; Zhong et al., 2015).  A mutated estrogen 
receptor is fused to Cre as a transgene (Cre-ER), which is activated via binding of 4 - OHT, 
(Zhong et al., 2015). The mechanism of activation of CreERT2 is outlined in Figure 4.1.  
Over 11,000 mouse Cre lines are described on the Jackson Laboratories Mouse Genome 
Informatics website (Jackson Laboratories, www.informatics.jax.org, accessed October 
2018). Time-dependent and tissue-specific CreERT2 have been reported in numerous tissues, 
including cartilage, endothelium, epithelium and lung. 
82 
 
 
Figure 4.1. Mechanism of action of the tamoxifen dependent CreERT2. A, Double transgenic animals are born without a phenotype and possess a floxed gene of interest (L-loxP site) 
and a tamoxifen-dependent CreERT2 (in this example Cre expression is driven by a fibroblast specific enhancer). B, when the Cre is synthesised the ERT2 modification directs its 
localisation to the cell cytoplasm where it remains membrane bound (1), when tamoxifen is administered (2.) the 4-OHT metabolite binds to the modified estrogen receptor causing 
a mutation, releasing the Cre from the membrane. C, Cre translocates to the nucleus, where it recognises the loxP sites (L). D, Recombination of the region within the loxP sites occurs, 
for this figure the result is excision of the flanked region resulting in loss of function of the CCN2 gene.
A
D
B
C
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 (Zhu et al., 2008; Feil, Valtcheva and Feil, 2009; Gui et al., 2012). These are used in 
conjunction with floxed genes of interest for gain and loss of function experiments. Activation 
of the CreERT2 can be initiated by I.P. injection of tamoxifen to pregnant females, postnatal 
pups, or adult mice. Dosing route and timing is primarily dependent on the animal age and 
target tissue (Gierut, Jacks and Haigis, 2014). 
 
4.1.2 Characterisation of inducible CreERT2 lines 
 
Characterisation of the expression profile of inducible CreERT2 lines was originally 
accomplished using a Cre reporter transgene, in which marker gene (e.g. LacZ) expression is 
dependent on Cre-mediated recombination (De Val et al., 2002; Muzumdar et al., 2007). 
Double reporter transgenes were a modification of this system and act via labelling cells that 
have undergone Cre-mediated recombination with one marker and non-recombined cells 
with another (Novak et al., 2000). One of the recent advances in this technology was 
described by Muzumdar et al., (2007) who developed a double fluorescent Cre reporter 
mouse, (mT/mG) that expresses membrane-targeted tdTomato (mT) prior to Cre excision 
and membrane-targeted EGFP (mG) following (Cre excision, Figure 4.2). This reporter line 
overcomes some of the key limitations when determining the reliability of expression 
patterns of new Cre lines. For example, the penetration of a substrate (e.g. X-gal in LacZ 
reporters) through tissue samples both in vivo and ex vivo may be insufficient to identify 
activity and result in mischaracterisation of the expression profile. Leading to unanticipated 
adverse events when the Cre is used in gene manipulation.
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Figure 4.2. Representative diagram of the mT/mG construct described by (Muzumdar et al., 2007). A, The mT/mG 
reporter construct consists of a ubiquitously expressed promoter driving expression of membrane-targeted 
tandem dimer Tomato (mT) that is flanked by loxP sites (L). tdTomato expression is ubiquitous and localised to the 
cell membrane. After Cre-mediated recombination (B), the mT sequence is excised allowing the promoter to drive 
expression of membrane-targeted enhanced green fluorescent protein (mG, C). Arrows denote the direction of 
transcription.
4.2 Chapter Aims 
 
The aims of this chapter were as follows: 
1) Establish and characterise a double transgenic mouse colony containing a floxed 
CCN2 transgene and a Ubiquitously expressed tamoxifen-inducible CreERT2 
(ROSA26CreERT2 CreERT2). 
The first objective was to develop a genotyping strategy for single and double transgenic mice 
to identify individuals containing the transgenes. The second objective was to select and 
maintain littermate pairings from the F1 breeding colony and subsequent offspring 
generations, to establish a mouse colony that was homologous for the CCN2 floxed gene, and 
positive for the ROSACreERT2. The final objective was to assess the response to tamoxifen 
administration and confirm the loss of function of the CCN2 gene.  
2) Establish and characterise a double transgenic mouse colony containing a floxed 
CCN2 transgene and a fibroblast specific tamoxifen-inducible CreERT2 (Col1α2-
CreERT2). 
Cre Cre
mT
mG
mGmG mT
A B
C
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The first objective was to develop a genotyping strategy for single and double transgenic mice 
to identify individuals containing the transgenes. The second objective was to select and 
maintain littermate pairings from the F1 breeding colony and subsequent offspring 
generations, to establish a mouse colony that was homologous for the CCN2 floxed gene, and 
positive for the COL1α2-CreERT2. The final objective was to assess the response to tamoxifen 
administration and confirm loss of function of the CCN2 gene. 
3) Characterise the expression pattern of the Col1α2-CreERT2 using the B6CB; 129-(Cg)-
Gt (ROSA) 26Sortm4 (ACTB-tdTomato,-EGFP) dual fluorescent reporter line. 
The first objective in characterising this line was to confirm that the expression pattern during 
development was comparable to the LacZ staining reported by Bou-Gharios et al., (1996) and 
Ponticos et al., (2004) The second objective was to confirm the expression pattern at 7 days 
after tamoxifen administration. This timepoint would be used in subsequent research with 
the loss of function transgenic animals. The final objective was to identify the location of 
COL1α2-CreERT2 at 14 days after pulmonary injury with bleomycin. This treatment and 
timepoint would be used in subsequent research with loss of function transgenic animals and 
the bleomycin induced model of pulmonary fibrosis. 
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4.3 Establishing colonies double transgenic animals   
 
4.3.1 Ubiquitous loss of function of CCN2 (ROSA-CCN2fl) 
Founder female mice expressing the ROSA26CreERT2 B6CB;129-
Gt(ROSA)26Sortm1(cre/ERT)Nat/Liv transgene were purchased from the Jaxson lab, Stock 
No: 008463 (B6.129-Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J) (Figure 4.3, B), referred to as 
(ROSACreERT2). These were bred with male animals containing the CCN2 floxed gene, B6; 
129S-CTGFtm1.Alea (Figure 4.3, A). These mice were a generous gift from Dr. Andrew Leask. 
The generation of this floxed CCN2 transgene is described in Liu, Shi-Wen, Abraham, & Leask, 
(2011). F1 offspring were genotyped for the presence of CCN2 and CreERT2, the methodology 
is described in methods section 2.4. Mice that were heterozygous for both transgenes were 
bred back onto founder parent animals to generate F2 offspring, typical genotyping results 
from F2 and subsequent generations are shown in Figure 4.4. The genotyping strategy for 
CCN2 was able to identify animals both heterozygous and homozygous for the CCN2 floxed 
gene (Figure 4.4, A, +/- heterozygous, +/+ homozygous) owing to the presence of a WT allele 
present in the genome. A primer pair was used that specific for sequence recognition sites 
outside the region of DNA recombination. The CreERT2 gene is not found endogenously in the 
mouse genome therefore it was possible to identify positive (+/-) or negative (WT) animals 
(Figure 4.4, B). A housekeeping gene (18s) was used to confirm presence of DNA to prevent 
false negatives (Figure 4.4, B) in ROSA26CreERT2 genotyping. Double transgenic animals that 
were genotyped as homozygous for CCN2 floxed and positive for ROSA26CreERT2 were 
selected and bred to maintain a colony of animals for use in CCN2 loss of function 
experiments. The in-house identifier for these mice was ROSA-CCN2fl, this nomenclature will 
be used for the remainder of these results. 
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4.3.2 Fibroblast specific loss of function of CCN2 
 
Founder breeding pairs were established from transgenic mice containing the CCN2 floxed 
transgene (described above) that were bred with mice carrying the transgene for a Col1α2-
CreERT2, B6CB-Tg (Col1a2-17=1.5kbenh-350mp-CreErt2) 3.18/Liv, generated by the Bou-
Gharios Lab. F1 offspring were genotyped for the presence of CCN2 and CreERT2, the process 
is described in methods section 2.4. Mice that were heterozygous for both transgenes were 
bred back on founder parent animals to generate F2 offspring, typical genotyping results 
from F2 and subsequent generations is shown in Figure 4.4. The genotyping strategy for CCN2 
floxed and CreERT2 was the same as described in the previous section. A further genotyping 
strategy was developed to confirm the presence of the COL1α2 enhancer driving the CreERT2 
(Figure 4.4, C). A primer pair was identified with the forward strand binding within the 
enhancer sequence, and the reverse strand binding within the CreERT2 gene.  Double 
transgenic animals that were genotyped as homozygous for CCN2 floxed and positive for 
Col1α2-CreERT2 were selected and bred to maintain a colony of animals for use in CCN2 loss 
of function experiments. The in-house identifier for these mice was Col1α2-CCN2fl, this 
nomenclature will be used for the remainder of these results.
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Figure 4.3. Location of genetic modifications using UCSC genome browser. A, CCN2 gene showing the localisation of loxP sites (L) for generation of CCN2 floxed transgene. B, Location 
of knock in of CreERT2 (pink & arrow) into intron 1 of Gt(ROSA)26Sor. C, Location of enhancer sequence driving fibroblast specific expression of CreERT2.
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Figure 4.4. DNA genotyping gel results from ear punch biopsy of transgenic mice. Primer locations are identified 
on the representative images of the gene of interest by black lines with Fw and Rv indicating the location of the 
forward and reverse sequence respectively A, Genotyping results for CCN2 flox. WT denotes unmodified CCN2 
allele, +/- indicates heterozygous expression and +/+ indicates homologous expression of CCN2 floxed transgene. 
B, genotyping strategy for the presence of CreERT2 used for both ubiquitous and fibroblast specific CCN2 knock out 
lines. WT indicates non-transgenic animals, +/- indicates CreERT2 transgene is present. C, Col1α2 enhancer specific 
genotyping strategy, WT indicates non-transgenic animals, +/- indicates the presence of the Col1α2- CreERT2. 
Control wells containing Col1α2- CreERT2 plasmid (+ve), Acan- CreERT2 (-ve) and master mix (mm) were included 
as PCR controls. For A & B a 1 kb DNA ladder was loaded for reference (NEB, N3232L). For C, a 2-log ladder was 
loaded for reference (NEB, N0469S).  
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4.4 Characterising the lung morphology of double transgenic mouse colonies 
 
Double transgenic animals from the ROSA-CCN2fl mouse colony and the Col1α2-CCN2fl 
colony were Sch1 at 6 weeks of age and processed for paraffin histology (methods section 
2.8). It was necessary to determine that no morphological defects occurred due to the of the 
presence of the transgenes. Lung samples were stained with H & E and examined for key 
anatomical features defined as bronchioles, blood vessels and alveoli. No defects or 
morphological differences were observed (Figure 4.5). 
It was determined that double transgenic animals displayed no difference in phenotype to 
that described for non-transgenic animals of the same background (mixed-C57B/6 x CBA). 
The next series of experiments aimed to confirm recombination of the CCN2 floxed gene 
occurred following administration of tamoxifen. 
4.4.1 Response to tamoxifen in-vitro 
 
Fibroblast cells were isolated and cultured from double transgenic animals from both the 
ROSA-CCN2fl and Col1α2-CCN2fl lines (described in methods 2.10). On day 7 of culture, 
media containing 100 nM of active tamoxifen metabolite 4-OHT was added to the cells. 
Cultures were left for 12 hours to allow recombination of the CCN2 floxed gene. Cells were 
imaged prior and post tamoxifen administration (Figure 4.6). Extensive cell death was 
observed in cultures from both ROSA-CCN2fl (Figure 4.6, A - D) and Col1α2-CCN2fl lines 
(Figure 4.6, E - G) 12 hours after tamoxifen administration. This response was seen across 
multiple culture and treatment experiments.  
As it was not possible to identify recombination in vitro the next experiments focussed on 
identifying recombination in vivo. 
4.4.1.1 DNA recombination assay 
Offspring from the ROSA-CCN2fl and Col1α2-CCN2fl lines aged ≥ 6 weeks, that were not 
required for colony maintenance were administered three I.P. injections of 0.025 mg/g 
tamoxifen, (described in methods section 2.5.1). Animals were Sch1 at 7, 14 and 28 days after 
the final I.P. injection and DNA was isolated from a tail snip. A representative DNA genotyping 
gel result for the CCN2 floxed gene in animals from the ROSA-CCN2fl line, Sch1 at 7 days, is 
shown in Figure 4.7. Notation is as follows; WT = animals homologous for the unmodified 
CCN2 allele, +/- = animals heterozygous for the CCN2 floxed allele (1 copy of CCN2 floxed, 1 
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copy unmodified CCN2) and +/+ - animals are homozygous for the CCN2 floxed allele. CreERT2 
negative animals (Figure 4.7, A-D) showed no recombination of the CCN2 allele, neither did 
WT CCN2 animals that contained CreERT2 (Figure 4.7, H). Heterozygous samples (Figure 4.7, 
F, J & K) showed recombination of the CCN2 floxed allele, but not the CCN2 WT allele. 
Homozygous samples (Figure 4.7, E & I) showed complete recombination of both alleles.
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Figure 4.5. H & E stained paraffin embedded lung samples from double transgenic mice. Individual lobes were 
isolated after Sch1 by anaesthetic overdose, processed for wax histology and stained with H & E. Anatomical 
features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels. A, Stitched image of lung lobe isolated 
from double transgenic animal homozygous for CCN2 floxed, and positive for Col1α2-CreERT2. B, Stitched image 
of lung lobe isolated from double transgenic animal homozygous for CCN2 floxed, and positive for ROSA-CreERT2. 
C & D, individual images taken from A & B respectively. All images were taken at 10x magnification. Scale bars in 
A & B represent 1 mm. Scale bars in C & D represent 200 µm. 
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Figure 4.6. Primary fibroblast cultures isolated from double transgenic mice. Fibroblasts were isolated from double 
transgenic animals, homozygous for CCN2 floxed, and positive for Col1α2-CreERT2 (A - D) or ROSA- CreERT2 (E - H). 
A & E, 10x magnification of cells prior to Tx administration. C & G, show the same cells prior to Tx administration 
at 20x magnification.   B & F, 10x magnification of cells 12 hr after Tx administration. D & H, show the same cell 
cultures 12 hr after Tx administration at 20x magnification.
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Figure 4.7. DNA gel result from in-vivo recombination assay. Tail snips were taken from mice 7 days after final dose of tamoxifen was administered. DNA was isolated and the CCN2 
floxed gene was analysed for recombination. Wild type (WT) mice contain two copies of the non-floxed CCN2 gene, +/- indicates a heterozygote transgenic mouse, and +/+ indicates 
a homozygous transgenic mouse. A sample of master mix (mm) containing ddH2O in place of DNA was used to confirm purity of the master mix solution. Animals A - D are Negative 
for CreERT2 and samples L & M are untreated control samples. A 1 kb DNA ladder (NEB, N3232L) was loaded as a reference.
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4.4.2 RT-qPCR analysis of CCN2 expression 
 
Lung samples were isolated and snap frozen for qPCR analysis of CCN2 gene expression. 
Animals from the ROSA-CCN2fl and Col1α2-CCN2fl lines were homologous for the CCN2 
floxed gene and positive for their specific CreERT2. Tamoxifen was administered as described 
in methods section 2.5.1. Animals were Sch1 using overdose of Pentobarbital at 7, 14 and 28 
days after the final I.P. injection and the lungs snap frozen in liquid nitrogen. RNA was 
extracted following the protocol in methods section 2.7.3 and analysed by ∆∆Ct for CCN2 
transcript levels (Figure 4.8). 
4.4.2.1 Fibroblast specific knock out of CCN2 
Figure 4.8, A – C presents the ∆∆Ct results for the fibroblast specific knock out of CCN2 
(Col1α2-CCN2fl colony). When gender was not accounted for, a significant (p ˃ 0.0001) 2.5-
fold increase in CCN2 transcript abundance was observed at 7 days (Figure 4.8, A), followed 
by reductions in CCN2 transcript abundance by 0.4 and 0.6-fold at 14 and 28 days respectively 
(Figure 4.8, B & C). Analysis of gender specific responses demonstrated different patterns of 
response between males and females. Males (Figure 4.8, B) demonstrated a decreasing trend 
of levels of CCN2 transcript abundance, with a 0.15-fold reduction in transcript level at day 
7, a 0.40-fold decrease at day 14 and a 0.60 decrease by day 28. Females (Figure 4.8, C) 
demonstrated an initial peak in transcript abundance, with a 3-fold increase at day 7, 
followed by a 0.40-fold decrease by day 14, in line with the results seen in male animals 
(Figure 4.8, B). 
4.4.2.2 Ubiquitous knock out of CCN2 
Figure 4.8, D – F presents the ∆∆Ct results for the ubiquitous knock out of CCN2 (ROSA-CCN2fl 
colony). No transcript was identified in the sample at day 14 (Figure 4.8, D).  No difference 
was seen between genders (Figure 4.8, E & F).  
4.4.3 Immunohistochemical analysis of CCN2 expression 
 
To confirm the alterations in CCN2 transcription translated to a reduction in protein 
expression, the next experiment used antibody staining of paraffin embedded lung lobes 
isolated from the tamoxifen treated animals 14 days after the last dose of tamoxifen was 
received. Sections of lungs isolated from Col1α2-CCN2fl and ROSA-CCN2fl lines were 
compared to an untreated control lung for localisation and prevalence of CCN2 (Figure 4.9). 
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All samples were prepared and stained by Mr. Lorenzo Ramos-Mucci, following the protocol 
in methods section 2.9. Images of stained slides were taken using a Zeiss LSM 800 confocal 
microscope at 10x magnification. 
In control lung, antibody staining of CCN2 was observed in the bronchioles, and in cells 
surrounding the alveoli, identified by black arrows (Figure 4.9, A, D & G). A reduction of 
staining in the bronchioles was seen in lungs isolated from mice where CCN2 was targeted in 
a fibroblast specific manner (Figure 4.9, B, E & H). Staining in cells surrounding alveoli was 
seen with a similar expression to control. In lungs isolated from mice where CCN2 was 
targeted ubiquitously, no staining of CCN2 was observed (Figure 4.9, C, F & I). 
From these results it was concluded that I.P. injection of tamoxifen was sufficient to induce 
recombination of the CCN2 floxed gene in vivo. The recombination was shown to reduce 
CCN2 expression both at the transcriptional level and the protein level. The efficiency of this 
reduction was dependent on the CreERT2 specificity. Whereby reduced expression levels of 
CCN2 were demonstrated in a fibroblast specific recombination, and complete ablation of 
CCN2 expression in ubiquitous recombination. 
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Figure 4.8. RT-qPCR analysis of CCN2 gene. ∆∆Ct analysis of CCN2 mRNA compared to 18s housekeeping gene. Samples were analysed from double transgenic animals homozygous 
for CCN2 floxed gene and positive for fibroblast specific Col1α2-CreERT2 (A - C) or ubiquitously expressed ROSA26CreERT2 (D - F), following tamoxifen treatment. RNA was extracted 
from whole lungs from male and female animals culled at 14 days after final tamoxifen injection. Transcript abundance was normalised to untreated, double transgenic littermates. 
Statistical significance was determined using a one-way ANOVA, and Tukey’s post hoc test. Significance and associated p-values are indicated by (*). A & D, ∆∆Ct analysis of CCN2 
mRNA carried out for all mice. B & E, ∆∆Ct analysis of CCN2 mRNA in male mice only. C & F, ∆∆Ct analysis of CCN2 mRNA in female mice only. 
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Figure 4.9. Antibody staining for CCN2 in lungs using Anti-CCN2 Antibody (ab6992). Lungs were isolated from double transgenic animals, homozygous for CCN2 floxed, and positive 
for Col1α2-CreERT2 (B, E & H) or ROSA- CreERT2 (C, F & I) 14 days after completion of tamoxifen dosing. Lungs from untreated mice were included for normal expression profile of 
CCN2 (A, D & G). Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels. Regions of antibody staining are indicated by black arrows. Scale bars 
represent 200 µm
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4.5 Characterising the expression pattern of the Col1α2-CreERT2 
 
Having established that tamoxifen dosing in vivo was sufficient to drive gene recombination, 
the next stage of the research focused on characterising the expression pattern of the 
Col1α2-CreERT2. Research in this section was submitted as part of published manuscript. 
“Characterisation of Mesenchymal-Fibroblast Cells using the Col1α2 Promoter/Enhancer”  
Li, I. M. H., Horwell, A. L., Chu, G., de Crombrugghe, B., & Bou-Gharios, G. (2017). In Methods 
in Molecular Biology (Vol. 1627, pp. 139–161). https://doi.org/10.1007/978-1-4939-7113-
8_10 
 
4.5.1 Establishing a colony of inducible, fluorescent dual-reporter, double transgenic mice 
 
Female mice containing the reporter construct B6CB; 129-(Cg)-Gt (ROSA) 26Sortm4 (ACTB-
tdTomato,-EGFP) Luo/Liv, (mTmG) described by Muzumdar et al., (2007), were purchased 
from Jackson Laboratories (007676).  These were bred with male mice containing the Col1α2 
driven CreERT2 B6CB-Tg (Col1a2-17=1.5kbenh-350mp-CreErt2)3.18/Liv. F1 offspring were 
genotyped for mTmG construct following the protocol in methods 2.4 and Col1α2-CreERT2 as 
described previously in this chapter. Heterozygous, double transgenic offspring were bred 
onto founder parents and subsequent crossing of littermate mice was used to establish and 
maintain a colony of double transgenic mice homozygous for the mTmG reporter gene, and 
positive for Col1α2-CreERT2. 
These animals were used for lineage tracing experiments to determine the expression 
pattern of the Col1α2-CreERT2 during development and during adulthood. 
4.5.2 Col1α2-CreERT2 expression during embryonic development 
 
A single I.P. injection of 3 mg tamoxifen was administered to pregnant female mice on 
embryonic day 11.5 or 13.5. Females were culled 2 days after tamoxifen administration by 
cervical dislocation and embryos at days E13.5 and E15.5 were collected and processed for 
cryogenic histology (described in methods 2.8.1). Control embryos were also collected at 
embryonic days E13.5 and E15.5 from females that had not been injected with tamoxifen. 
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Sections were imaged using a Zeiss Axio Observer apotome microscope and Axio Cam MR R3 
camera. A wavelength of 610 nm was used for imaging of tdTomato and 519 nm for EGFP. 
Images were viewed using ZEN Blue microscopy software. 
Representative images are shown in Figure 4.10, taken from control embryos collected at 
developmental days E13.5 (Figure 4.10, A & B), and E15.5 (Figure 4.10, C & D). Fluorescent 
imaging of both developmental stages (Figure 4.10, A, E13.5 & C, E15.5) showed expression 
of tdTomato only. Sections were examined at a higher magnification to ensure no EGFP signal 
was present. Representative images taken at 20x magnification from control embryo at E15.5 
are shown in Figure 4.11. No EGFP signal was identified in control embryos at either 
timepoint. After fluorescent imaging was complete slides were stained with H & E and 
imaged using a Zeiss LSM 800 confocal microscope. H & E staining confirmed tdTomato 
expression was synonymous with the presence of tissue (Figure 4.10, B & D).  
Figure 4.12 shows a series of representative sections taken from a whole embryo, which was 
administered with tamoxifen at developmental day E11.5 and collected at E13.5. Figure 4.13 
shows a series of representative sections taken from a whole embryo that was administered 
tamoxifen at developmental day E13.5 and collected at E15.5. Examination of fluorescent 
images confirmed activation of the CreERT2 as EGFP signal was observed at both 
developmental stages (Figure 4.12, (A-E) & Figure 4.13 (A-E)). After fluorescent imaging was 
completed, slides were stained with H&E and imaged using a Zeiss LSM 800 confocal 
microscope. H&E staining confirmed tdTomato expression was synonymous with the 
presence of tissue (Figure 4.12, (E - H) & Figure 4.13, (E-H)).   
To characterise the expression pattern at the cellular level, sections from embryos at both 
E13.5 and 15.5 were imaged at 20x magnification. Representative images from lung, liver and 
ribs are shown in Figure 4.14. At E13.5, EGFP signal was identified in the lung (Figure 4.14, A) 
in cartilage tissue surrounding the trachea and the cells immediately surrounding the 
bronchioles. Examination of EGFP signal in the lung at E15.5 (Figure 4.14, D) revealed signal 
localised to individual cells surrounding blood vessels and in individual cells located around 
the epithelial lining of the alveoli.  In the liver at both E13.5 and E15.5 tdTomato signal was 
identified in cells surrounding the central vein and the surrounding vascular network 
branching from this. EGFP signal was localised to cells within the hepatocyte population 
(Figure 4.14, B & E). EGFP expression was identified in some chondrocytes present in the ribs 
for both E13.5 and E15.5 (Figure 4.14). 
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 4.5.3 Col1α2-CreERT2 expression in adult mice 
 
Three I.P. injections of 0.025 mg/g tamoxifen were administered to mice aged ≥6 weeks 
following the protocol outlined in methods section 2.5.1. Col1α2-CreERT2 expression was 
examined 7 days after the final tamoxifen injection and 3 months after tamoxifen expression. 
Animals were Sch1 by cervical dislocation and tissues were processed for cryogenic histology 
(described in methods 2.8.1). Littermate animals that were not administered tamoxifen were 
Sch1 at the same time as the tamoxifen treated counterparts and tissues processed for 
cryogenic histology for baseline control expression of the mT/mG reporter construct.  
Figure 4.15 shows representative fluorescence images taken from skin and lung samples, 7 
days after tamoxifen administration (A, B, D & E) compared to skin and lung taken from 
untreated littermate control animals (C & E). Untreated lung and skin (Figure 4.15, C & E) 
demonstrated expression of tdTomato only. Expression of EGFP in skin was localised to the 
dermis region (Figure 4.15, A & B), hair follicle and epithelium retained tdTomato expression. 
In lung (Figure 4.15, D & E), EGFP expression was localised to individual cells surrounding the 
vessels and alveoli.  
Examination of fluorescence in tissues 3 months after the final injection of tamoxifen showed 
EGFP expression was present in skin, kidney, liver, heart, spleen, lung and eye (Figure 4.16, 
A, C - H). Expression patterns in skin and lung (Figure 4.16, A & G) were identical to those 
observed at 7 days (Figure 4.16, A & B, D & E). 
4.5.4 Col1α2-CreERT2 expression in lungs of adult mice treated with bleomycin  
 
Three I.P. injections of 0.025 mg/g tamoxifen were administered to mice aged ≥6 weeks 
following the protocol outlined in methods section 2.5.1. 7 days after the final tamoxifen 
injection, mice were administered a single dose of 0.375 ng/g OA bleomycin. Col1α2-CreERT2 
expression was examined in the lung 14 days after insult with bleomycin. A littermate control 
was treated with tamoxifen but not bleomycin for tissue and expression comparison. Animals 
were Sch1 by overdose of pentobarbital and lungs were processed for cryogenic histology 
(described in methods 2.8.1). Lungs not treated with bleomycin (Figure 4.17, A & B) 
demonstrated EGFP expression in cells within the bronchioles, surrounding the vessels, with 
in single cells surrounding the alveoli also showing EGFP expression. In bleomycin treated 
lungs (Figure 4.17, C - F), increased regions of tdTomato expressing tissue were seen, 
revealing a loss of usual morphology. Regions of EGFP signalling could be identified within 
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the tdTomato signal (Figure 4.17, C & D). Individual EGFP expressing cells were visualised 
surrounding vessels and lining alveoli in Figure 4.17, (E & F).  
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Figure 4.10. Fluorescence and H & E stained  sections from double transgenic mice containing the mT/mG reporter 
construct (Muzumdar et al., 2007) and Col1α2-CreERT2 gene. Embryos were collected at embryonic days E13.5 
(A & B) and E15.5 (C & D). Fluorescence images (A & C) were imaged using a Zeiss Axio Observer apotome 
microscope and Axio Cam MR R3 camera. FITC (519 nm) and mCherry (610 nm) fluorescence channels were used 
to identify tdTomato and EGFP expression. B & D, H & E staining of the same section. No tamoxifen was 
administered to the mice, therefore no cre activity (EGFP expression) is seen. Images were taken at 10x 
magnification. Scale bars represent 1 mm.   
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Figure 4.11. Fluorescence images of control E15.5 double transgenic mice. Fluorescence images of eye (A), snout 
(B), hind paw (C), kidney (D), liver (E) and back (F) were taken at 20x magnification from untreated double 
transgenic mice containing the mT/mG reporter construct (Muzumdar et al., 2007) and Col1α2-CreERT2 gene , at 
embryonic developmental stage E15.5. No tamoxifen was administered to the mice, therefore no cre activity (EGFP 
expression) is seen. Tissues were imaged using a Zeiss Axio Observer apotome microscope and Axio Cam MR R3 
camera. FITC (519 nm) and mCherry (610 nm) fluorescence channels were used to identify tdTomato and EGFP 
expression. Anatomical features are noted as: vb- vibrissae, ch- chondrocytes, v- blood vessels, ri- ribs, sk- skin. 
Scale bars represent 200 µm.
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Figure 4.12. Fluorescence and H & E stained  sections from double transgenic mice containing the mT/mG reporter construct (Muzumdar et al., 2007) and Col1α2-CreERT2 gene. 
Embryos were collected at embryonic days E13.5 following tamoxifen injection at E11.5. Fluorescence images (A - D) were imaged using a Zeiss Axio Observer apotome microscope 
and Axio Cam MR R3 camera. FITC (519 nm) and mCherry (610 nm) fluorescence channels were used to identify tdTomato and EGFP expression. E - H, H & E staining of the same 
section. Col1α2-CreERT2 activity is indicated by EGFP signal. Images were taken at 10x magnification. Scale bars represent 1 mm.  
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Figure 4.13. Fluorescence and H & E stained  sections from double transgenic mice containing the mT/mG reporter construct (Muzumdar et al., 2007) and Col1α2-CreERT2 gene. 
Embryos were collected at embryonic days E15.5 following tamoxifen injection at E13.5. Fluorescence images (A - D) were imaged using a Zeiss Axio Observer apotome microscope 
and Axio Cam MR R3 camera. FITC (519 nm) and mCherry (610 nm) fluorescence channels were used to identify tdTomato and EGFP expression. E - H, H & E staining of the same 
section. Col1α2-CreERT2 activity is indicated by EGFP signal. Images were taken at 10x magnification. Scale bars represent 1 mm. 
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Figure 4.14. Fluorescence images of tamoxifen treated double transgenic mice at E13.5 and E15.5. Fluorescence Images of lung (A & D), liver (B & E), and ribs (C & F) were taken at 
10x magnification from tamoxifen-treated double transgenic mice containing the mT/mG reporter construct (Muzumdar et al., 2007) and Col1α2-CreERT2 gene , at embryonic 
developmental stage E13.5 (A - C) and E15.5 (D - F). Col1α2-CreERT2 activity is indicated by EGFP signal. Tissues were imaged using a Zeiss Axio Observer apotome microscope and 
Axio Cam MR R3 camera. FITC (519 nm) and mCherry (610 nm) fluorescence channels were used to identify tdTomato and EGFP expression. Anatomical features are noted as: tr- 
trachea, br- bronchioles, ca- cartilage, a- alveoli, v- blood vessels, cv- central vein, ri-ribs. Scale bars represent 200 µm. 
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Figure 4.15. Fluorescence images of tamoxifen treated double transgenic adult mice, 7 days after tamoxifen treatment. Skin (A - C) and lung (D - F) were isolated from double transgenic 
mice containing the mT/mG reporter construct (Muzumdar et al., 2007) and Col1α2-CreERT2 gene. Tissues were collected 7 days after tamoxifen treatment (A & B, D & E) or from 
untreated littermate control animals (C & F). Tissues were imaged at 10x magnification (A, D & F) and 20x magnification (B, C & E). Col1α2-CreERT2 activity is indicated by EGFP signal. 
Tissues were imaged using a Zeiss Axio Observer apotome microscope and Axio Cam MR R3 camera. FITC (519 nm) and mCherry (610 nm) fluorescence channels were used to identify 
tdTomato and EGFP expression. Anatomical features are noted as: a- alveoli, v- blood vessels, f- hair follicles. 
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Figure 4.16. Fluorescence images of tamoxifen treated double transgenic adult mice, 3 months after tamoxifen treatment (Li et al., 2017).  Tamoxifen was administered by I.P. injection 
at ≥6 weeks of age to double transgenic mice containing the mT/mG reporter construct (Muzumdar et al., 2007) and Col1α2-CreERT2 gene. Tissues were collected at 12 weeks. Col1α2-
CreERT2 activity is indicated by EGFP signal. A) skin, C), kidney, D) liver, E) heart, F) spleen, G) Lung, H) eye. B) untreated control skin. Anatomical features are identified by: f- follicles, 
t- tubules, v- blood vessels, a- alveoli, ch-choroid, splenic nodules round circles (F). Tissues were imaged at 10x magnification using a Zeiss Axio Observer apotome microscope and 
Axio Cam MR R3 camera. FITC (519nm) and mCherry (610nm) fluorescence channels were used to identify tdTomato and EGFP expression. Scale bar represents 32 µm 
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Figure 4.17. Fluorescence images of tamoxifen and bleomycin treated double transgenic adult mice, 14 days after bleomycin treatment. Lungs were isolated from double transgenic 
mice containing the mT/mG reporter construct (Muzumdar et al., 2007) and Col1α2-CreERT2 gene. Tamoxifen was administered to all mice on days 1, 3 &5, after a 7-day interval a 
single OA challenge of 0.375 ng/g bleomycin was administered (B - D, F - H). Tissues were collected 14 days after bleomycin treatment. Tissues were imaged at 10x magnification 
(A - D) and 20x magnification (E - H). Col1α2-CreERT2 activity is indicated by EGFP signal. Tissues were imaged using a Zeiss Axio Observer apotome microscope and Axio Cam MR R3 
camera. FITC (519 nm) and mCherry (610 nm) fluorescence channels were used to identify tdTomato and EGFP expression. Anatomical features are noted as: a- alveoli, v- blood 
vessels, br- bronchioles. Scale bars represent 100 µm.
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4.6 Discussion 
 
This chapter described the generation of three new double transgenic mouse lines. The 
purpose of the first two of these mouse lines, Col1α2-CCN2fl and ROSA-CCN2 was to bring 
about the loss of function of CCN2 in fibroblast cells, using the Col1α2-CreERT2 previously 
generated by the Bou-Gharios lab (Bou-Gharios et al., 1996; De Val et al., 2002) and in a 
ubiquitous manner using a Gt(ROSA)26Sortm1-CreERT2, (ROSA-CreERT2) (Ventura et al., 
2007). Site specific gain and loss of function animals under the spatio temporal control of 
tamoxifen inducible CreERT2 have been an essential tool for the study of specific proteins and 
their roles in development, homeostasis and disease pathology (Gierut, Jacks and Haigis, 
2014). The protein of interest in this research, CCN2, has previously been identified as an 
essential for normal embryonic development (Lambi et al., 2012), therefore loss of function 
must be timed to adulthood. Single transgenic mice possessing the CCN2 floxed allele (Liu et 
al., 2011), were bred with single transgenic animals expressing the Col1α2-CreERT2. 
Littermate breeding was maintained to establish a colony of double transgenic animals, 
homologous for the CCN2 floxed allele, and positive for Col1α2-CreERT2, identified in the 
following discussion as ‘Col1α2-CCN2fl’. The same breeding strategy was adopted to 
generate a homologous CCN2 floxed, expressing ROSA-CreERT2 double transgenic mouse line, 
identified in the following discussion as ‘ROSA-CCN2fl’.  
The third new line was developed to characterise the expression profile of the newly 
generated shorter fibroblast-specific enhancer; Col1α2-CreERT2, utilising the dual 
fluorescence reporter construct reported by (Muzumdar et al., 2007). Previous research has 
used the LacZ reporter system to assess the activity of this CreERT2 (De Val et al., 2002; 
Ponticos et al., 2004). The research presented here aimed to reproduce these expression 
patterns using a dual fluorescent reporter. Single transgenic animals for the mT/mG dual 
fluorescent reporter construct were bred with single transgenic animals expressing the 
Col1α2-CreERT2. Littermate breeding was maintained to establish a colony of double 
transgenic animals, homologous for the mT/mG dual fluorescent reporter construct, and 
positive for Col1α2-CreERT2. 
The first experiments in this chapter described the genotyping strategies developed to 
identify the transgenes in offspring from the loss of function CCN2 transgenic lines (Col1α2-
CCN2fl and ROSA-CCN2fl). Ear punch biopsies were taken from every animal and the DNA 
was extracted and assessed for transgene expression by PCR. Biopsy location also served as 
a means of identifying individual animals. Genotyping results (Figure 4.4) were generated for 
120 
 
every animal for both transgenes. Double transgenic animals were identified and used for 
breeding or for loss of function experiments described in chapter 5. This strategy was 
reproducible and consistent for the duration of these experiments. 
Once double transgenic lines were established, lungs from these mice were extracted and 
examined by histology to assess whether the presence of the transgenes presented with a 
defective phenotype (Figure 4.5). Both double transgenic lines were assessed for 
morphological differences in the lungs, no phenotypes were observed for either strain. 
The next series of experiments aimed to induce recombination of the CCN2 floxed gene by 
administration of tamoxifen. The first strategy for inducing CCN2 knock out, used primary 
fibroblast cells isolated from double transgenic animals from both the Col1α2-CCN2fl and 
ROSA-CCN2fl mouse lines. Active metabolite 4-OHT was added to a final concentration of 
100 nM, as described in literature for primary fibroblast cultures (Schmidt et al., 2002; 
Jaskelioff et al., 2010). Cells were assessed 12 hr after 4-OHT administration. Extensive cell 
death was observed (Figure 4.6). It was not apparent as to why this occurred. Multiple 
replicates following the same protocol resulted in the same response. No samples for 
recombination analysis were obtained from any cell culture experiments, therefore 
recombination was assessed in vivo.  
Mice were administered tamoxifen via I.P. injection on experimental days 1, 3 and 5. Tail 
snips were isolated, and DNA extracted for PCR analysis 7 days after the final tamoxifen dose 
was administered. Visualisation of the DNA gel confirmed that this regime of tamoxifen 
dosing was sufficient to induce recombination of the CCN2 floxed gene in vivo (Figure 4.4). 
Non-floxed CCN2 alleles were not affected and animals negative for CreERT2 showed no 
response to tamoxifen treatment. 
Concentration of tamoxifen was dependent on the transgenic line. Col1α2-CCN2fl mice were 
administered a dose of 0.025 mg/g. Animals from the ROSA-CCN2 colony experienced 
increased incidence of adverse effects when administered the 0.025 mg/g dose (data not 
shown). This was resolved when a dose of 0.0125 mg/g was substituted. CCN2 is implicated 
in the wound healing process (Hall-Glenn and Lyons, 2011; Ramazani et al., 2018), and it was 
postulated that the efficiency of the ROSA-CreERT2 in removing CCN2 may have prevented 
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proper healing response in these animals following tamoxifen injection at 0.025 ng/g. This 
concept was examined further and will be discussed further in the next results chapter. 
Results for recombination in Figure 4.4 are from ROSA-CCN2fl animals treated with 
0.0125 ng/g tamoxifen, therefore this concentration was still sufficient to induce 
recombination in vivo.  
To confirm the DNA recombination resulted in knock down of the CCN2 gene, RNA was 
extracted from the lungs of male and female animals from both the Col1α2-CCN2fl and ROSA-
CCN2fl lines and assessed by RT-qPCR for transcription levels of CCN2. Tamoxifen treated 
lungs were compared to control lungs isolated from untreated littermates and non-
transgenic animals of the same background. Inclusion of non-transgenic animal samples was 
used to confirm that there was no difference in CCN2 transcription owing to the presence of 
the CCN2 floxed transgene and/or CreERT2 genes. No difference was observed.  
Col1α2-CCN2fl colony results required assessing on a gender specific basis as a differential 
response to tamoxifen was observed between male and female animals. Males 
demonstrated a reduction in CCN2 transcription at all timepoints.  Decreases in CCN2 
transcript abundance of 0.15, 0.40 and 0.60-fold were observed at days 7, 14 and 28 
respectively. Females demonstrated an initial peak in transcription at day 7, with a 3-fold 
increase in transcription, followed by a 0.4-fold decrease in transcript abundance by day 14 
day, in line with the results seen in male animals. CCN2 removal was targeted to fibroblast 
cells in this line so the partial reduction in transcription observed was expected. It is not 
known why female and male mice demonstrated different responses at 7 days. Analysis using 
this loss of function colony in the next results chapter examined the transcriptional 
differences in a gender specific manner based on these results.  
The ROSA-CCN2fl colony demonstrated a complete ablation of CCN2 transcription activity 
at 14 days. Research using this loss of function colony was planned for a timepoint of 14 
days only so no further timepoints were assessed. However as complete recombination was 
identified by DNA analysis it is likely that cessation of CCN2 transcription had already 
occurred by 7 days and would be unlikely to resume at later timepoints. No differences 
were identified between genders. However, based on the results from the Col1α2-CCN2fl 
colony that analyses of loss of function experiments presented in the next results chapter 
would analyse qPCR results on a gender specific basis for both Col1α2-CCN2fl and ROSA-
CCN2fl colonies.  
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To determine if these transcriptional changes were translated to a reduction in protein 
expression, antibody staining for CCN2 was carried out on lungs isolated 14 days after 
tamoxifen administration from mice from both Col1α2-CCNfl and ROSA-CCN2fl colonies. 
Antibody staining patterns were compared to an untreated control lung for localisation and 
prevalence of CCN2.  
A reduction of staining in the bronchioles of the Col1α2-CCN2fl was noted. Staining in regions 
surrounding alveoli was seen with a similar expression to control. This was not unexpected 
as CCN2 has been shown to be expressed by many different cell types including epithelial 
cells, vascular smooth muscle cells (VSMCs), as well as fibroblasts (Moussad and Brigstock, 
2000; Chang et al., 2004; Yu et al., 2009; Bai et al., 2013). Background staining was notably 
darker in lungs isolated from the Col1α2-CCN2fl colony. In lungs isolated from mice where 
CCN2 was targeted ubiquitously, no staining was observed. Commercially available 
antibodies for CCN2 have been difficult to optimise, with researchers within the CCN2 field 
opting to generate their own in-house antibodies (Wang, McLennan and Twigg, 2011; 
Charrier et al., 2014). These staining results were deemed appropriate and it was concluded 
that I.P. injection of tamoxifen was sufficient to induce recombination of the CCN2 floxed 
gene in vivo that resulted in a knock down of protein expression. 
CCN2 knock down was demonstrated both at the transcriptional level and the protein level. 
The efficiency of this reduction was dependent on the CreERT2 specificity. These results 
concluded the first and second aims of this chapter to establish and characterise the double 
transgenic mouse colonies, containing the floxed CCN2 transgene and a ubiquitously 
expressed ROSA26CreERT2 (ROSA-CCN2fl), or a fibroblast specific tamoxifen-inducible 
CreERT2 (Col1α2-CCN2fl). 
To address the third aim of this research chapter, to characterise the expression of the 
Col1α2-CreERT2, experiments were carried out using the third new double transgenic mouse 
colony, expressing the mT/mG dual fluorescent reporter construct (Col1α2-R26TmG).  
The first experiments using this mouse colony investigated the expression patterns of 
Col1α2-CreERT2 expression during embryonic development. Pregnant females were Sch1 by 
cervical dislocation and embryos were collected at developmental days E13.5 and E15.5. A 
single I.P. dose of 3 mg tamoxifen was administered to pregnant females at embryonic 
developmental stages E11.5 and E13.5 for Col1α2-CreERT2 expression analysis at E13.5 and 
E15.5 respectively. Control embryos were collected at the same developmental stages from 
untreated females for comparison. 
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Expression of the mT/mG reporter was confirmed by fluorescence imaging, control embryos 
at both E13.5 and E15.5 emitted red fluorescent signal, which was confirmed to by 
synonymous with tissue deposition by subsequent staining of the sections with H & E. To 
ensure no Col1α2-CreERT2 activity occurred spontaneously, sections were examined at higher 
magnification. No expression was seen.  
EGFP fluorescent signal was used as a readout for Col1α2-CreERT2 activity when assessing 
samples that were administered tamoxifen. Serial sections were analysed for EGFP signal at 
E13.5 and E15.5. Activation of the CreERT2 was confirmed by observation of EGFP signal at 
both developmental stages. The expression patterns observed were comparable to those 
described by (De Val et al., 2002), with EGFP signal seen in the skull bone, dermal layer of 
the skin, liver, ribs, lungs, and kidney. Single cell populations exhibiting EGFP signal were 
identified when these sections were observed at higher magnification.  
Col1α2-CreERT2 expression was then analysed in adult tissue. Mice of ≥ 6 weeks of age were 
administered tamoxifen and tissues were isolated and examined for tdTomato and EGFP 
signal 7 days and 3 months after tamoxifen. Tissues were isolated from untreated littermate 
animals for comparison. No EGFP signal was found in any tissue collected from untreated 
mice.  
Analysis of these sections demonstrated expression matching that described previously for 
homeostatic adult tissue (Ponticos et al., 2004). Manne, Markova, Siracusa, & Jimenez, 
(2013) described the expression patterns of collagen for skin and lung, and the results shown 
for EGFP expression in the skin and lung reproduce this expression pattern faithfully. EGFP 
localisation in tissues isolated at 3 months was previously reported in Li, Horwell, Chu, de 
Crombrugghe, & Bou-Gharios, (2017). Skin and kidney expression was identical to that seen 
at 7 days, in fact there was no difference in EGFP signalling / Col1α2-CreERT2 activity when 
comparing skin and lung samples collected at 7 or 90 days (3 months). 
The final experiment in this chapter investigated the expression pattern of Col1α2-CreERT2 
when the lungs were subject to injury using the bleomycin model of fibrosis described in 
chapter 3. Animals were administered a single dose of bleomycin following the protocol 
developed in chapter 3. Lungs were extracted for analysis at day 14. This protocol was 
described and Col1α2-CreERT2 activity examined using β-galactosidase activity by Ponticos et 
al., (2004). Increased tdTomato signalling was seen, revealing a loss of usual morphology as 
expected and characteristic of bleomycin treated lungs. Regions of EGFP signalling could be 
identified within the tdTomato signal. Individual EGFP expressing cells were visualised 
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surrounding vessels and lining alveoli. This expression pattern was consistent with the 
expression pattern reported by Ponticos et al., (2004). 
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4.7 Summary 
 
The research in this chapter aimed to establish and characterise two double transgenic 
mouse colonies, containing the floxed CCN2 transgene and a ubiquitously expressed 
ROSA26CreERT2 (ROSA-CCN2fl), or a fibroblast specific tamoxifen-inducible CreERT2 (Col1α2-
CCN2fl) for use in loss of functional CCN2 experiments (reported in Chapter 5). This was 
achieved by developing genotyping strategies to identify animals containing the desired 
transgenes. Subsequent breeding pairs were chosen based on these results and littermates 
were interbred to produce offspring that were homologous for the floxed CCN2 gene, and 
positive for one of the two CreERT2 (ROSA26CreERT2 or Col1α2-CCN2fl).  
A tamoxifen dosing regime was then assessed for recombination of the CCN2 floxed gene 
both in vitro and in vivo. In vitro studies failed to yield any data. In vivo, recombination of the 
CCN2 floxed gene was demonstrated at the DNA, transcriptional and translational level for 
both the fibroblast specific (Col1α2-CCN2fl) and ubiquitously targeting (ROSA-CCN2fl) animal 
lines. 
This research also aimed to characterise the expression profile of the Col1α2-CreERT2 using a 
dual fluorescent (mT/mG) reporter construct. Mice containing the mT/mG reporter construct 
described by Muzumdar et al., (2007), were bred with mice containing the Col1α2-CreERT2. 
Littermate breeding pairs were maintained to produce a double transgenic mouse colony 
that was homozygous for the mT/mG reporter construct, and positive for Col1α2-CreERT2. 
These animals were then used for lineage tracing experiments to determine the expression 
pattern of the Col1α2-CreERT2 during development and during adulthood. This new shorter 
collagen enhancer expressed more widely in almost all fibroblast compared with the previous 
Cre ERT1 generated by (Denton et al., 2001). 
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5. Investigating the Effects of CCN2 Loss of Function on the 
Initiation and Propagation of Fibrosis using a Bleomycin 
Model of IPF 
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5.1 Fibrotic disease 
 
Fibrosis is characterised by excessive accumulation of ECM and is the end result of chronic 
inflammation arising from a number of stimuli including persistent infections, chemical 
insults, and tissue injury (Wynn, 2008). In IPF this accumulation of ECM is localised to the 
lung resulting  in destruction of its normal architecture, ultimately leading to organ failure 
and death (Sime and O’reilly, 2001; Biernacka, Dobaczewski and Frangogiannis, 2011; Kolb, 
Gauldie and Bellaye, 2016).  
At the cellular level, the key mediators of fibrosis are the fibroblast and their profibrotic 
phenotype, the myofibroblast. The myofibroblast serves as the primary collagen-producing 
cell during wound healing and fibrosis (Klingberg, Hinz and White, 2013). During the repair 
process fibroblasts are stimulated to differentiate into their active, ECM synthesising 
myofibroblast phenotype (Kuhn and McDonald, 1991; Kolb, Gauldie and Bellaye, 2016). One 
of the current hypotheses is that a state of chronic inflammation and recurrent micro-
damage leads to dysregulation in the fibroplasia phase of the tissue repair process (Wynn, 
2008). The traditional view was that these activated myofibroblasts derive from resident 
fibroblast populations. However, recent evidence suggests that fibroblasts may originate 
from other cellular sources, such as pericytes (Lin et al., 2008), mesenchymal cells (Misharin 
et al., 2017) and epithelium (Krenning, Zeisberg and Kalluri, 2010).  
TGF-β is known to be a key mediator of fibrogenesis and is capable of driving the activation 
of the myofibroblast (Chen et al., 2009; Midgley et al., 2013; Tomcik et al., 2015). Although 
this makes TGF-β an attractive therapeutic target for IPF, the pleiotropic roles it plays in tissue 
homeostasis (Xu et al., 2018), immunity (Travis and Sheppard, 2014) and cell proliferation 
(Huang and Huang, 2005) raise concerns that too many potential side effects may be caused 
by targeting TGF-β signalling (Biernacka, Dobaczewski and Frangogiannis, 2011). Therefore, 
research has explored downstream mediators of TGF-β signalling as candidates for 
therapeutic intervention.  
CCN2 has been proposed to be a key downstream mediator of the profibrotic effects of TGF- 
β, and its role in fibrosis has been investigated independently of TGF-β (Sonnylal et al., 2010). 
CCN2 has consistently been shown to be upregulated in connective disease in the lung (Allen 
and Spiteri, 2002), in tandem with TGF-β upregulation (Lasky et al., 1998; Xu et al., 2006). 
CCN2 is known to be a key mediator of many of the signalling pathways associated with 
fibrosis, such as activating cell adhesion and migration (Bradham et al., 1991), angiogenesis 
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(Babic, Chen and Lau, 1999), myofibroblast activation (Tsai et al., 2018), and extracellular 
matrix deposition and remodelling (Lipson et al., 2012).  A monoclonal antibody to CCN2, 
currently in clinical development (FG-3019) has demonstrated the ability to reverse the 
fibrosis in various murine models of fibrosis (Koshman et al., 2015; Bickelhaupt et al., 2017) 
and is showing promising efficacy in human trials (Raghu et al., 2012, 2016; Picozzi et al., 
2016).  
5.2 Chapter Aims 
 
The aims of this chapter were as follows: 
1) Investigate the effects of fibroblast specific removal of CCN2 in a bleomycin model 
of IPF. 
In the previous chapter a double transgenic mouse line was generated that was homologous 
for the CCN2 floxed allele, and positive for Col1α2-CreERT2, (Col1α2-CCN2fl). This research 
used this transgenic mouse line in conjunction with the bleomycin model of IPF that was 
generated in Chapter 3 to achieve the following objectives: 
• Identify if the fibroblast specific removal of CCN2 results in a phenotype in the lung. 
µCt analysis, histology and qPCR were used to assess lung samples from Col1α2-
CCN2fl mice, at time points 7, 14 and 28 days post treatment with tamoxifen. 
• Identify if there is an altered response in the rate of fibrosis formation when CCN2 is 
removed from fibroblasts prior to treatment with bleomycin. µCt analysis, histology 
and qPCR were used to assess lung samples from Col1α2-CCN2fl mice, at time points 
7, 14 and 28 days post treatment with tamoxifen and bleomycin. 
 
2) Investigate the effects of ubiquitous removal of CCN2 in a bleomycin model of 
idiopathic pulmonary fibrosis (IPF) and compare this to the response seen in Col1α2-
CCN2fl mice at 14 days post bleomycin treatment. 
In the previous chapter a second double transgenic mouse line was generated that was 
homologous for the CCN2 floxed allele, and positive for ubiquitously expressed ROSA-
CreERT2, (ROSA-CCN2fl). This research used this transgenic mouse line in conjunction with the 
bleomycin model of IPF that was generated in Chapter 3 to achieve the following objectives: 
129 
 
• Identify if the ubiquitous removal of CCN2 results in a phenotype in the lung. µCt 
analysis, histology and qPCR were used to assess lung samples from ROSA-CCN2fl 
mice, at a time point of 14 days post treatment with tamoxifen. 
• Identify if there is an altered response in the rate of fibrosis formation when CCN2 is 
removed from all cells prior to treatment with bleomycin. µCt analysis, histology and 
qPCR were used to assess lung samples from ROSA-CCN2fl mice, at a time points of 
14 days post treatment with tamoxifen and bleomycin. 
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5.3 Phenotypic analysis of lungs from tamoxifen treated Col1α2-CreERT2  
 
The first experiments in this research characterised the responses to tamoxifen treatment in 
the Col1α2-CCN2fl double transgenic mouse line. Experimental day 1 was considered as 7 
days after tamoxifen dosing was completed. This was to ensure analyses in these studies 
were directly comparable to later experiments when a 7-day recovery period was required 
prior to bleomycin treatment. Tamoxifen injection activated recombination of the CCN2fl 
gene by Col1α2-CreERT2. 
Male and female mice from the Col1α2-CCN2fl were aged to ≥6 weeks and administered 
three I.P. 0.025 mg/g injections of tamoxifen as described in methods section 2.5.1. On 
experimental days 7, 14 and 28 animals were culled by Sch1 by overdose of Pentobarbital 
prepared for µCT scanning as per methods section 2.6. No morphological differences in the 
lungs were observed by µCT analysis at any time point (Figure 5.1). 
Closer examination of the morphology of the lungs was carried out by histological analysis. A 
lobe from experimental lungs was isolated immediately after µCT scanning and processed for 
histology following the protocol described in methods section 2.8. Sections of 5 µm were 
stained with H & E, or Goldner’s trichrome stains. Protocols can be found in methods section 
2.8.  
H & E stain was used to identify anatomical features of the lung including the bronchioles, 
alveoli and blood vessels. A stitched image taken at 10x magnification was used to visually 
assess the whole lung lobe section (Figure 5.2), where scale bars represent 1 mm. For closer 
analysis of the morphology of the lung, individual images were taken at 10x magnification 
(Figure 5.3), scale bars represent 200 µm. Single cell epithelial lining of the alveoli was 
identifiable at 10x magnification for all samples (Figure 5.3). Blood vessels were seen 
associated with the bronchioles as well as being dispersed throughout the alveoli. No 
differences in morphology were identified when comparing lung lobes treated with 
tamoxifen to an untreated control lung. 
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Figure 5.1. µCT scans of unfixed, inflated mouse lungs isolated from tamoxifen treated Col1α2-CCN2fl mice at 7, 
14 and 28 Days. Animals were administered 3x doses of tamoxifen at 0.025 ng/g. A week’s recovery period was 
given before experimental day 1. Animals were Sch1 by overdose of Pentobarbital, the lungs manually inflated 
prior to extraction. Isolated lungs were then suspended between pieces of Styrofoam (sf) in 3 – 5 % (wt / vol) KI 
contrast agent for µCT scanning. Lungs were scanned using a SkyScan 1272 µCT system at a resolution of 20 µm 
(0.25 mm aluminium filter, 0.3 ° rotation step). Images were reconstructed using Skyscan Nrecon software and 
visualised using DataViewer. Tamoxifen treatment causes loss of CCN2 in fibroblasts. Anatomical features are 
identified by the following: br- bronchioles, He- heart. Representative images from whole lung 3D scans are shown 
using DataViewer software. Example scans for lungs collected at the following timepoints are A) Untreated, B) 
Experimental day 7, C) Experimental day 14, D) Experimental day 28.
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Figure 5.2. Histological evaluation of whole lung lobe samples lungs isolated from tamoxifen treated Col1α2-CCN2fl mice at 7, 14 and 28 Days using H & E stain. Lungs were isolated immediately 
after Sch1 by anaesthetic overdose and manually inflated for scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Lungs were 
processed for wax histology and stained with H & E. Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels. All images were taken at 10x magnification. A) 
Untreated, B) Experimental day 7, C) Experimental day 14, D) Experimental day 28. Scale bars represent 1 mm.  
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Figure 5.3. Histological evaluation of lung samples isolated from tamoxifen treated Col1α2-CCN2fl mice at 7, 14 and 28 days using H & E stain. Lungs were isolated immediately after Sch1 by 
anaesthetic overdose and manually inflated for scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Lungs were processed for 
wax histology and stained with H & E. Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels. All images were taken at 10x magnification. A) Untreated, B) 
Experimental day 7, C) Experimental day 14, D) Experimental day 28. Scale bars represent 200 µm.  
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Goldner’s trichrome stain was used to identify collagen deposits from muscular tissues. Cell 
nuclei appear black, cytoplasm - red and collagen - green. A stitched image taken at 10 x 
magnification was used to visually assess the presence of collagen across in the whole lung 
lobe lung section (Figure 5.4), where scale bars represent 1 mm. For closer analysis of the 
morphology of the lung, individual images were taken at 10x magnification (Figure 5.5), scale 
bars represent 200 µm. Anatomical features of the lung are identified in the figure as: 
bronchioles, alveoli and blood vessels.  
Collagen is a major constituent of the pulmonary interstitium and major structures including 
the bronchioles, blood vessels alveoli and bronchioles. Therefore, some green staining of 
these structures was anticipated and seen in both control and tamoxifen treated lungs 
(Figure 5.5). Red staining inside bronchioles demonstrates the presence of the epithelial cells 
lining these structures. No differences in morphology were identified when comparing lung 
lobes treated with tamoxifen to an untreated control lung.
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Figure 5.4. Histological evaluation of whole lung lobe samples lungs isolated from tamoxifen treated Col1α2-CCN2fl mice at 7, 14 and 28 Days using Goldner’s trichrome stain. Lungs 
were isolated immediately after Sch1 by anaesthetic overdose and manually inflated for scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium 
filter, 0.3 ° rotation step). Lungs were processed for wax histology and stained with H & E. Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels. 
All images were taken at 10x magnification. A) Untreated, B) Experimental day 7, C) Experimental day 14, D) Experimental day 28. Scale bars represent 1 mm.  
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Figure 5.5. Histological evaluation of lung samples isolated from tamoxifen treated Col1α2-CCN2fl mice at 7, 14 and 28 Days using Goldner’s trichrome stain. Lungs were isolated 
immediately after Sch1 by anaesthetic overdose and manually inflated for scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation 
step). Lungs were processed for wax histology and stained with H & E. Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels. All images were taken 
at 10x magnification. A) Untreated, B) Experimental day 7, C) Experimental day 14, D) Experimental day 28. Scale bars represent 200 µm.  
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The gene expression levels of Collagen I (COL1α2), Collagen III (COL3) and Fibronectin E-DA 
(FN-EDA) gene transcription was quantified by PCR analysis on the remaining lobes of the 
lungs (Figure 5.6). These proteins are all constituents of the ECM in the lung and were 
selected for analysis due to their association with fibrotic lung phenotypes. Sample cycle 
threshold (Ct) values were normalised to untreated animals of the same background and are 
expressed as a fold change using the ∆∆Ct method. Significance was determined using a one-
way ANOVA, and Tukey’s post hoc test for correction for multiple testing was performed 
using GraphPad Prism. P-values below 0.05 were considered statistically significant. Samples 
from male and female mice were analysed independently.  
In male animals no difference in transcription of COL1α2 and FN-EDA was observed at any of 
the experimental time points (Figure 5.6 A & C). Statistically significant increase (P ˂ 0.0001) 
in COL3 was observed at experimental day 7 (Figure 5.6). In female animals, Figure 5.6 D – F) 
statistically significant reduction (P ˂ 000.1) in COL1α2 (D) and COL3 (E) transcription was 
observed at experimental day 14. At experimental day 7 a statistically significant increase in 
FN-EDA was observed (P ˂ 000.1), followed by a statistically significant reduction (P ˂ 0.05) 
at experimental day 14 (Figure 5.6, F). The ∆∆Ct fold change of FN-EDA between 7 and 14 
days was also found to be statistically significant (P ˂ 0.0001), (Figure 5.6, F). These analyses 
showed that although no phenotype manifested at any time point, there were alterations in 
gene transcription of Collagen I, Collagen III and Fibronectin ED-A when CCN2 was removed 
from fibroblasts over a 28-day experimental period. 
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Figure 5.6. RT-qPCR analysis of COL1α2, COL3 and FN-EDA expression in lung samples isolated from tamoxifen treated Col1α2-CCN2fl mice at 7, 14 and 28 Days. ∆∆Ct analysis of 
COL1α2 (A & D), COL3 (B & E) and FN-EDA (C & F) mRNA in double transgenic animals homozygous for CCN2 floxed gene and positive for fibroblast specific Col1α2-CreERT2. (A - C) 
Male mice, (D - F), Female mice. RNA was extracted from whole lungs, after µCT scanning. Samples were collected on experimental days 7, 14 and 28 days. ∆∆Ct fold change results 
are plotted, significance was determined using a one-way ANOVA, and Tukey’s post hoc test. Significance and associated p-value are indicated by (*).  
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5.4 Investigating the effects of fibroblast specific loss of function of CCN2, in a 
bleomycin model of IPF using the tamoxifen-inducible double transgenic Col1α2-
CCN2fl mouse line 
 
The next series of experiments aimed to determine if the removal of CCN2 from fibroblast 
cells affected the fibrosis formed using the bleomycin model of IPF described in chapter 4 
with Col1α2-CCN2fl double transgenic mouse line. Timepoints of 7, 14 and 28 days after 
bleomycin administration were investigated. Experimental day 1 was considered as 7 days 
after tamoxifen dosing was completed.  
Male and female mice from the Col1α2-CCN2fl were aged to ≥6 weeks and administered with 
three I.P. 0.025 mg/g injections of tamoxifen as described in methods section 2.5.1. 
Tamoxifen treatment induced recombination of the CCN2 gene and ultimately caused the 
loss of function of CCN2 from fibroblast cells. A 7-day recovery period was required following 
tamoxifen treatment. Research reported in chapter 4 confirmed that this period was 
sufficient for CCN2 protein expression to be reduced. A single dose of bleomycin (0.375 ng/g) 
was then administered by OA as described in methods section 2.5.2. On experimental days 
7, 14 and 28 animals were Sch1 by overdose of Pentobarbital and prepared for µCT scanning 
as per methods section 2.6. A single lobe was isolated after µCT scanning and processed for 
paraffin wax histology. The remaining lung tissue was snap frozen and RNA was extracted 
following the protocol in methods section 2.7.2. Littermate animals were administered the 
bleomycin treatment in the absence of tamoxifen for direct comparison of the extent of 
fibrosis at experimental timepoints. These mice are described as wild type (WT) for these 
results as the expression of CCN2 was unaltered. Animals where CCN2 loss of function was 
induced are referred to as ‘CCN2 k/o’. 
Visual assessment of the µCT scans (Figure 5.7) showed the expected progression for 
developing fibrosis in the bleomycin model across the 28-day experimental period for both 
tamoxifen treated and control animals. Early fibrotic focal regions were observed at 7 days 
(Figure 5.7, B, red arrows), numerous regions of established fibrosis at 14 days (Figure 5.7, 
C, red arrows), followed by apparent resolution by 28 days (Figure 5.7, D, red arrows). The 
extent of fibrosis identified at 14 days in CCN2 k/o lungs appeared to be reduced when 
compared to WT lungs (Figure 5.7 C & D, red arrows).  
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Figure 5.7. µCT scans of unfixed, inflated mouse lungs isolated from tamoxifen and bleomycin treated Col1α2-CCN2fl mice at 7, 14 and 28 Days. Animals were administered 3x doses 
of tamoxifen at 0.025 ng/g. A week’s recovery period was given before experimental day 1. Animals were Sch1 by overdose of pentobarbital, and the lungs manually inflated prior to 
extraction. Isolated lungs were then suspended between pieces of Styrofoam (sf) in 3 – 5 % (wt / vol) KI contrast agent for µCT scanning. Lungs were scanned using a SkyScan 1272 
µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Images were reconstructed using Skyscan Nrecon software and visualised using DataViewer. 
Anatomical features are identified by the following: br- bronchioles, He- heart. Air bubbles are marked as-ab. Representative images from whole lung 3D scans are shown using 
DataViewer software. A – D) Example scans from mice treated with bleomycin only, A) Untreated, B) Experimental day 7, C) Experimental day 14, D) Experimental day 28. E-H) Example 
scans from mice treated with tamoxifen before bleomycin treatment. E) Untreated, F) Experimental day 7, G) Experimental day 14, H) Experimental day 28. Red arrows indicate regions 
of fibrosis. 
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Closer examination of the morphology of the lungs was carried out by histological analysis. A 
lobe from experimental lungs was isolated immediately after µCT scanning and processed for 
histology following the protocol described in methods section 2.8. Sections of 5 µm were 
stained with H & E, or Goldner’s trichrome stains. Protocols can be found in methods section 
2.8. 
H & E stain was used to identify anatomical features of the lung including the bronchioles, 
alveoli and blood vessels. Representative images taken at 10x magnification are shown in 
(Figure 5.8), scale bars represent 200 µm. Regions identified as fibrotic, from visual 
assessment of the µCT scans, were found to correspond to tissue deposits in H & E stained 
sections (Figure 5.8, black arrows). In sections from experimental day 7 (Figure 5.8, B & E) 
fibrotic foci were observed (black arrows) in lungs where CCN2 loss of function was induced 
in fibroblasts and in WT lungs. At 14 days, large regions of tissue deposits were identified in 
both WT and CCN2. These were more extensive than those observed at 7 days (Figure 5.8). 
Examination of sections at 28 days revealed some regions of fibrosis remained (Figure 5.8, D 
& G). These were not as frequent or extensive as those seen at day 14. Increase in tissue 
volume of the section was associated with an altered morphology of alveoli. A thickening in 
the cells lining the alveoli was observed in regions adjacent to tissue deposits (Figure 5.8). 
Staining with Goldner’s Trichrome (Figure 5.9) indicated that these tissue deposits consisted 
of collagen, as corresponding regions of sections stained green. An increase in green staining 
was observed in corresponding patterns those described for H & E staining. Regions of 
fibrosis were closely associated with the bronchioles, with tissue deposition observed and 
fibrotic foci formation occurring most frequently in the immediate vicinity of the bronchioles. 
Increased nuclear staining was observed in all lungs that were treated with bleomycin when 
compared to the untreated lung (Figure 5.8 and Figure 5.9). This was observed at the greatest 
extent in lungs isolated at experimental day 14 in tissue deposits (black arrows) surrounding 
bronchioles.  
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Figure 5.8. Histological evaluation of lung samples isolated from Col1α2-CCN2fl mice at 7, 14 and 28 days post tamoxifen and bleomycin treatment using H & E stain. Lungs were 
isolated immediately after Sch1 by anaesthetic overdose and manually inflated for scanning, using a SkyScan 1272 µCT system at a resolution of 20µm (0.25mm aluminium filter, 0.3° 
rotation step). Lungs were processed for wax histology and stained with H & E. Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels, black arrows 
indicate regions of fibrosis. All images were taken at 10x magnification. A) Untreated, B - D) Bleomycin treated only, Experimental days 7, 14, and 28 respectively. E - G) Tamoxifen 
followed by bleomycin treatments, Experimental days 7, 14, and 28 respectively. Scale bars represent 200 µm.  
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Goldner’s trichrome stain was used to identify collagen deposits from muscular tissues. Cell 
nuclei appear black, cytoplasm - red and collagen - green. Images were taken at 10x 
magnification (Figure 5.9), scale bars represent 200 µm. Anatomical features of the lung are 
identified in the figure as: bronchioles (br), alveoli (a) and blood vessels (v). Collagen is a 
major constituent of the pulmonary interstitium and major structures including the 
bronchioles, blood vessels, alveoli and bronchioles. Therefore, green staining of these 
structures was anticipated and seen in all lungs (Figure 5.9). Red staining inside bronchioles 
demonstrates the presence of the epithelial cells lining these structures. The same 
morphology as described for the H & E stained images was noted, with the additional 
comment that tissue deposits were stained green, supporting the notion that these are 
fibrotic tissue deposits of ECM. 
In sections from experimental day 7 (Figure 5.9, B & E) fibrotic foci exhibited similar staining 
patterns, intensity and localisation (red arrows) in lungs from CCN2 k/o animals compared to 
WT lungs. At 14 days, large regions of tissue deposits were identified in both WT and CCN2 
(Figure 5.9 C & F). These were more extensive than those observed at 7 days, and fibrotic foci 
were observed forming in close proximity to bronchioles. Sections from CCN2 k/o animals 
appeared to show a subtle reduction in staining and instance of foci formation (Figure 5.9, 
F). Examination of sections at 28 days identified some regions of fibrosis remained (Figure 
5.9, D & G, red arrows). These were not as frequent or extensive as those seen at day 14. 
Resolution of fibrosis was apparent in sections from both normal and transgenic animals at 
28 days. No significant differences in staining were noted at any time point when directly 
comparing fibroblast CCN2 k/o with WT.  
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Figure 5.9. Histological evaluation of lung samples isolated from Col1α2-CCN2fl mice at 7, 14 and 28 days post tamoxifen and bleomycin treatment using Goldner’s trichrome stain. 
Lungs were isolated immediately after Sch1 by anaesthetic overdose and manually inflated for scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium 
filter, 0.3 ° rotation step). Lungs were processed for wax histology and stained with H & E. Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels, 
red arrows indicate regions of fibrosis. All images were taken at 10 x magnification. A) Untreated, B - D) Bleomycin treated only, Experimental days 7, 14, and 28 respectively. E - G) 
Tamoxifen followed by bleomycin treatments, Experimental days 7, 14, and 28 respectively. Scale bars represent 200 µm.  
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Collagen I (COL1α2), Collagen III (COL3) and Fibronectin – EDA (FN-EDA) gene transcription 
was examined by qPCR analysis of the remaining lobes of the lungs (Figure 5.10). These 
proteins are all constituents of the ECM in the lung and were selected for analysis due to 
their association with fibrotic lung phenotypes. Sample cycle threshold (Ct) values were 
normalised to untreated animals of the same background and are expressed as a fold change 
using the ∆∆Ct method. Significance was determined using a one-way ANOVA, and Tukey’s 
post hoc test for correction for multiple testing was performed using GraphPad Prism. P-
values below 0.05 were considered statistically significant. Samples from male and female 
mice were analysed independently.  
Analysis of WT male animals (Figure 5.10, A & C), identified a statistically significant 
upregulation of COL1α2, COL3 and FN-EDA transcription between control and bleomycin 
treated lungs at 14 days (P ˂ 0.0001). No statistically significant difference in the ∆∆Ct fold 
change was observed between control and WT bleomycin treated lungs at 28 days. The 
reduction in transcription (decrease in mean ∆∆Ct) of COL1α2, COL3 and FN-EDA between 14 
and 28 days was found to be statistically significant (P ˂ 0.05). 
Analysis of CCN2 k/o male animals (Figure 5.10 D - F), identified a statistically significant 
upregulation of COL1α2 (D), transcription between control and bleomycin treated lungs at 7 
(P ˂ 0.05), 14 (P ˂ 0.0001) and 28 days (P ˂ 0.0001). Analysis of COL3 transcription (Figure 
5.10, E) identified a statistically significant upregulation of COL3, transcription between 
control and bleomycin treated lungs at 7 (P ˂ 0.0001), 14 (P ˂ 0.0001) and 28 days 
(P ˂ 0.0001). Analysis of FN-EDA transcription identified a statistically significant increase in 
∆∆Ct between control and bleomycin treated lungs at 7 (P ˂ 0.01), 14 (P ˂ 0.0001) and 28 
days (P ˂ 0.01) (Figure 5.10, F). The change in transcription of COL1α2, COL3 and FN-EDA 
between experimental timepoints was not found to be statistically significant. 
Analysis of WT female animals (Figure 5.11, A - C), identified no statistically significant 
changes in transcription of COL1α2 (A) or COL3 (B). A statistically significant upregulation of 
FN-EDA transcription was observed between control and bleomycin treated lungs at 7 days 
(P ˂ 0.0001) and 14 days (P ˂ 0.05) (Figure 5.11, C). The reduction in transcription of FN-EDA 
between 7 and 14 days, and 7 and 28 days was also found to be statistically significant 
(P ˂ 0.01, P ˂ 0.01) (Figure 5.11, F). No statistically significant difference in FN-EDA 
transcription was observed between 14 and 28 days (Figure 5.11, F). 
Analysis of CCN2 k/o female animals (Figure 5.11, D - F), identified no statistically significant 
differences in COL1α2, transcription between control and bleomycin treated lungs (Figure 
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5.11, D). A statistically significant decrease in transcription of COL1α2 was observed between 
7 and 28 days (P ˂ 0.05) (Figure 5.11, D). No statistically significant differences were observed 
between other time points (Figure 5.11, D). No statistically significant differences were 
observed at any time point for COL3 transcription (Figure 5.11, E). Analysis of FN-EDA 
transcription (Figure 5.11, F) identified a statistically significant upregulation of FN-EDA 
transcription between control and bleomycin treated lungs at 7 (P ˂ 0.01), 14 (P ˂ 0.01) and 
28 days (P ˂ 0.05). identified a statistically significant upregulation of COL1α2, transcription 
between control and bleomycin treated lungs at 7 (P ˂ 0.01), 14 (P ˂ 0.0001) and 28 days 
(P ˂ 0.01). The change in transcription of FN-EDA between experimental timepoints was not 
found to be statistically significant. 
The average ∆∆Ct values are presented in (Table 5.1). In both male and female mice where 
CCN2 was removed from fibroblasts prior to bleomycin treatment, the average ∆∆Ct value 
for each gene was reduced when compared to a WT at 14 days. At 28 Days the ∆∆Ct values 
for females are similar, with the exception of FN-EDA, where CCN2 k/o shows a slight increase 
in ∆∆Ct compared to WT counterparts. In male mice CCN2 removal from fibroblasts resulted 
in a higher ∆∆Ct value at 28 days than observed for WT mice. In male mice the highest fold 
increases in gene transcription were observed at the 14-day time point. In female mice the 
highest fold increases in gene transcription were observed at the 14-day time point.  
Based on the fibrotic phenotype and transcriptional changes identified in animals collected 
at 14 days, it was decided that this timepoint would be used to compare the effects of a 
ubiquitous knock out of CCN2 with the fibroblast specific knock out of CCN2, in the bleomycin 
model of IPF. 
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Figure 5.10. RT-qPCR analysis of COL1α2, COL3 and FN-EDA expression in lung samples isolated from tamoxifen and bleomycin treated male Col1α2-CCN2fl mice at 7, 14 and 28 days. 
∆∆Ct analysis of COL1α2 (A & D), COL3 (B & E) and FN-EDA (C & F) mRNA in double transgenic animals homozygous for CCN2 floxed gene and positive for fibroblast specific Col1α2-
CreERT2. (A - C) Bleomycin treated only, (D - F), Tamoxifen and bleomycin treated mice. RNA was extracted from whole lungs, after µCT scanning. Samples were collected on 
experimental days 7, 14 and 28 days. ∆∆Ct fold change results are plotted, significance was determined using a one-way ANOVA, and Tukey’s post hoc test. Significance and associated 
p-value are indicated by (*).  
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Figure 5.11. RT-qPCR analysis of COL1α2, COL3 and FN-EDA expression in lung samples isolated from tamoxifen and bleomycin treated Female Col1α2-CCN2fl mice at 7, 14 and 28 
days. ∆∆Ct analysis of COL1α2 (A & D), COL3 (B & E) and FN-EDA (C & F) mRNA in double transgenic animals homozygous for CCN2 floxed gene and positive for fibroblast specific 
Col1α2-CreERT2. (A - C) Bleomycin treated only, (D - F), Tamoxifen and bleomycin treated mice. RNA was extracted from whole lungs, after µCT scanning. Samples were collected on 
experimental days 7, 14 and 28 days. ∆∆Ct fold change results are plotted, significance was determined using a one-way ANOVA, and Tukey’s post hoc test. Significance and associated 
p-value are indicated by (*).  
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Table 5.1. Summary table of mean ∆∆Ct values COL1α2, COL3 and FN-EDA gene expression. Lung samples were isolated from tamoxifen and bleomycin treated Col1α2-CCN2fl mice 
(FB CCN2 k/o) and bleomycin alone treated mice (WT) at 7, 14 and 28 Days after bleomycin administration. The number of animals in each treatment group (n =) and mean ∆∆Ct fold 
change is shown for each timepoint. 
Gene of 
interest
Mouse 
strain
n = Avg. ∆∆Ct Std. Dev n = Avg. ∆∆Ct Std. Dev n = Avg. ∆∆Ct Std. Dev
WT - - - 11 3 1.50 4 1.29 0.6900
FB CCN2 k/o 10 1.61 0.51 8 2 0.60 12 1.99 0.59
WT - - - 11 5 2.74 4 1.99 0.85
FB CCN2 k/o 10 2.96 0.15 8 4 1.16 12 3.35 1.26
WT - - - 11 6 3.73 4 1.50 0.99
FB CCN2 k/o 10 3.36 1.84 8 4 2.40 12 3.01 1.49
Female 
Gene of 
interest
Mouse 
strain
n = Avg. ∆∆Ct Std. Dev n = Avg. ∆∆Ct Std. Dev n = Avg. ∆∆Ct Std. Dev
WT 4 2.88 1.08 11 1.69 1.50 13 1.02 0.20
FB CCN2 k/o 2 1.84 0.31 21 1.40 0.50 6 0.94 0.78
WT 2 3.75 1.26 21 2.47 2.38 6 1.37 0.26
FB CCN2 k/o 4 2.11 0.36 11 1.90 0.95 13 1.36 0.90
WT 2 12.69 5.16 21 4.01 5.30 6 2.00 0.94
FB CCN2 k/o 3 3.98 1.14 11 2.89 1.83 12 2.34 1.98
FN-EDA
7 Days 14 Days 28 Days
7 Days 14 Days 28 Days
COL I
COL III
FN-EDA
COL I
COL III
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5.5 Comparing the effects of fibroblast specific loss of function of CCN2, with a 
ubiquitous loss of function of CCN2 in a bleomycin model of IPF using the tamoxifen-
inducible double transgenic Col1α2-CCN2fl and ROSA-CCN2fl mouse line  
 
The subsequent series of experiments aimed to determine if there was a differential 
response in fibrosis formation when loss of function of CCN2 was induced in a fibroblast 
specific (Col1α2-CCN2fl) or ubiquitous (ROSA-CCN2fl) manner, prior to the administration of 
bleomycin. A timepoint of 14 days after bleomycin administration was investigated. 
Experimental day 1 was considered as 7 days after tamoxifen dosing was completed.  
Male and female mice from the ROSA-CCN2fl mouse colony were aged to ≥6 weeks and 
administered three I.P. 0.025 mg/g injections of tamoxifen as described in methods section 
2.5.1. Tamoxifen treatment induced recombination of the CCN2 gene and ultimately caused 
the loss of function of CCN2 from all cells (ROSA-CCN2fl). A 7-day recovery period was 
required following tamoxifen treatment. Research reported in chapter 4 confirmed that this 
period was sufficient for CCN2 protein expression to be completely stopped. A single dose of 
bleomycin (0.375 ng/g) was then administered by OA as described in methods section 2.5.2. 
On experimental day 14 animals were Sch1 by overdose of Pentobarbital and prepared for 
µCT scanning as per methods section 2.6. A single lobe was isolated after µCT scanning and 
processed for paraffin wax histology. The remaining lung tissue was snap frozen and RNA was 
extracted following the protocol in methods section 2.7.2. Littermate animals were 
administered the bleomycin treatment in the absence of tamoxifen for direct comparison of 
the extent of fibrosis at 14 days where CCN2 activity was unmodified.  
The results from these experiments were compared to the previously described results in 
animals where CCN2 loss of function was induced in fibroblasts. Where loss of function of 
CCN2 was induced in fibroblasts prior to bleomycin administration, animals are referred to 
as ‘Fb k/o’ (Col1α2-CCN2fl double transgenic line). Animals where CCN2 loss of function was 
induced in all cells prior to bleomycin administration are referred to as ‘Ub k/o’ (ROSA-CCN2fl 
double transgenic line).  
Visual comparison of the µCT scans (Figure 5.12) showed no difference in phenotype of WT 
animals from Col1α2-CCN2fl (A) and ROSA-CCN2fl (E) double transgenic mouse lines. The 
response to bleomycin in WT animals was not observed to be different between Col1α2-
CCN2fl (C) and ROSA-CCN2fl (G) double transgenic mouse lines. No difference in phenotype 
between WT and Fb k/o mice was observed when loss of function of CCN2 was induced 
without subsequent challenge with bleomycin (Figure 5.12, B). In Ub k/o animals where loss 
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of function of CCN2 was induced without subsequent challenge with bleomycin small regions 
of fibrosis were observed in subpleural regions of the lungs (Figure 5.12, F, red arrows). The 
extent of fibrosis identified at 14 days in Fb k/o lungs (Figure 5.12, D, red arrows) appeared 
to be reduced when compared to WT lungs (Figure 5.12, C & G). The µCT scans of Ub k/o 
mice (Figure 5.12, H) showed far more extensive fibrosis than both WT and Fb k/o mice 
(Figure 5.12, C, D & G). Large dense regions of tissue were observed in the lungs, 
accompanied by a loss of identifiable anatomical features excluding the bronchioles. Very 
few regions of suspected functional tissue could be identified (Figure 15.12, H, green arrows).  
H & E stain was used to identify anatomical features of the lung including the bronchioles, 
alveoli and blood vessels. Representative images taken at 10x magnification are shown in 
(Figure 5.13), scale bars represent 200 µm. Regions identified as fibrotic, from visual 
assessment of the µCT scans, were found to correspond to tissue deposits in H & E stained 
sections (Figure 5.13, black arrows). Regions of fibrosis (black arrows) were closely associated 
with the bronchioles, with tissue deposition observed and fibrotic foci formation occurring 
most frequently in the immediate vicinity of the bronchioles. Increased nuclear staining was 
observed in all lungs that were treated with bleomycin (Figure 5.13, C, D, G & H) when 
compared to the untreated lung (Figure 5.13 A). Tissue samples from Ub k/o mice (Figure 
5.13, H) confirmed that the morphology identified in the µCT scan (Figure 5.12, H) was 
accurately represented as tissue deposition was extensive in these sections.     
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Figure 5.12. µCT scans of unfixed, inflated mouse lungs isolated from tamoxifen and bleomycin treated Col1α2-CCN2fl mice and ROSA-CCN2fl mice at experimental day 14. Animals 
were administered 3x doses of tamoxifen at 0.025 ng/g. A week’s recovery period was given before experimental day 1. Animals were Sch1 by overdose of Pentobarbital, the lungs 
manually inflated prior to extraction. Isolated lungs were then suspended between pieces of Styrofoam (sf) in 3 – 5 % (wt / v) KI contrast agent for µCT scanning. Lungs were scanned 
using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). Images were reconstructed using Skyscan Nrecon software and visualised 
using DataViewer. Tamoxifen treatment causes loss of CCN2 in fibroblasts in Col1α2-CCN2fl mice and a ubiquitous removal of CCN2 in ROSA-CCN2fl mice. Anatomical features are 
identified by the following: br- bronchioles, He- heart.  Representative images from whole lung 3D scans are shown using DataViewer software. A) Untreated Col1α2-CCN2fl mouse, 
B) Tamoxifen treated Col1α2-CCN2fl mouse, C) Bleomycin treated Col1α2-CCN2fl mouse, D) Tamoxifen and Bleomycin treated Col1α2-CCN2fl mouse, E) Untreated ROSA-CCN2fl mouse, 
F) Tamoxifen treated ROSA-CCN2fl mouse, G) Bleomycin treated ROSA-CCN2fl mouse, H) Tamoxifen and Bleomycin treated ROSA-CCN2fl mouse. Red arrows indicate fibrosis, green 
arrows indicate regions of normal tissue morphology. 
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Figure 5.13. Histological evaluation of lung samples isolated from tamoxifen and bleomycin treated Col1α2-CCN2fl and ROSA-CCN2fl mice at experimental day 14 using H & E stain. 
Lungs were isolated immediately after Sch1 by anaesthetic overdose and manually inflated for scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium 
filter, 0.3 ° rotation step). After scanning a single lobe was isolated, processed for wax histology, sectioned to 5 µm and stained with H & E. Tamoxifen treatment causes loss of CCN2 
in fibroblasts in Col1α2-CCN2fl mice and a ubiquitous removal of CCN2 in ROSA-CCN2fl mice. Anatomical features are identified as follows: a- alveoli, br- bronchioles, v- blood vessels, 
black arrows indicate regions of fibrosis. All images were taken at 10x magnification. A) Untreated Col1α2-CCN2fl mouse, B) Tamoxifen treated Col1α2-CCN2fl mouse, C) Bleomycin 
treated Col1α2-CCN2fl mouse, D) Tamoxifen and Bleomycin treated mouse, E) Untreated ROSA-CCN2fl mouse, F) Tamoxifen treated ROSA-CCN2fl mouse, G) Bleomycin treated ROSA-
CCN2fl mouse, H) Tamoxifen and Bleomycin treated ROSA-CCN2fl mouse. Scale bars represent 200 µm.  
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Goldner’s trichrome stain was used to identify collagen deposits from muscular tissues. 
Images were taken at 10x magnification (Figure 5.14), scale bars represent 200 µm. 
Anatomical features of the lung are identified in the figure as: bronchioles (br), alveoli (a) and 
blood vessels (v). Green staining of the blood vessels, alveoli and bronchioles was anticipated 
and seen in all lungs (Figure 5.14). Red staining inside bronchioles demonstrates the presence 
of the epithelial cells lining these structures. The same morphology as described for the H & 
E stained images was noted, with the additional comment that tissue deposits were stained 
green, supporting the notion that these are fibrotic tissue deposits of ECM.
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Figure 5.14. Histological evaluation of lung samples isolated from tamoxifen and bleomycin treated Col1α2-CCN2fl and ROSA-CCN2fl mice at experimental day 14 using Goldner’s 
trichrome stain. Lungs were isolated immediately after Sch1 by anaesthetic overdose and manually inflated for scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm 
(0.25 mm aluminium filter, 0.3 ° rotation step). After scanning a single lobe was isolated, processed for wax histology, sectioned to 5 µm and stained with H & E. Tamoxifen treatment 
causes loss of CCN2 in fibroblasts in Col1α2-CCN2fl mice and a ubiquitous removal of CCN2 in ROSA-CCN2fl mice. Anatomical features are identified as follows: a- alveoli, br- 
bronchioles, v- blood vessels, red arrows indicate regions of fibrosis. All images were taken at 10x magnification. A) Untreated Col1α2-CCN2fl mouse, B) Tamoxifen treated Col1α2-
CCN2fl mouse, C) Bleomycin treated Col1α2-CCN2fl mouse, D) Tamoxifen and Bleomycin treated mouse, E) Untreated ROSA-CCN2fl mouse, F) Tamoxifen treated ROSA-CCN2fl mouse, 
G) Bleomycin treated ROSA-CCN2fl mouse, H) Tamoxifen and Bleomycin treated ROSA-CCN2fl mouse. Scale bars represent 200 µm.  
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The levels of Collagen I (COL1α2), Collagen III (COL3) and Fibronectin – EDA (FN-EDA) gene 
transcription in the remaining lobes of the lungs were examined by qPCR analysis (Figure 
5.15). These proteins are all constituents of the ECM in the lung and were selected for 
analysis due to their association with fibrotic lung phenotypes. Sample cycle threshold (Ct) 
values were normalised to untreated animals of the same background and are expressed as 
a fold change using the ∆∆Ct method. Significance was determined using a one-way ANOVA, 
and Tukey’s post hoc test for correction for multiple testing was performed using GraphPad 
Prism. P-values below 0.05 were considered statistically significant. Samples from male and 
female mice were analysed independently. The first analysis compared the lungs from mice 
administered tamoxifen only.  
In male mice, as previously described, no statistically significant difference in ∆∆Ct was 
observed for COL1α2, COL3 or FN-EDA (Figure 5.15, A – C respectively) when CCN2 was 
removed from fibroblast cells (Col1α2-CCN2fl). A statistically significant increase in COL1α2 
transcription (P ˂ 0.05) was observed compared to control when CCN2 was removed from all 
cells (Figure 5.15, A). A statistically significant increase in COL3 transcription was observed 
compared to control, (P ˂ 0.0001) and compared to Fb k/o (P ˂ 0.0001) when CCN2 was 
removed from all cells (FIGURE B). No statistically significant difference in the ∆∆Ct fold 
change was observed for FN-EDA (Figure 5.15, C).    
In female mice, statistically significant decreases in ∆∆Ct were observed for COL1α2, COL3 
and FN-EDA (Figure 5.15, D - F respectively). When CCN2 was removed from fibroblast cells 
statistically significant reductions were seen in COL1α2 (P ˂ 0.0001), COL3 (P ˂ 0.01) and FN-
EDA (P ˂ 0.0001) transcription when compared to control (Figure 5.15, D - F respectively). 
The same result was observed when CCN2 was removed from all cells, with statistically 
significant reductions observed in COL1α2 (P ˂ 0.0001), COL3 (P ˂ 0.0001) and FN-EDA 
(P ˂ 0.0001) transcription when compared to control (Figure 5.15, D - F respectively).  A 
statistically significant difference was observed between the ∆∆Ct values of Fb k/o compared 
to Ub k/o for all genes; COL1α2 (P ˂ 0.01), COL3 (P ˂ 0.05) and FN-EDA (P ˂ 0.05), (Figure 
5.15, D – E). 
The second analysis compared the lungs from mice administered both tamoxifen and 
bleomycin treatments. The effects of bleomycin in WT lungs was compared with the 
response in lungs where CCN2 was removed in fibroblasts (Fb k/o) or ubiquitously (Ub k/o).  
In male mice, there were no statistically significant differences in mean ∆∆Ct for COL1α2 or 
FN-EDA (Figure 5.16, A & C). A statistically significant increase in mean ∆∆Ct for COL3 was 
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observed when Fb k/o was compared to Ub k/o (P ˂ 0.05) (Figure 5.16, B). No statistically 
significant differences in mean ∆∆Ct for COL3 transcription was observed when Fb k/o and 
Ub k/o were compared to control.    
In female mice, there were no statistically significant differences in mean ∆∆Ct for COL1α2 
or COL3 (Figure 5.16, D & E). Statistically significant reductions in ∆∆Ct for FN-EDA were 
observed when Fb k/o and Ub k/o were compared to control (P ˂ 0.05, P ˂ 0.01). No 
statistically significant difference was observed when Fb k/o and Ub k/o ∆∆Ct was compared. 
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Figure 5.15. RT-qPCR analysis of COL1α2, COL3 and FN-EDA expression in lung samples isolated from tamoxifen treated Col1α2-CCN2fl and ROSA-CCN2fl mice at experimental day 14. 
∆∆Ct analysis of COL1α2 (A & D), COL3 (B & E) and FN-EDA (C & F). Lungs were isolated immediately after Sch1 by anaesthetic overdose and manually inflated for scanning, using a 
SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). After scanning a single lobe was isolated for histology, the remainder of the lung 
was snap frozen and RNA extracted. Tamoxifen treatment causes loss of CCN2 in fibroblasts in Col1α2-CCN2fl mice and a ubiquitous removal of CCN2 in ROSA-CCN2fl mice. A - C) 
Male mice, D - F), Female mice. ∆∆Ct fold change results are plotted, significance was determined using a one-way ANOVA, and Tukey’s post hoc test. Significance and associated p-
value are indicated by (*).  
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Figure 5.16. RT-qPCR analysis of COL1α2, COL3 and FN-EDA expression in lung samples isolated from tamoxifen and bleomycin treated Col1α2-CCN2fl and ROSA-CCN2fl mice at 
experimental day 14. ∆∆Ct analysis of COL1α2 (A & D), COL3 (B & E) and FN-EDA (C & F). Lungs were isolated immediately after Sch1 by anaesthetic overdose and manually inflated 
for scanning, using a SkyScan 1272 µCT system at a resolution of 20 µm (0.25 mm aluminium filter, 0.3 ° rotation step). After scanning a single lobe was isolated for histology, the 
remainder of the lung was snap frozen and RNA extracted. Tamoxifen treatment causes loss of CCN2 in fibroblasts in Col1α2-CCN2fl mice and a ubiquitous removal of CCN2 in ROSA-
CCN2fl mice. A - C) Male mice, D - F), Female mice. ∆∆Ct fold change results are plotted, significance was determined using a one-way ANOVA, and Tukey’s post hoc test. Significance 
and associated p-value are indicated by (*).  
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5.6 Discussion 
 
This chapter presents the first original data on the effects of loss of function of CCN2 from 
fibroblast cells and from all cells in adult mice using two novel, inducible, double transgenic 
mouse lines; Col1α2-CCN2fl and ROSA-CCN2. This research also investigated the effects of 
these of loss of function phenotypes in a murine model of IPF. Myofibroblast are the primary 
collagen-producing cell in fibrosis (Klingberg, Hinz and White, 2013). Activation of fibroblasts 
to this profibrotic phenotype has been shown to be under the control of TGF-β CCN2 
signalling (Shi-Wen, Leask and Abraham, 2008). Inhibition of CCN2 signalling has been shown 
to have anti-fibrotic effects in various murine models of fibrosis (Koshman et al., 2015; 
Bickelhaupt et al., 2017), and in human clinical trials (Raghu et al., 2012, 2016; Picozzi et al., 
2016). It was therefore hypothesised that the loss of function of CCN2 would provide a 
preventative effect on the formation of fibrosis in response to bleomycin. 
The first experiments in this chapter described the phenotype in the lung, induced by 
fibroblast specific removal of CCN2 across a period of 28 days. No difference in the gross 
morphology of the lungs was observed at any timepoint by qualitative evaluation of the lungs 
(Figure 5.1 - 5.5). This was not unexpected as CCN2 is expression and activity is limited during 
adulthood under normal homeostasis (Ramazani et al., 2018) and phenotypes resulting from 
knock out models of CCN2 are usually observed in response to injury (Liu et al., 2011; Wang 
et al., 2014; Tracy, Minasian and Caterson, 2016; Bickelhaupt et al., 2017).  
RT-qPCR analysis of the lungs found no statistically significant difference in transcription of 
COL1α2 or FN-EDA in male mice (Figure 5.6, A & C). A statistically significant increase (P ˂ 
0.0001) in COL3 was observed at experimental day 7 only (Figure 5.6, B). In female animals 
statistically significant differences in transcription of COL1α2, COL3 and FN-EDA were 
observed across the experimental time period (Figure 5.6, D – F). Female and male mice have 
been shown to exhibit different responses to tamoxifen (Falke et al., 2017). It is believed to 
be a result of the hormone responses seen in these animals as the 4-OHT metabolite of 
tamoxifen has been shown to elicit responses from endogenous estrogen receptors 
(Robinson et al., 1991; Delle et al., 2012; Kim et al., 2014; Falke et al., 2017). As such, it was 
not surprising to note different responses in response to tamoxifen induced removal of CCN2 
between male and female animals. What was unusual was the opposing trends apparent 
between the two sexes. In male mice the general trend observed was an increase in average 
∆∆Ct value, whereas in females this was reversed with general reduction in average ∆∆Ct, 
with the exception of FN-EDA at 7 days (FIGURE 5.6). These analyses showed that although 
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no physical phenotype manifested, loss of function of CCN2 in fibroblasts was sufficient to 
cause statistically significant differences in gene transcription of Collagen I, Collagen III and 
Fibronectin ED-A. 
The next series of experiments aimed to determine if the removal of CCN2 from fibroblast 
cells affected the fibrosis formed using the bleomycin model of IPF. Visual assessment of the 
µCT scans (Figure 5.7) showed the expected progression for developing fibrosis in the 
bleomycin model across the 28-day experimental period for both tamoxifen treated and 
control animals (Izbicki et al., 2002). The extent of fibrosis identified at 14 days using µCT and 
histological analysis (Figure 5.7 - 5.9) was found to be reduced in lungs where CCN2 was 
removed from fibroblasts prior to bleomycin administration. This was considered an 
encouraging result, as previous literature using different models of CCN2 loss of function in 
different cell types has described similar protective effects in models of IPF (Gao and 
Brigstock, 2004; Xu et al., 2006; Shi-Wen, Leask and Abraham, 2008; Brigstock, 2009; Ponticos 
et al., 2009; Jun and Lau, 2011; Liu et al., 2011; Rittié et al., 2011; Kubota and Takigawa, 
2015).    
Analysis of WT male animals (Figure 5.10, A & C), identified a statistically significant 
upregulation of COL1α2, COL3 and FN-EDA transcription between control and bleomycin 
treated lungs at 14 days (P ˂ 0.0001). No statistically significant difference in the ∆∆Ct fold 
change was observed between control and WT bleomycin treated lungs at 28 days. Analysis 
of male animals where CCN2 was removed from fibroblasts before bleomycin treatment (Fb 
k/o) identified a statistically significant upregulation of COL1α2, COL3 and FN-EDA 
transcription between control and bleomycin treated lungs at all timepoints (Figure 5.10, D 
– F). The extent of fibrosis observed in the lungs of both WT and Fb k/o mice correlated with 
the trend in ∆∆Ct changes. Peak expression of COL1α2, COL3 and FN-EDA was observed at 
day 14, where the greatest extent of fibrosis was observed. When the average ∆∆Ct was 
compared (Table 5.1), it was found that the increase in gene expressions seen at 14 days 
were reduced in Fb k/o mice and increased at 28 days when compared to WT responses. 
Differential expression of COL1α2, COL3 and FN-EDA has been described in the bleomycin 
model of IPF (Swiderski et al., 1998; Cabrera et al., 2013), the trends in transcriptional 
changes and their associated phenotypes were found to be comparable to those of this 
research.  
Analysis of WT female animals identified no statistically significant changes in transcription 
of COL1α2 or COL3 (Figure 5.11, A - C). A statistically significant upregulation of FN-EDA 
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transcription was observed at 7 and 14 days. Analysis of CCN2 k/o female animals identified 
no statistically significant changes in transcription of COL1α2 or COL3 when compared to 
control (Figure 5.11, D - F). Analysis of FN-EDA transcription (Figure 5.11, F) identified 
statistically significant changes in ∆∆Ct at all timepoints.  When the average ∆∆Ct was 
compared (Table 5.1), it was found that for all genes (COL1α2, COL3 and FN-EDA) the average 
∆∆Ct at every time point. Both male and female animals exhibited a peak in translational 
increase of COL1α2, COL3 and FN-EDA followed by reductions in later timepoints. In females 
this peak in transcriptional activity was observed at 7 days, whereas in males it was observed 
at 14 days. The expression for male animals was expected  (Swiderski et al., 1998; Cabrera et 
al., 2013). Whereas the peak in transcriptional activity in females was surprising as this 
timepoint is usually associated with the resolution of inflammation rather than exponential 
matrix deposition (Izbicki et al., 2002) and was not reflected in the phenotype of the lungs. It 
has been shown that male and female mice respond differently to bleomycin treatment 
(Gharaee-Kermani et al., 2005; Voltz et al., 2008; Redente et al., 2011) therefore it was not 
surprising to find differences in the expression profiles between the two sexes. However, 
these differences were not identified in qualitative analyses and no obvious distinction was 
made in the pathologies observed for male or female animals. The conclusions from these 
results were that removal of CCN2 from fibroblasts prior to treatment with bleomycin 
demonstrated a less extensive fibrosis at 14 days than WT counterparts. A reduction in ECM 
associated genes (COL1, COL3 and FN-EDA) was observed in both male and female animals 
when compared with WT.  
Based on the phenotype response to bleomycin, the subsequent series of experiments used 
a 14-day timepoint to examine the response in fibrosis formation when loss of function of 
CCN2 was induced in a ubiquitous (ROSA-CCN2fl) manner. This was compared to fibroblast 
specific removal of CCN2. Both fibroblast specific (Fb k/o) and ubiquitous (Ub k/o) loss of 
function models were activated prior to the administration of bleomycin. The effect of loss 
of function of CCN2 was compared to WT lungs treated with bleomycin.  
Visual comparison of the gross morphology by µCT (Figure 5.12) and histological analysis 
(Figure 5.13 and Figure 5.14) of the lungs showed no difference in phenotype of untreated 
WT animals from Col1α2-CCN2fl or ROSA-CCN2fl mouse lines. No difference in baseline 
response to bleomycin was observed for either mouse line. In Ub k/o animals where 
ubiquitous loss of function of CCN2 was induced without subsequent challenge with 
bleomycin, small regions of fibrosis were observed in subpleural regions of the lungs (Figure 
5.12, F, red arrows). This was an unexpected observation as no difference in phenotype was 
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observed in Fb k/o mice. The fibrosis was observed by both µCT and histological analysis 
(Figure 5.12 - 5.14).  
RT-qPCR analysis on the remaining lobes of the lungs in male mice found a statistically 
significant increase in COL1α2 and COL3 transcription in Ub k/o where the effect of loss of 
CCN2 function was examined independently from bleomycin injury. This was interesting as 
these results provided further evidence that the tissue regions apparent in the µCT and 
histological analysis were likely to be a ‘spontaneous’ fibrosis. It was interesting to find that 
although the average ∆∆Ct value was higher in Ub k/o than Fb k/o lungs for all genes (Figure 
5.15, A - C), this increase was only statistically significant for collagen III transcription, yet a 
fibrotic phenotype was observed for Ub k/o and not Fb k/o.  
In female mice, statistically significant decreases in ∆∆Ct were observed for COL1α2, COL3 
and FN-EDA (Figure 5.15, D - F respectively) for both Fb k/o and Ub k/o where the effect of 
loss of CCN2 function was examined independently from bleomycin injury. A statistically 
significant difference was also observed between the ∆∆Ct values of Fb k/o compared to 
Ub k/o for all genes (Figure 5.15, D – E). 
These results were of interest as the appearance of early fibrosis in the subpleural regions of 
the lung was observed in Ub k/o mice of both genders, even though genetic profiles from RT-
qPCR analysis revealed contradictory alterations to gene expression of collagen I, III and 
fibronectin ED-A. The localisation of the fibrosis was comparable to that of human patients 
presenting with IPF, whereby usual IIP honeycombing patterns are generally identified in 
subpleural regions of the lungs by CT scan (Society, 2002; Travis et al., 2013; Lynch et al., 
2018).  
The RT-qPCR results from lungs from mice administered both tamoxifen and bleomycin 
treatments were then analysed.  
In male mice, there were no statistically significant differences in mean ∆∆Ct for COL1α2, 
COL3 or FN-EDA (Figure 5.16, A & C) when either a Fb k/o or Ub k/o was compared to WT 
response to bleomycin. Although not statistically significant, the mean ∆∆Ct values for Ub 
k/o mice compared to WT and Fb k/o were consistently higher. Mean ∆∆Ct for each 
treatment group and gene were COL1α2: WT = 2.72, Fb = 2.12, Ub = 3.51; COL3: WT = 5.47, 
Fb = 3.87, Ub = 7.39; FN-EDA: WT = 6.09, Fb = 4.12, Ub = 7.3. The variation in response of 
individuals within each group is likely the reason these differences were not statistically 
significant.  
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In female mice, there were no statistically significant differences in mean ∆∆Ct for COL1α2 
or COL3 (Figure 5.16, D & E). Statistically significant reductions in ∆∆Ct for FN-EDA were 
observed in both Fb k/o and Ub k/o when compared to control. No statistically significant 
difference was observed when Fb k/o and Ub k/o ∆∆Ct was compared. However conversely 
to the males, the mean ∆∆Ct values for Ub k/o mice compared to WT and Fb k/o were 
consistently lower. Mean ∆∆Ct for each treatment group and gene were COL1α2: WT = 1.69, 
Fb = 1.39, Ub = 1.09; COL3: WT = 2.47, Fb = 1.90, Ub = 1.50; FN-EDA: WT = 7.31, Fb = 3.05, 
Ub = 2.01.  
It is of interest to note that the opposing expression profiles between sexes were also 
observed when bleomycin treatment followed CCN2 loss of function. The difference in 
response to bleomycin treatment described by Gharaee-Kermani et al., (2005); Redente et 
al., (2011) and Voltz et al., (2008) identified a protective effect of tamoxifen in females 
administered bleomycin and other fibrotic agents. When the mean ∆∆Ct values of males 
were compared with females (Figure 5.16) this phenomenon could be implied based on qPCR 
results. However, no difference between the phenotypes in male and female mice were 
noted during qualitative analyses. 
5.6 Summary  
 
This chapter presented the first research using the two double transgenic mouse colonies, 
containing the floxed CCN2 transgene and a ubiquitously expressed ROSA26CreERT2 (ROSA-
CCN2fl), or the fibroblast specific tamoxifen-inducible CreERT2 (Col1α2-CCN2fl), in 
conjunction with the bleomycin model of IPF. The loss of function of CCN2 in a fibroblast 
specific manner did not present any observed phenotype in the lung when no injury was 
induced. Where bleomycin induced fibrosis was induced, fibroblast specific loss of CCN2 was 
found to convey a protective effect. Reductions in the extent of fibrosis observed in the lung 
were observed at 14 days. A decrease in the level of upregulation in transcription of 
associated ECM components; collagen I, collagen III and fibronectin ED-A was also observed 
in Fb k/o mouse lungs challenged with bleomycin, although this was not found to be 
statistically significant from these experiments. This was the first time that fibroblast cells 
were specifically targeted using the Col1α2-CreERT2 in the bleomycin model of IPF. 
Alternative CCN2 knock-outs in different cells and tissues show that cell specific loss of 
function of CCN2 conveys similar levels of protection when examined in the context of 
fibrosis.  The loss of function of CCN2 in a ubiquitous manner resulted in a grossly 
exacerbated response to bleomycin injury, with extensive fibrosis throughout the lung by 14 
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days. This contradicted the current dogma that the mechanism of action of CCN2 is 
predominantly profibrotic in the pathogenesis of fibrosis. Ubiquitous removal of CCN2 
without injury identified small early regions of fibrosis forming in the sub pleural regions of 
the lung by experimental day 14. This was both unexpected and interesting as it highlighted 
a previously underappreciated role of CCN2 as an inhibitor of tissue fibrosis. It also presented 
the potential for ubiquitous removal of CCN2 to be used as a new model system for IPF.  
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6. General Discussion 
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As early as 1935, reports of clinical cases describe patients presenting with extreme and 
progressive dyspnoea and cough, accompanied by clubbing of the fingers and toes. The 
histological findings upon autopsy reported excessive proliferation of fibrous tissue in the 
interstitium as a common feature in these patients (Hamman and Rich, 1933; 1935; Homolka, 
1987). Although termed interstitial non-purulent pneumonia at the time, the disease 
described is known today as IPF. IPF  is a chronic, progressive and ultimately lethal disease of 
the lung with no known cause (Raghu et al., 2011). Incidence and mortality appear to be on 
the rise, and prevalence is expected to increase with the aging population (Ley and Collard, 
2013). The 5 – year survival rate for IPF is worse than a number of cancers including breast, 
prostate and skin (Vancheri et al., 2010). An increase in basic and clinical research in recent 
decades has led to the development and approval of two new drugs for IPF, Nintedanib 
(Wollin et al., 2014; Drugs, 2016) and Pirfenidone (NICE, 2013; King et al., 2014), with a third 
(FG-3019 / Pamrevlumab) currently undergoing clinical assessment (Raghu et al., 2016; 
Lipson et al., 2017). However, the pathobiology of IPF still remains elusive and there is an 
ever more pressing need to understand the molecular processes behind this disease to 
identify potential therapeutic targets for this disease (Hui Hoo and B Whyte, 2012). 
Animal models of IPF have been an essential tool for investigating the pathology and 
mechanisms underlying this disease (Roberts et al., 1995; Moore and Hogaboam, 2008; 
Schaefer et al., 2011; Wollin et al., 2014; Marenzana and Vande Velde, 2015; Qian et al., 
2016; Masopust, Sivula and Jameson, 2017). Although limited by their inability to 
encapsulate the full range of features present in human disease, they remain a useful means 
for examining key physiological traits and as a screening platform for candidate 
pharmaceutical molecules. Of these models, the most widely used for IPF is bleomycin. With 
the recent success of Nintedanib and Pirfenidone being approved in human trials following 
pre-clinical assessment using the bleomycin model of IPF (Schaefer et al., 2011; Wollin et al., 
2014) it was decided that this research for this thesis would utilise this technique to 
investigate the role of CCN2 in IPF.   
The first attempt to reproduce a previously established protocol for bleomycin induces IPF 
(Ponticos et al., 2009) resulted in a severe response to bleomycin treatment in around 25 % 
of the animals. This was not anticipated and lead to animals being culled earlier than their 
designated time points. An alternative protocol was developed using a lower dose of 
bleomycin which proved to be far better tolerated and was reproducible between mice. The 
fibrosis observed was comparable in both progression and morphology to that described in 
the literature (Adamson and Bowden, 1974; Izbicki et al., 2002; Lakatos et al., 2006; Egger et 
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al., 2013). It was uncertain as to why the earlier dose was so poorly tolerated and no 
definitive conclusions were reached as to why the mice demonstrated such an exacerbated 
response. However, the results from this study highlighted several key issues in the 
experimental design, primarily the need to assess the extent of fibrosis throughout the entire 
lung prior to isolating individual lobes from the lung for differential analysis. As such the 
options for whole lung imaging techniques available at the University of Liverpool were 
assessed and the ex-vivo Bruker SkyScan 1272 µCT scanner was decided to be suitable. 
Initially a chemical dehydration method was used to examine the morphology of the lungs, 
however it was not feasible to analyse these samples for the genetic profile of transgenic 
animals. Therefore, a novel protocol was established that enabled scanning of the lungs 
immediately after Sch1 of the animal without the need for chemical fixatives. The results in 
this thesis demonstrated that a comparable level of detail to that obtained from dehydrated 
scans was achieved, and with the assistance of Professor Rob Van ‘T Hof, a macro was 
developed that was able to quantify the level of fibrosis in the lungs. Subsequent histological 
analysis confirmed that the suspected regions of fibrosis observed using the µCT scanner 
were in fact collagenous tissue. It was concluded that the model was sufficient to produce a 
visible fibrosis in mice by 14 days and that imaging and analysis protocols developed during 
this research were suitable for identifying and quantifying this. These protocols are the first 
to describe a method using an ex-vivo scanner whereby the same lungs can be used for both 
a qualitative and quantitative analysis. Typically researchers using ex-vivo µCT scans will 
chemically fix the samples required for scanning (Sharir, Ramniceanu and Brumfeld, 2011; 
Downey et al., 2012; Scotton et al., 2013), requiring larger experimental group sizes if genetic 
analysis is required. The major limitation from ex-vivo analysis is the requirement for Sch1 of 
the animal at designated timepoints. The basic assumption remains that animals culled and 
assessed at earlier timepoints would have continued to express the same phenotypes seen 
in animals that continued on study. The new gold-standard for this technique describes the 
use of in-vivo µCT scanning, whereby the same animal can be assessed longitudinally. The 
rise in availability and reduction in costs of the benchtop in-vivo µCT scanners has led to an 
increase in literature describing this scanning technique for the assessment of bleomycin 
induced IPF (Cavanaugh et al., 2006; Driehuys and Hedlund, 2007; Johnson, 2008; Schambach 
et al., 2010; Misharin et al., 2017; Ruscitti et al., 2017). The University of Liverpool has 
recently purchased an in-vivo scanner, as such the application of ex-vivo scanning of 
bleomycin treated lungs is likely to be replaced in favour of in-vivo imaging. However, the 
research to develop the bleomycin model at the University will remain relevant for future 
research in this area. 
182 
 
The 4th chapter in this thesis focussed on the development of three novel, 
tamoxifen - inducible, double transgenic mouse lines. Two of these mouse lines were 
designed to instigate a loss of CCN2 function in either a ubiquitous manner, or in fibroblast 
cells only. The third utilised the dual-fluorescent reporter line described by  (Muzumdar et 
al., 2007) to characterise the fibroblast specific Col1α2 - CreERT2 generated by the Bou-
Gharios lab (Bou-Gharios et al., 1996; De Val et al., 2002; Ponticos et al., 2004). In this 
research we presented the original data for assessing the levels of CCN2 k/o achieved when 
recombination of the CCN2 was induced by tamoxifen administration. In chapter 5 the effects 
of these phenotypes were assessed in conjunction with the bleomycin IPF model. 
CCN2 is known to be a contributor of IPF in patients and animal models of lung fibrosis and 
has been identified as a key downstream mediator of the effects of the known master 
regulator of repair TGF – β Leask and Abraham, 2006; Shi-wen et al., 2006; Arnott et al., 2007; 
Ponticos et al., 2009; Holmes et al., 2001; Leask et al., 2003; Geisinger et al., 2012. As such, 
CCN2 has been proposed as a therapeutic target in IPF as well as a possible biomarker for 
companion diagnostics for treatment of this disease. It was proposed that the cellular 
propagator of fibrosis was the fibroblast owing to its key role in ECM production and 
deposition. Research in patients with IPF identified increased levels of CCN2 in a number of 
cell types including fibroblasts (Plantier et al., 2016) bronchoalveolar lavage cells (Allen et al., 
1999), plasma (Kono et al., 2011) and general lung tissue (Pan et al., 2001). However, as 
fibroblasts were the only cells identified as capable of generating ECM components it was 
hypothesised that the removal of CCN2 from fibroblasts would prove beneficial. Animal 
models of IPF have also shown CCN2 is  increased in fibroblasts (Lasky et al., 1998; Liu et al., 
2011; Yang et al., 2014; Ashley et al., 2017). Knock out animal models of CCN2 have 
demonstrated the presence of fewer myofibroblasts and reductions in ECM disposition, 
indicating that CCN2 is necessary for induction of fibrosis in these animals (Liu et al 2011). 
This thesis aimed to investigate this hypothesis further by targeting CCN2 for removal in 
fibroblast cells and in all cells using the bleomycin model of IPF utilising the newly generated 
tamoxifen - inducible double transgenic animal models described above. 
Research in the Bou-Gharios lab had previously identified a 1.5 kb enhancer sequence 
upstream of the transcriptional start site of the COL1α2 gene (Bou-Gharios et al., 1996; De 
Val et al., 2002). This was used to generate a tamoxifen-inducible CreERT2 mouse line 
(Col1α2CreERT2) (Ponticos et al., 2004, 2009). Research in this thesis aimed to characterise 
the expression profile of the Col1α2-CreERT2 using a dual fluorescent (mT/mG) reporter 
construct. Mice containing the mT/mG reporter construct described by Muzumdar et al., 
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(2007), were bred with mice containing the Col1α2-CreERT2. Littermate breeding pairs were 
maintained to produce a double transgenic mouse colony that was homozygous for the 
mT/mG reporter construct, and positive for Col1α2-CreERT2. These animals were then used 
for lineage tracing experiments to determine the expression pattern of the Col1α2-CreERT2 
during development and during adulthood. This new shorter collagen enhancer was found 
to express more widely in almost all fibroblast compared with the previous CreERT1 generated 
by (Denton et al., 2001). 
This Col1α2CreERT2 was then used to generate a new tamoxifen-inducible double transgenic 
mouse line capable of removing CCN2 from fibroblasts. The removal of CCN2 specifically in 
fibroblasts using the Col1α2 - CreERT2 has not previously been described in conjunction with 
the IPF bleomycin model, therefore we generated this mouse to investigate whether the 
protective effects seen in other cell specific k/o models of CCN2 would be true in this 
transgenic system.  
No difference in the gross morphology of the lungs was observed at any timepoint by 
qualitative evaluation of the lungs when CCN2 was removed from fibroblast cells. This was 
not unexpected owing to the limited expression and activity of CCN2 during adulthood under 
normal homeostasis (Ramazani et al., 2018). No injury was induced for these analyses and 
phenotypes resulting from knock out models of CCN2 are usually observed in response to 
injury (Liu et al., 2011; Wang et al., 2014; Tracy, Minasian and Caterson, 2016; Bickelhaupt et 
al., 2017). Therefore, the next experiments investigated if the removal of CCN2 from 
fibroblast cells demonstrated any effect on the formation of fibrosis bleomycin model of IPF. 
Although not statistically significant these results found that the extent of fibrosis identified 
at 14 days was visibly reduced, and genetic analyses showed a decrease in transcription of 
collagen I, collagen III and fibronectin ED-A. This was considered an encouraging result, as 
these results were comparable to the literature (Gao and Brigstock, 2004; Xu et al., 2006; Shi-
Wen, Leask and Abraham, 2008; Brigstock, 2009; Ponticos et al., 2009; Jun and Lau, 2011; Liu 
et al., 2011; Rittié et al., 2011; Kubota and Takigawa, 2015) and suggested that targeting 
CCN2 in IPF patients should have a beneficial therapeutic effect. 
Based on these promising results, the ubiquitous k/o of CCN2 was assessed for efficacy in 
reducing fibrosis at 14 days. It was hypothesised that the protective effects demonstrated by 
the fibroblast k/o of CCN2 would convey a greater level of protection when CCN2 was 
removed from all cells. However, the resulting fibrosis in mice where CCN2 was removed 
ubiquitously was grossly exacerbated. In many cases the fibrosis extended to such a degree 
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that it was astonishing that the mice were not exhibiting any signs of an adverse response 
and in some animals the fact that they remained able to breathe was wholly impressive. The 
second result of interest in these mice was that a fibrosis was seen developing in animals 
where bleomycin was not administered. At 14 days small regions of fibrosis were identified 
in the subpleural regions of the lungs. These results raise several questions regarding the 
roles that CCN2 plays both in fibrosis and in normal lung homeostasis.  
This research has demonstrated that deleting CCN2 from fibroblasts can cause an 
amelioration in the pathology of fibrosis at 14 days. This is considered a favourable result, 
especially when considering that anti-CCN2 antibodies are currently in clinical trials in the 
form of monoclonal antibody, FG-3109 (Pamrevlumab). Interestingly current results from 
these trials appear promising, with a double-blind placebo - controlled trial demonstrating 
significantly reduced decline of the forced vital capacity in patients treated with 
Pamrevlumab compared to placebo treatment. Efficacy and tolerance are also proving 
positive with no current adverse events being reported (Raghu et al., 2016; Lipson et al., 
2017).  
Survival rates in several animal models of fibrosis are also improved following removal of 
CCN2 in fibroblasts, and demonstrate a reduction in the expression of ECM components and 
preservation of alveolar epithelial cell morphology (Bickelhaupt et al., 2017). Yet when CCN2 
was removed from all cells, the results were entirely contradictory with a rapid progression 
of fibrosis occurring with bleomycin and even occurring spontaneously when CCN2 was 
simply removal from all cells. This leads to the next question posed by this data; if not 
fibroblasts, then which cells are secreting and responding to CCN2 in order to elicit a fibrotic 
response when this protein is removed from the microenvironment? Misharin et al., (2017) 
recently reported that monocyte derived alveolar macrophages and tissue resident alveolar 
macrophages demonstrate distinct roles during the development of lung fibrosis. Both of 
which were found to secrete large amount of CCN2. Using a genetic lineage tracing system, 
they showed that deletion of monocyte derived alveolar macrophages after their 
recruitment to the lung in a bleomycin model of IPF markedly attenuated the severity of 
fibrosis. The differentiation from monocyte to alveolar macrophage would appear to be the 
target for any anti-fibrotic intervention as this is reportedly the stage where a fibrotic 
phenotype can be instigated. Incomplete differentiation between the phenotypes has been 
shown to lead to increased expression of pro-fibrotic genes. The persistence of these partially 
differentiated macrophages in the lung microenvironment is likely to play a part in the 
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initiation and propagation of fibrosis (Landsman, Varol and Jung, 2007; Lavin et al., 2014). 
These results now point the spotlight to the macrophage rather than the fibroblast as the 
cellular mediator of fibrotic responses.  
To address this hypothesis a series of experiments was designed that would utilise a cell 
sorting technique to isolate the different cell populations from the lung for individual 
analysis. The experiments in this thesis used a whole lung homogenate therefore it wasn’t 
possible to determine which cells were producing the ECM in the absence of the ubiquitous 
model of CCN2 knock out and bleomycin model retrospectively. Unfortunately, time 
constraints meant that these experiments were not completed during this PhD but would 
provide valuable mechanistic information with regards to the reasons the ROSA-CCN2fl mice 
responded so poorly to bleomycin. It would also be interesting to maintain the animals only 
treated with tamoxifen to later timepoints to see if the fibrosis continued to develop from 
the subpleural regions into a pathology similar to that of humans. If this could be proven this 
would present the ROSA-CCN2fl mouse as a new model system to study IPF. 
The other interesting finding of these study which has yet to be discussed, was the difference 
between males and females when examining the transcriptional responses of the ECM genes 
to CCN2 knock out. Although the phenotypes were comparable, the underlying molecular 
changes seen were contradictory. With converse increases and decreases in transcription 
observed for all the analyses in this research. Many diseases show differential prevalence 
between the sexes, and in fact IPF is one such disease, with an increased prevalence in males 
(Strongman, Kausar and Maher, 2018). Many examples of differences between the sexes in 
animal models are described in the literature however very little research exists on the 
biological and molecular mechanisms driving this response. It would be interesting to assess 
hormone response pathways in these mouse models to see if any gender related differences 
could be elucidated. 
In summary, the studies reported in this thesis presented novel findings on the role of CCN2 
in the pathogenesis of fibrosis. Two novel transgenic mouse lines were established for the 
genetic manipulation of CCN2 in vivo. These were used in conjunction with the bleomycin 
model, which was established for the first time at the University of Liverpool. The results 
from these experiments unveiled unexpected results and raised further questions as to the 
role CCN2 plays in homeostatic regulation of ECM production by demonstrating a potent anti-
fibrotic effect of CCN2. When removed from all cells a ‘spontaneous’ fibrosis was observed 
and when challenged with bleomycin, a grossly exacerbated response was seen resulting in 
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extensive fibrosis. A third transgenic mouse line was used to characterise the expression 
profile of a fibroblast specific CreERT2 developed by the Bou-Gharios lab group and found that 
the fibroblast specificity was prevalent in a wider population of Fibroblasts than described 
previously. 
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Appendix 3. Lung µCT Macro Analysis 
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